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PREFACE
About 230 million people, or 5 per cent of the world’s 
adult population, are estimated to have used an illicit drug 
at least once in 2010. Problem drug users number about 
27 million, which is 0.6 per cent of the world adult 
population. Throughout the world, illicit drug use appears 
to be generally stable, though it continues to be rising in 
several developing countries. Heroin, cocaine and other 
drugs kill around 0.2 million people each year, shattering 
families and bringing misery to thousands of other people. 
Illicit drugs undermine economic and social development 
and contribute to crime, instability, insecurity and the 
spread of HIV.
Global opium production amounted to 7,000 tons in 
2011. That is more than a fifth less than the peak of 2007 
but an increase from the low level of 2010, the year in 
which a plant disease destroyed almost half of the opium 
harvest in Afghanistan, which continues to be the world’s 
biggest producer. The total area under coca bush cultiva-
tion in the world fell by 18 per cent between 2007 and 
2010 and by 33 per cent since 2000. Efforts to reduce 
cultivation and production of the main plant-based prob-
lem drugs have, however, been offset by rising levels of 
synthetic drug production, including significant increases 
in the production and consumption of psychoactive sub-
stances that are not under international control.
Although Member States are to be commended for their 
hard work in dealing with the drug problem, often with 
the support of UNODC, the figures sketched above indi-
cate the scale of the challenge. The response by UNODC 
has been twofold: first, develop an integrated approach; 
and second, focus on prevention, treatment, alternative 
development and the promotion of fundamental human 
rights.
Developing an integrated approach
Drug trafficking flows have global dimensions. The flows 
link regions and continents, sometimes with dramatic con-
sequences for the countries they affect. Our research and 
trend analysis is designed to improve understanding of 
those issues. The results are fed into integrated programmes 
to reduce illicit drug supply and demand.
UNODC is building integrated regional programmes, as 
well as promoting interregional and inter-agency responses. 
One such inter-agency approach is the United Nations 
system Task Force on Transnational Organized Crime and 
Drug Trafficking, established in 2011.
In December 2011, the UNODC Regional Programme 
for Afghanistan and Neighbouring Countries was launched. 
To support this programme, UNODC and its partners 
have created cross-border, intelligence and precursor con-
trol initiatives to share information and experience and to 
conduct joint operations. All these regional initiatives are 
interlinked with existing law enforcement networks.
There are also new initiatives for countering money-
laundering and for coupling law enforcement with 
alternative livelihoods. An initiative has been launched to 
disrupt drug trafficking by sea in West and South Asia. 
UNODC has also launched a new Regional Programme 
for South-Eastern Europe to focus action on areas where 
heroin flowing along the Balkan route enters Europe. 
A regional hub for Central America and the Caribbean has 
been developed in Panama. The strengthened UNODC 
Regional Office for Mexico and countries in that region 
will be linked to the hub. In the Dominican Republic and 
Mexico, centres of excellence are being established to 
promote drug demand reduction. 
A network of prosecutors in Central America is using best 
practices to strengthen criminal justice in the region. At 
the same time, the Container Control Programme is 
expanding, operating in more countries and controlling 
containers transported by sea, as well as by air. In West and 
Central Africa, successes are being achieved through the 
establishment of transnational crime units. 
In South-East Asia, UNODC provides the groundwork 
for cross-border cooperation between the countries of the 
Greater Mekong subregion, helps secure sustainable 
livelihoods through alternative development schemes and 
gives countries an evidence base for taking action against 
the interrelated threats of organized crime and drug 
trafficking. 
UNODC is also improving capacities to counter money-
laundering and corruption in all regions by interrupting 
the flow of illicit drug proceeds, which are used by criminal 
networks to carry out further criminal activities. 
Rebalancing drug control policy through  
alternative development, prevention, treatment 
and fundamental human rights
UNODC will continue to build international cooperation 
and to help Member States respond to these threats. If we 
are to confront these challenges, however, both supply and 
demand need to be reduced. There is growing recognition 
that treatment and rehabilitation of illicit drug users are 
more effective than punishment.  
Of course, this does not mean abandoning law enforce-
ment activities; instead, the supply and demand sides need 
to complement each other. This means balancing our 
efforts against drug trafficking with alternative develop-
ment programmes for farmers and helping drug users to 
be rehabilitated and reintegrated into society. 
Alternative development is the key to reducing illicit drug 
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crop cultivation and drug production. At present, only 
around one quarter of all farmers involved in illicit drug 
crop cultivation worldwide have access to development 
assistance. If we are to offer new opportunities and genuine 
alternatives, this needs to change. 
UNODC is also promoting activities that significantly 
reduce illicit drug demand. Such activities are necessary 
because of growing signs of drug use in the so-called transit 
countries. For example, there are increasing numbers of 
cocaine users in West and Central Africa; and the highest 
prevalence rates for opium and heroin use are in Afghani-
stan and the Islamic Republic of Iran. 
Drug control means restoring the balance and paying 
greater attention to the health side by reducing overdoses, 
psychiatric problems and the incidence of infections such 
as HIV and hepatitis. Prevention, treatment, rehabilita-
tion, reintegration and health all have to be recognized as 
key elements in the global strategy to reduce drug demand. 
To support its activities, UNODC takes an approach based 
on human rights, the international drug control conven-
tions and international standards and norms. 
Moving forwards not backwards 
Recently several countries facing high rates of violence, 
kidnapping, corruption and human trafficking related to 
transnational organized crime and drug trafficking have 
called for international assistance. These countries need 
our support. It is our shared responsibility to do everything 
possible to help. 
In doing so, we need to be equally clear about the 
importance of the international conventions on drugs, 
organized crime and corruption. Indeed, almost everything 
mentioned in this preface — focusing on drug demand, 
rehabilitation and reintegration, alternative development, 
shared responsibility and fundamental human rights — are 
underscored in the conventions. 
The Commission on Narcotic Drugs put this succinctly 
when, in its resolution 55/3, on the 100th anniversary of 
the International Opium Convention, it expressed its 
determination to strengthen action and cooperation at the 
national, regional and international levels towards the goals 
of the international drug control conventions, which 
remain the cornerstone of the international drug control 
system. Our direction is guided by the international con-
ventions on drug control and crime prevention. We need 
to move as one; if not, we risk going backwards, not 
forwards. 
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
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Explanatory notEs
The following abbreviations have been used in this Report:
AIDS acquired immunodeficiency syndrome
ATS amphetamine-type stimulant
BZP N-benzylpiperazine
CICAD Inter-American Drug Abuse Control 
Commission (Organization of  
American States)
mCPP m-chlorophenylpiperazine
DEA Drug Enforcement Administration 
(United States of America)
EMCDDA European Monitoring Centre for  
Drugs and Drug Addiction
Europol European Police Office
FARC Revolutionary Armed Forces of 
Colombia
GDP gross domestic product
ha hectare
HIV human immunodeficiency virus
INTERPOL International Criminal Police 
Organization
IRA Irish Republican Army
LSD lysergic acid diethylamide
MDA methylenedioxyamphetamine
MDE N-ethyl-tenamfetamine
MDMA methylenedioxymethamphetamine
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-pro-
panone
MDPV methylenedioxypyrovalerone
4-MMC 4-methylmethcathinone
OECD Organisation for Economic  
Co-operation and Development 
P-2-P 1-phenyl-2-propanone
PKK Kurdistan Workers’ Party
PMK piperonyl methyl ketone
SIM subsciber identity module
SMS short message service
THC tetrahydrocannabinol
WHO World Health Organization
The boundaries and names shown and the designations 
used on maps do not imply official endorsement or accept-
ance by the United Nations. A dotted line represents 
approximately the line of control in Jammu and Kashmir 
agreed upon by India and Pakistan. The final status of 
Jammu and Kashmir has not yet been agreed upon by the 
parties. Disputed boundaries (China/India) are represented 
by cross hatch due to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of the 
material in this publication do not imply the expression 
of any opinion whatsoever on the part of the Secretariat 
of the United Nations concerning the legal status of any 
country, territory, city or area or of its authorities, or con-
cerning the delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were 
in official use at the time the relevant data were collected.
All references to Kosovo in the present publication should 
be understood to be in compliance with Security Council 
resolution 1244 (1999).
Since there is some scientific and legal ambiguity about 
the distinctions between “drug use”, “drug misuse” and 
“drug abuse”, the neutral terms “drug use” and “drug con-
sumption” are used in this report.
The data on population used in this report are from: 
United Nations, Department of Economic and Social 
Affairs, Population Division, World Population Prospects: 
The 2010 Revision. Available from http://esa.un.org/unpd/
wpp.
The following symbols have been used in the tables 
throughout the report:
Two dots (..) indicate that data are not available or are not 
seperately reported.
References to dollars ($) are to United States dollars, unless 
otherwise stated.
References to “tons” are to metric tons, unless otherwise 
stated.
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EXECUTIVE SUMMARY
Chapter I of this year’s World Drug Report provides an 
overview of recent trends and the drug situation in terms 
of production, trafficking and consumption and the con-
sequences of illicit drug use in terms of treatment, drug-
related diseases and drug-related deaths. 
Chapter II presents a long-term perspective on the char-
acteristics and evolution of the drug problem and the main 
factors that shaped it. It starts with a discussion of the main 
characteristics of the contemporary drug problem, followed 
by an overview of the shifts observed over the last few 
de cades, before concluding with an analysis of the driving 
factors that shaped the evolution of the drug problem, 
including a brief outlook for its likely future direction.
CHAPTER I. RECENT STATISTICS 
AND TREND ANALYSIS OF ILLICIT 
DRUG MARKETS
Latest available data indicate that there has been no sig-
nificant change in the global status quo regarding the use, 
production and health consequences of illicit drugs, other 
than the return to high levels of opium production in 
Afghanistan after a disease of the opium poppy and sub-
sequent crop failure in 2010. But while the troubled waters 
of the world’s illicit drug markets may appear to be stag-
nant, shifts and changes in their flows and currents can be 
observed below the surface. These are significant and also 
worrying, not because of how they currently impact on 
the data but because they are proof of the resilience and 
adaptability of illicit drug suppliers and users and because 
of the potential future repercussions of those shifts and 
changes in the world’s major drug markets. 
The global picture
The extent of global illicit drug use remained stable in the 
five years up to and including 2010, at between 3.4 and 
6.6 per cent of the adult population (persons aged 15-64). 
However, some 10-13 per cent of drug users continue to 
be problem users with drug dependence and/or drug-use 
disorders, the prevalence of HIV (estimated at approxi-
mately 20 per cent), hepatitis C (46.7 per cent) and hepa-
titis B (14.6 per cent) among injecting drug users continues 
to add to the global burden of disease, and, last but not 
least, approximately 1 in every 100 deaths among adults 
is attributed to illicit drug use. 
Opioids continue to be the dominant drug type account-
ing for treatment demand in Asia and Europe and also 
contribute considerably to treatment demand in Africa, 
North America and Oceania. Treatment for cocaine use is 
mainly associated with the Americas, while cannabis is the 
main drug causing treatment demand in Africa. Demand 
for treatment relating to the use of amphetamine-type 
stimulants (ATS) is most common in Asia.
Globally, the two most widely used illicit drugs remain 
cannabis (global annual prevalence ranging from 2.6 to 
5.0 per cent) and ATS, excluding "ecstasy", (0.3-1.2 per 
cent) but data relating to their production are scarce. Total 
production and cultivation of coca is known to be stable, 
while the production of opium has returned to levels com-
parable to 2009. Global annual prevalence of both cocaine 
and opiates (opium and heroin) has remained stable, with 
ranges from 0.3-0.4 per cent and 0.3-0.5 per cent, respec-
tively, of the adult population aged 15-64:
Opioids
With estimated annual prevalence ranging from 0.6 to 0.8 
per cent of the population aged 15-64, the use of opioids 
(mainly heroin, morphine and non-medical use of prescrip-
tion opioids) is stable in all of the main markets. After a 
blip in global production in 2010, caused by a disease of 
the opium poppy in Afghanistan, production has now 
more or less returned to its 2009 level. Average wholesale 
and retail prices in the most regularly monitored markets 
for opiates, in Western and Central Europe and the Ameri-
cas, have also shown little change since 2009, but this does 
not reflect the situation seen in such major opium-produc-
ing countries as Afghanistan and Myanmar where, despite 
an increase in opium production, farm-gate prices contin-
ued to rise in 2010 and 2011. 
The latter may imply that illicit demand for opium and 
its derivatives is continuing to increase in spite of the recent 
recovery of opium production. While it is difficult to iden-
tify one specific reason for this, it could be an underesti-
mation of global heroin consumption, especially in 
countries in Asia that are major markets and countries in 
Africa that are possible emerging markets, or to an expan-
sion in the market for raw opium (not processed into 
heroin), which could feed increased opium consumption 
and, perhaps, a parallel illicit market for opiates such as 
morphine. High prices at source could also be explained 
by speculation in the local market.
Annual prevalence and number of illicit drug 
users at the  global level, 2010
Prevalence  
(percentage)
Number  
(thousands)
 Low High Low High
Cannabis 2.6 5.0 119 420 224 490
Opioids 0.6 0.8 26 380 36 120
Opiates 0.3 0.5 12 980 20 990
Cocaine 0.3 0.4 13 200 19 510
Amphetamine-
type stimulants 0.3 1.2 14 340 52 540
“Ecstasy” 0.2 0.6 10 480 28 120
Any illicit drug 3.4 6.6 153 000 300 000
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It is too early to know exactly the impact of the 2010 
opium crop failure in Afghanistan on the major illicit mar-
kets for opiates, but a general decrease in seizures in 2010 
occurred in most of the countries supplied by Afghan opi-
ates and a heroin shortage was observed in some European 
countries in 2010-11. There are indications that this 
shortage has encouraged users in some countries to replace 
heroin with other substances such as desomorphine (also 
known as “krokodil”), acetylated opium (known as 
“kompot”) and synthetic opioids such as fentanyl and 
buprenorphine. 
Although large quantities of heroin continue to be traf-
ficked along the main Balkan route, leading from Afghani-
stan to Western and Central Europe via South-Eastern 
Europe, declining seizures were reported in most of the 
countries in those regions in 2010. However, the coastal 
markets of Africa are reporting increasing seizures, as are 
countries in South-East Asia. Whether this implies that 
traffickers are seeking alternative routes or that heroin use 
is on the increase in those places, the lack of available data 
makes it impossible to draw definitive conclusions. But 
one thing is clear: the opiate market continues to be 
extremely flexible and adaptable.
Cocaine
The general stability of global cocaine use and manufacture 
masks different trends in different regions and countries. 
Available data on cultivation, yield and trafficking indicate 
that there has been an overall decline in global manufac-
ture of cocaine, prompted by a major decline in cocaine 
manufacture in Colombia in the five-year period 2006-
2010. A sizeable shift has taken place as coca bush cultiva-
tion and coca production increased in the same period in 
the other two coca-producing countries, Bolivia (Plurina-
tional State of ) and Peru, which are becoming increasingly 
important producers. 
The major markets for cocaine continue to be in North 
America, Europe and Oceania (mainly Australia 
and New Zealand). North America has seen a marked 
decline in cocaine use, mainly due to a decline in the 
United States, from 3.0 per cent (2006) to 2.2 per cent 
(2010) among adults aged 15-64; however, there has not 
been such a decline in Europe, where cocaine use stabilized 
over the same period. Latest data from Australia show an 
increase in cocaine use.
There is evidence that, while the United States market 
continued to be almost exclusively supplied by cocaine 
produced in Colombia, from 2006 there was a shift in the 
European markets, which compensated, at least partially, 
for the shortage of cocaine produced in Colombia with 
cocaine produced in Bolivia (Plurinational State of ) and 
Peru. The decline in seizures in Europe, despite the appar-
ent stability of the region’s cocaine supply, implies that a 
change in trafficking modes is occurring as traffickers may 
be making increasing use of containers. In the United 
States of America, the decrease in availability of cocaine 
has been reflected by rising prices since 2007. In Europe, 
however, no dramatic changes in prices have been observed 
since 2007. Overall, they remained at the same level in 
dollar terms between 2007 and 2010 and even decreased 
in some countries. 
An additional factor influencing the availability of, and 
overall demand for, cocaine in different regions is the emer-
gence of new, albeit small, cocaine markets in, for example, 
Eastern Europe and South-East Asia. There is also some 
evidence that cocaine trafficking through West Africa may 
have had a spillover effect on countries in that subregion, 
with cocaine emerging as a drug of major concern, along 
with heroin. Some data indicate an expansion of the 
cocaine market, particularly of “crack” cocaine, in some 
countries of South America.
Amphetamine-type stimulants
The illicit manufacture of ATS (mainly methamphetamine, 
amphetamine and “ecstasy”), the second most widely used 
class of drugs worldwide, is difficult to measure because it 
is widespread and often on a small scale. While the use and 
global seizures of ATS remained largely stable, 2010 was 
marked by an increase in methamphetamine seizures to 
more than double the amount in 2008, partly due to sei-
zures increasing in Central America and East and South-
East Asia. For the first time since 2006, global 
methamphetamine seizures surpassed global amphetamine 
seizures, which fell by 42 per cent (to 19.4 tons) mainly 
as a result of a decrease in seizures in the Near and Middle 
East and South-West Asia. 
Despite a significant rise in the dismantling of clandestine 
amphetamine laboratories, amphetamine seizures in 
Europe continued their downward trend, reaching their 
lowest level since 2002 (5.4 tons). There are signs, however, 
of a recovery in the European “ecstasy” market, with sei-
zures of “ecstasy”-group substances more than doubling 
(from 595 kg in 2009 to 1.3 tons in 2010). The drug’s 
availability and use also appear to be on the increase in the 
United States, while there has also been an increase in 
“ecstasy” seizures in Oceania and South-East Asia.
There is also growing evidence to suggest that criminal 
organizations involved in smuggling ATS, particularly 
methamphetamine, exploit West Africa in a similar way 
to cocaine traffickers. Seizures of methamphetamine from 
West Africa started to increase in 2008; the substance was 
being smuggled into East Asian countries, predominantly 
Japan and the Republic of Korea. 
Cannabis
Cannabis is the world’s most widely used illicit substance: 
there are between 119 million and 224 million cannabis 
users worldwide, and consumption is stable. Cannabis sei-
zure and eradication data suggest that the production of 
cannabis herb (marijuana) is increasingly widespread, but 
the often localized, small-scale nature of cannabis cultiva-
tion and production make it very difficult to assess. New 
Executive summary
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data on larger-scale global production of cannabis resin 
(hashish) are only available for Afghanistan.
The relative importance of cannabis resin and herb varies 
by region, with cannabis resin being dominant in the Near 
and Middle East and South-West Asia, cannabis resin and 
herb markets being comparable in size in North Africa and 
Europe. The rest of the world, including the United States, 
where production continues to be high, is dominated by 
cannabis herb. Data for Africa is hard to come by but sei-
zure data suggest that herb is also the dominant form of 
cannabis in that region, except in North Africa where resin 
is predominant.
The production of cannabis resin is assumed to be very 
small in Europe yet the region is the world’s biggest market 
for cannabis resin and North Africa has long been Europe’s 
predominant supplier. Most of the North African cannabis 
resin consumed in Europe traditionally comes from 
Morocco, but recent data show that that country’s relative 
importance as a supplier could be on the wane. Indeed, 
Afghanistan now appears to be one of the most important 
countries worldwide in terms of cannabis resin production.
The proliferation of indoor cannabis cultivation sites and 
differing trends in prices and seizures of cannabis herb and 
resin indicate that there may be a shift in the European 
cannabis market away from the dominance of resin towards 
herb, with most European Union member States reporting 
the cultivation of cannabis herb to be a phenomenon that 
appears to be on the increase.1 Though usually small-scale, 
indoor cultivation sites may also include major operations 
run by organized criminal groups who often choose to 
supply local markets in order to reduce the risks involved 
in cannabis trafficking.
Furthermore, the rise in indoor cultivation of cannabis is 
often related to an increase in cannabis potency, which is 
reflected in the data only to a limited extent. Such increases 
in potency may explain, in part at least, the increase in 
treatment demand among cannabis users, though this may 
also be related to the cumulative effects of prolonged use 
of cannabis. 
Beyond the traditional “highs”:  
new substances and the non-medical 
use of prescription pharmaceuticals 
Global figures for the non-medical use of prescription 
drugs other than opioids and amphetamines are not avail-
able. Nevertheless, this is reportedly a growing health prob-
lem, with prevalence rates higher than for numerous 
controlled substances in many countries. In the United 
States, for example, lifetime, annual and monthly preva-
lence of non-medical use of psychotherapeutics (mostly 
pain relievers) among persons aged 12 and over was 
reported as 20.4, 6.3 and 2.7 per cent, respectively, for 
1 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe (Luxembourg, 
Publications Office of the European Union, 2011).
2010,2 higher rates than for any drug other than cannabis. 
And while illicit drug use among males in general greatly 
exceeds that among females, the non-medical use of tran-
quillizers and sedatives among females, in those countries 
where data are available (in South America, Central Amer-
ica and Europe), is a notable exception to the rule (and 
exceeds the use of cannabis).3 There is also evidence that 
these substances are increasingly being used in combina-
tion with more traditional illicit substances, in polydrug 
use designed to either enhance or counterbalance their 
effects.
New chemically engineered psychotropic substances 
designed to remain outside international control are also 
increasingly being used and identified. Numerous coun-
tries in all regions, particularly Europe, North America 
and Oceania, reported the use of such substances as an 
emerging trend in 2010. The most notable of these sub-
stances included the methcathinone analogue 4-methyl-
methcathinone (also known as mephedrone), and 
methylenedioxypyrovalerone (MDPV), which are often 
sold as "bath salts" or "plant food" and used as substitutes 
for controlled stimulants such as cocaine or “ecstasy”. Simi-
larly, piperazine derivatives4 are also being sold as substi-
tutes for “ecstasy”, while several synthetic cannabinoids 
that emulate the effect of cannabis but contain uncon-
trolled products have been detected since 2008 in herbal 
smoking blends.
Drug trafficking organizations continue to adapt their 
manufacturing strategies in order to avoid detection, and 
such changes in the illicit manufacturing process of syn-
thetic substances present new challenges to drug control 
authorities worldwide. 
Data challenges
Considerable challenges also remain in the reporting of 
trend data on illicit drug use, production and trafficking. 
The main challenges continue to be the availability and 
reporting of data on different aspects of illicit drug demand 
and supply in Member States. The lack of data is particu-
larly acute in Africa and parts of Asia, where data on the 
prevalence of illicit drug use and trends remain vague at 
best. Other aspects such as prices and purity of drugs, sei-
zures and trafficking patterns and methodological difficul-
ties in estimating in some regions the illicit production of 
substances — particularly cannabis and ATS — make it 
difficult to analyse and present a complete picture of the 
2 United States of America, Department of Health and Human 
Services, Substance Abuse and Mental Health Services Admin-
istration, Results from the 2010 National Survey on Drug 
Use and Health: Summary of National Findings, NSDUH 
Series H-41, HHS Publication No. SMA 11-4658 (Rockville, Mary-
land, 2011).
3 In fact, monthly prevalence of tranquillizer use among females in 
South America (1.3 per cent) and Europe (4.2 per cent) is greater 
than annual prevalence of the use of cannabis among females in South 
America (1.0 per cent)  or Europe (3.5 per cent).
4 These include N-benzylpiperazine (BZP) and 3-trifluoromethyl-
phenyl piperazine.
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ever-evolving illicit drug market. Most of the challenges 
can be overcome by sustained efforts in priority regions 
and countries to support and improve the collection of 
quality data on these different aspects of illicit drug use. It 
is only then that the ebb and flow of the world’s illicit drug 
market can be properly measured.
CHAPTER II. THE CONTEMPORARY 
DRUG PROBLEM: CHARACTERIS-
TICS, PATTERNS AND DRIVING  
FACTORS
What are the fundamental character-
istics of the contemporary illicit drug 
problem
While psychoactive substances have been consumed for 
thousands of years, the drug problem has developed some 
key characteristics over the last few decades, against a back-
drop of rapid socioeconomic transitions in a number of 
countries. Illicit drug use is now characterized by a con-
centration among youth — notably young males living in 
urban environments — and an expanding range of psy-
choactive substances. Although established illicit drug mar-
kets in many developed countries have shown signs of 
stabilization, the growth of drug use seems to continue in 
many developing countries. 
While illicit drug production, trafficking and use remain 
issues of concern, the international drug control system 
appears to have kept the consumption of illegal drugs well 
below the levels reported for legal psychoactive substances. 
Global estimates suggest that past-month prevalence of 
tobacco use (25 per cent of the population aged 15 and 
above) is 10 times higher than past-month prevalence of 
illicit drug use (2.5 per cent). Annual prevalence of the use 
of alcohol is 42 per cent (the use of alcohol being legal in 
most countries), which is eight times higher than annual 
prevalence of illicit drug use (5.0 per cent). Heavy episodic 
weekly drinking is eight times more prevalent than prob-
lem drug use. Drug use accounts for 0.9 per cent of all 
disability-adjusted life years lost at the global level, or 10 
per cent of all life years lost as a result of the consumption 
of psychoactive substances (drugs, alcohol and tobacco).
Drug consumption levels would likely be higher without 
an age-containment effect at work. The international drug 
control system seems to be acting as a brake on drug use, 
particularly among adults who are less willing to transgress 
laws by consuming drugs. While the initiation of psycho-
active substance use typically occurs during the teens or 
early years of adulthood, the (legal) use of tobacco and 
alcohol continues in much larger proportions with age in 
the same population groups. The use of khat — which is 
legal in a number of countries — shows the same patterns. 
While the prevalence of khat use in Yemen among persons 
aged 61 and above is just 13 per cent lower than among 
those in the age group 21-30, the use of cannabis in the 
United States is some 93 per cent lower among those aged 
61 and above than among those aged 21-30. In other 
words, the use of legal psychoactive substances tends to be 
far more homogeneously distributed across age groups than 
the use of illegal drugs.
There is also a pronounced gender gap in relation to illicit 
drug consumption, with use levels among females 
significantly lower than among males in nearly all countries 
for which solid gender-disaggregated data are available. In 
the United States, characterized by a small gender gap, 
female drug use is about two thirds that of males, whereas 
in some other countries, including India and Indonesia, 
female drug use is as low as one tenth that of males, though 
there is a risk that female drug use may be underreported. 
There are some signs, however, that the gender gap may 
be diminishing in some highly mature illicit drug markets, 
particularly among young people. Nonetheless, the 
overrepresentation of males among drug users, which is 
confirmed by household surveys, workforce drug tests, 
treatment data, arrest statistics and other relevant 
information, is still a salient feature of drug use patterns.
What is the impact on society
One of the key impacts of illicit drug use on society is the 
negative health consequences experienced by its members. 
Drug use also puts a heavy financial burden on society. 
Expressed in monetary terms, some US$ 200 billion-250 
billion (0.3-0.4 per cent of global GDP) would be needed 
to cover all costs related to drug treatment worldwide. In 
reality, the actual amounts spent on treatment for drug 
abuse are far lower — and less than one in five persons 
who needs such treatment actually receives it. 
The impact of illicit drug use on a society’s productivity 
— in monetary terms — seems to be even larger. A study 
in the United States suggested that productivity losses were 
equivalent to 0.9 per cent of GDP, and studies in several 
other countries showed losses equivalent to 0.3-0.4 per 
cent of GDP.
The costs associated with drug-related crime are also sub-
stantial. In the United Kingdom of Great Britain and 
Northern Ireland, a study suggested that the costs associ-
ated with drug-related crime (fraud, burglary, robbery and 
shoplifting) in England and Wales were equivalent to 1.6 
per cent of GDP, or 90 per cent of all the economic and 
social costs related to drug abuse. 
How have the patterns of the drug  
problem shifted over time
While several of the overall characteristics have remained 
relatively constant over the last few decades, the patterns 
of illicit drug production, trafficking and use have, none-
theless, shifted significantly. 
The illicit market for opiates — the most problematic type 
of drugs — clearly declined over the last century. Licit and 
illicit production of opium (including in the form of poppy 
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straw) fell by some three quarters between 1906/07 and 
2010. The decline mainly took place in the first half of the 
twentieth century. Global opium production levels 
increased again until 2000, and remained basically stable 
thereafter. While consumption of opiates has stabilized or 
declined over the past decade in Western Europe (for a 
long time, the key market for heroin consumption), 
developments in other markets have been mixed. 
The global cocaine market, in contrast, has expanded since 
the late nineteenth century and has only recently been 
showing some signs of decline. Global production of 
cocaine increased sharply in the 1980s and the 1990s and 
has only stabilized over the past decade. In recent years, 
however, the amounts of cocaine available for consump-
tion — after deducting seizures made along the trafficking 
routes — appear to have declined. Cocaine consumption 
in North America, the region with the largest cocaine 
market, has declined significantly over the past decade, 
though that decrease has been partially offset by rising 
consumption in Europe and South America. 
Cannabis was and continues to be the world’s most wide-
spread illicit drug. While cannabis use is stable or declining 
in several developed countries, it is still increasing in many 
developing ones. Hydroponic cannabis cultivation, often 
indoors, is now common in many developed countries. 
The result has been a more potent drug as well as shorter 
supply lines and a reduced need for interregional 
trafficking.
Illicit manufacture and consumption of ATS continue to 
rise, in contrast with current overall trends for plant-based 
drugs. Global seizures of ATS increased some threefold 
over the period 1998-2010, far more than the increases for 
plant-based drugs. The strongest increases in demand over 
the past decade have been reported in countries in Asia.
The consumption of drugs is a dynamic phenomenon, 
with users trying different combinations of drugs, some-
times mixing of legal and illegal drugs, as well as various 
modes of consumption. Polydrug use, or the use of various 
substances either simultaneously or sequentially, is report-
edly increasing in many countries. While the most frequent 
substance combination is that of alcohol and various illegal 
drugs, combinations such as “speedball”, a mix of cocaine 
and heroin, are also common in many places. High levels 
of non-medical use of prescription drugs are reported in 
many countries. The non-medical use of opioids is espe-
cially problematic, with overdose deaths involving prescrip-
tion opioids having quadrupled since 1999 in the United 
States. 
Which factors shape the evolution  
of the problem
The evolution of the complex global illicit drug problem 
is clearly driven by a range of factors. Sociodemographic 
trends, such as the population’s gender and age balance 
and the rate of urbanization, are influential. If the demo-
graphic profile of a given society changes, drug use behav-
iour may also change accordingly. Socioeconomic factors, 
such as levels of disposable income, inequality and unem-
ployment, also play a role. Increased levels of disposable 
income may enable a larger number of people to buy illicit 
drugs, whereas high levels of inequality or unemployment 
may increase the propensity to use illicit drugs among those 
affected. A broad sociocultural category of drivers — 
including changes to traditional value systems and the 
emergence of a relatively uniform “youth culture” in many 
countries — also influences the evolution of the problem, 
though in ways that are often challenging to quantify. 
Analysis also shows that the availability of and perceptions 
of the inherent dangers of drugs are key variables in shap-
ing drug use. 
The international drug control system and its implemen-
tation have had a decisive influence on the evolution of 
the drug problem. A broad range of social and political 
events, generally unforeseeable and seemingly not con-
nected to drug-related issues, have also fundamentally 
altered the drug problem that the world is faced with today. 
Events such as the war in Viet Nam, as well as broader and 
more profound transformations, such as those taking place 
at the end of the cold war, all impacted indirectly but sig-
nificantly on the situation with regard to illicit drug use.
How is the drug problem likely to  
evolve in the future
One key development to monitor will be the ongoing shift 
away from developed to developing countries, which would 
mean a heavier burden for countries relatively less equipped 
to tackle it. Demographic trends suggest that the total 
number of drug users in developing countries would increase 
significantly, owing not only to those areas’ higher projected 
population growth, but also their younger populations and 
rapid rates of urbanization. Moreover, the gender gap may 
start closing as developing countries are likely to experience 
higher levels of female drug use in the wake of disappearing 
sociocultural barriers and increasing gender equality. 
In terms of specific substances, the prominence of heroin 
and cocaine in illicit drug markets may continue to decline. 
In contrast, there are no signs that the popularity of can-
nabis is going to decrease significantly. Cannabis is likely 
to remain the most widely used illegal substance, and the 
use of a broad range of licit and illicit synthetic drugs is 
likely to continue to increase. These forecasts hinge on the 
assumption that key factors will remain unchanged. This 
assumption may not necessarily hold, as a number of 
unforeseen and largely unforeseeable events and circum-
stances may still occur and influence the problem, as has 
repeatedly happened in the past. The further one looks into 
the future, the more unpredictable the evolution becomes. 
What can be said for sure is that Governments and socie-
ties will continue to face different policy choices when 
tackling drug-related and crime-related problems while 
securing international peace and development and uphold-
ing human rights.
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RECENT STATISTICS AND TREND ANALYSIS 
OF ILLICIT DRUG MARKETS
A. EXTENT OF ILLICIT DRUG USE 
AND HEALTH CONSEQUENCES
The global picture
Globally, it is estimated that in 2010 between 153 million 
and 300 million people aged 15-64 (3.4-6.6 per cent of 
the world’s population in that age group) had used an illicit 
substance at least once in the previous year. The extent of 
illicit drug use has thus remained stable, but the estimated 
15.5 million-38.6 million problem drug users (almost 12 
per cent of illicit drug users), including those with drug 
dependence and drug-use disorders, remain a particular 
concern. 
It is also estimated that there were between 99,000 and 
253,000 deaths globally in 2010 as a result of illicit drug 
use, with drug-related deaths accounting for between 0.5 
and 1.3 per cent of all-cause mortality among those aged 
15-64.1 Moreover, it was estimated that in 2008 there were 
16 million injecting drug users worldwide and that 3 mil-
lion (18.9 per cent) of them were living with HIV, though 
no new figures are available after 2008. Global prevalence 
of hepatitis C infection among injecting drug users in 2010 
was 46.7 per cent, meaning that some 7.4 million inject-
ing drug users worldwide are infected with hepatitis C. 
And some 2.3 million injecting drug users are infected 
with hepatitis B. Evidence is also emerging that non-inject-
ing drug use is also associated with an increased risk of 
HIV infection, principally due to unprotected sex. 
1 All-cause mortality among those aged 15-64 taken as 18.74 million 
(United Nations, Department of Economic and Social Affairs, Popula-
tion Division, World Population Prospects: The 2010 Revision. Avail-
able from http://esa.un.org/unpd/wpp).
With estimated annual prevalence of cannabis use in 2010 
ranging from 2.6 to 5 per cent of the adult population 
(between 119 million and 224 million estimated users aged 
15-64), cannabis remains the world’s most widely used 
illicit substance (see figure 1). There may be shifts in can-
nabis use between the drug’s two principal forms, resin and 
herb, and there is even evidence of the increasing popular-
ity of synthetic marijuana among young people in some 
regions, but in general annual prevalence of cannabis use 
remained stable in 2010.
In terms of prevalence, amphetamine-type stimulants 
(ATS) (excluding "ecstasy") remain second only to can-
nabis, with an estimated prevalence of 0.3-1.2 per cent in 
2010 (between 14.3 million and 52.5 million users). 
Increasing reports of methamphetamine seizures in South-
West Asia and in Central Asia and Transcaucasia, as well 
as the illicit manufacture of the substance in some areas, 
are also leading to speculation that its use may also be on 
the increase in those subregions. 
Global prevalence of opioid use in 2010 is estimated at 
0.6-0.8 per cent of the population aged 15-64 (between 
26.4 million and 36 million opioid users), of which nearly 
half, or between 13 million and 21 million, use opiates, 
particularly heroin. Experts in Asian and African countries 
perceive that heroin use has increased in their regions, 
whereas the latest available data suggest that it is declining 
or stable in Europe and the use of synthetic opioids appears 
to be on the increase in some European countries. 
Fig. 1. Annual prevalence of illicit drug use among the population aged 15-64, 2008-2010
Source: UNODC.
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Global cocaine use has remained stable at 0.3-0.4 per cent 
of the population aged 15-64 (between 13.2 million and 
19.5 million users) but there have also been some shifts in 
its use, with a substantial decrease in the prevalence of 
cocaine use in North America and in some countries in 
South America and indications of increases in Oceania, 
Asia, Africa and some countries in South America. 
Global use of “ecstasy”-group substances, estimated at 0.2-
0.6 per cent of the population aged 15-64 (between 10.5 
million and 28 million users), is at levels comparable to 
those of cocaine use. But while “ecstasy” use is on the 
decline in Oceania, where its prevalence remains high at 
2.9 per cent — essentially reflecting the situation in Aus-
tralia and New Zealand — there is evidence that there is a 
possible resurgence in “ecstasy” use in both Europe and the 
United States. 
In general, illicit drug use among males greatly exceeds that 
among females; however, a notable exception to the rule is 
the non-medical use of tranquillizers and sedatives. Current 
trends in countries for which data are available show that 
non-medical use of tranquillizers and sedatives is more prev-
alent among females than males and, frequently, the annual 
prevalence among females even exceeds that of cannabis. 
This can be observed in adult and youth populations.
The use of new psychoactive synthetic substances that 
mimic the effects of controlled substances and are chemi-
cally engineered to remain outside international control 
continues to evolve rapidly, with new substances being 
identified in the market. In 2010, many countries, par-
ticularly in Europe, North America and Oceania, reported 
the use of such substances as an emerging trend. It is one 
that requires close monitoring.
Cannabis
Cannabis remains the most widely used illicit substance 
globally, with an estimated annual prevalence in 2010 of 
2.6-5.0 per cent of the adult population (between 119 
million and 224 million users aged 15-64 years). Overall, 
annual prevalence of cannabis use remained stable in 2010 
(2.8-4.5 per cent of the adult population in 2009), the 
highest prevalence of cannabis use being reported in 
Oceania (essentially Australia and New Zealand) at 9.1-
14.6 per cent, followed by North America (10.8 per cent), 
Western and Central Europe (7.0 per cent) and West and 
Central Africa (5.2-13.5 per cent). While the prevalence 
of cannabis use in Asia (1.0 - 3.4 per cent) remains lower 
than the global average, due to Asia's large population the 
absolute number of users in Asia, estimated between 26 
million and 92 million, remains the highest worldwide.
In 2010, experts from many countries in West and Central 
Africa, Southern Africa, South Asia and Central Asia 
reported a perceived increase in cannabis use. Cannabis 
use has remained stable in North America (at an annual 
Map 1. Prevalence of cannabis use in 2010 (or latest year)
Source:UNODC estimates based on annual report questionnaire data and other official sources. 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the 
Republic of South Sudan has not yet been determined
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prevalence of 10.8 per cent), as well as in Oceania (at an 
annual prevalence of 9.1-14.6 per cent), while it has actu-
ally decreased in South America (from 2.9-3 per cent in 
2009 to 2.5 per cent in 2010). The latter essentially reflects 
revised estimates based on new data for the region.
Amphetamine-type stimulants  
(excluding "ecstasy")
ATS (excluding "ecstasy") have an estimated prevalence of 
0.3-1.2 per cent in 2010, or between 14 million and 52.5 
million estimated global users.  This group of drugs 
remains the second most widely used globally. Oceania, 
North America and Central America are the regions with 
a high prevalence of ATS use, but experts from countries 
in Asia, not only in East and South-East Asia but also in 
Central Asia and Transcaucasia, have reported an increase 
in ATS use. With reports of increasing seizures of meth-
amphetamine, it is speculated that the use of ATS is likely 
to increase in those regions.
Opioids
The estimated annual prevalence of opioids in 2010 was 
0.6-0.8 per cent of the population aged 15-64 (between 26 
million and 36 million opioid users), nearly half of whom 
used opiates, particularly heroin. The estimated annual 
prevalence of opiate use is between 0.3 and 0.5 per cent of 
the adult population (between 13 million and 21 million 
past-year users). North America (3.8-4.2 per cent), Oceania 
(2.3-3.4 per cent) and Eastern Europe and South-Eastern 
Europe (1.2 - 1.3 per cent) are the regions with a higher 
than global average prevalence of opioid users. It is impor-
tant to note, however, that in North America and Oceania 
prescription opioids are used more than heroin, whereas in 
Eastern Europe and South-Eastern Europe, opiates (heroin 
and, to a lesser extent, “kompot”2) are the main concern 
(prevalence of opiate use is estimated at 0.8 per cent). 
In 2010, an increase in heroin users was observed in South 
Asia and in East and South-East Asia in particular,3 but 
experts from many African countries also reported a per-
ceived increase in the use of heroin. In comparison with 
other regions, opiate use in Europe has been reported as 
showing a declining or stable trend, particularly in coun-
tries with substantial opiate use. Furthermore, reports from 
European countries such as Estonia and Finland suggest 
that the use of synthetic opioids, particularly fentanyl and 
buprenorphine, may have displaced heroin use, while in 
some parts of the Russian Federation reports suggest that 
2 A preparation made from boiled poppy straw and certain acids, typi-
callyontaining morphine, codeine, monoacetylmorphine and diacetyl-
morphine (heroin), which is usually injected.
3 The observed increase is the result of revised estimates of opiate users 
in Asia, mainly in Armenia, Azerbaijan and Georgia in Central Asia 
and Transcaucasia and in Indonesia, Singapore and Sri Lanka in South 
Asia and South-East Asia.
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Map 2. Prevalence of amphetamine-type stimulants (excluding "ecstasy") in 2010 (or latest year)
Source: UNODC estimates based on annual report questionnaire data and other official sources.
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the 
Republic of South Sudan has not yet been determined.
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Map 3. Prevalence of the use of opioids (heroin, opium and non-medical use of synthetic opioids) in 
2010 (or latest year)
Map 4. Prevalence of the use of opiates (heroin or opium) in 2010 (or latest years for which data are 
available)
Source (map 4 and 5): UNODC estimates based on annual report questionnaire data and other official sources. 
Note: The boundaries and names shown and the designations used on these maps do not imply official endorsement or acceptance by the United Nations. 
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the 
Republic of South Sudan has not yet been determined. 
Note: According to the Government of Canada, data on heroin use based on the household survey is not reportable and the Government of Canada does 
not report an estimate based on indirect methods.
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a heroin shortage has led many heroin users to use, as a 
substitute for heroin, desomorphine (also known as 
“krokodil”), acetylated opium or fentanyl.4 In terms of the 
harm to health that they cause, opioids, particularly heroin, 
are reported as the main type of drug that is injected and 
as a major cause of drug-related deaths.
Cocaine
In 2010, the regions with a high prevalence of cocaine use 
remained North America (1.6 per cent), Western and Cen-
tral Europe (1.3 per cent) and Oceania (1.5-1.9 per cent) 
— the latter effectively reflecting its use in Australia and 
New Zealand. While global estimates of cocaine use have 
remained stable at 0.3-0.4 per cent of the population aged 
15-64 (between 13 million and 19.5 million users), a sub-
stantial decrease was reported in North America and some 
countries in South America, with the annual prevalence of 
cocaine use in North America decreasing from 1.9 per cent 
in 2009 to 1.6 per cent in 2010. The overall average in 
South America decreased from 0.9 to 0.7 per cent in the 
same period, reflecting revised estimates in Argentina and 
a marked decline in Chile. There is a perceived increase in 
cocaine use in Brazil, but the lack of new data for that 
country prevents a better understanding of the impact on 
4 Information provided by the Russian Federation in the annual report 
questionnaire (2010).
regional estimates. On the other hand, there was an 
increase in cocaine use reported in Oceania, from an esti-
mated 1.4-1.7 per cent in 2009 to 1.5-1.9 per cent in 
2010, essentially reflecting the increase in cocaine use in 
Australia,5 whereas cocaine use remained stable in Western 
and Central Europe. 
North America and Western and Central Europe remain 
the two main regions in terms of their high numbers of 
cocaine users, with nearly one quarter of global estimated 
cocaine users in Western and Central Europe (4.2 million 
past-year cocaine users) and more than one third in North 
America (5 million past-year cocaine users). While there 
are limited data available on cocaine use in Africa and parts 
of Asia, there are indications of increasing or emerging 
cocaine use in those regions. For example, anecdotal infor-
mation on increasing cocaine trafficking through African 
coastal countries, as well as limited data on drug use from 
some countries, suggest an increase in cocaine use in those 
countries.
“Ecstasy” 
In 2010, the use of “ecstasy”-group substances — primar-
ily methylenedioxymethamphetamine (MDMA) and its 
5 The annual prevalence of cocaine use among persons 14 years of age 
and older increased from 1.6 per cent in 2007 to 2.1 per cent in 2010.
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Map 5. Prevalence of cocaine use in 2010 (or latest year)
Source: UNODC estimates based on annual report questionnaire data and other official sources. 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. 
Final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined. Dashed lines represent undetermined bound-
aries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and 
Kashmir has not yet been agreed upon by the parties. The final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been 
determined.
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analogues — was at levels comparable to those of cocaine 
use. Globally, the annual prevalence of “ecstasy” use is esti-
mated at 0.2-0.6 per cent of the population aged 15-64 
(between 10.5 million and 28 million users) but higher 
rates were reported in Oceania (2.9 per cent), North Amer-
ica (0.9 per cent) and Western and Central Europe (0.8 
per cent). The use of “ecstasy” is particularly high among 
young people. For example, in the United States, of the 
2.6 million past-year “ecstasy” users in 2010, nearly 2.5 
million were among those aged 14-34, while in Europe, 
of the estimated 2.5 million people who had used “ecstasy” 
in the past year, 2 million were estimated to be 15-34 years 
of age.6
While “ecstasy” use had previously been declining, it 
appears that it started to increase in 2010. In Europe, over-
all trends in “ecstasy” use have remained stable but recent 
reports indicate an increase in the purity of “ecstasy” avail-
able in Europe and a possible resurgence in its use. Euro-
pean studies suggest that patterns of “ecstasy” use are 
becoming increasingly divergent and show higher preva-
lence of “ecstasy” use among club goers in comparison with 
6 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Summary of 
National Findings.
such use among the general population.7, 8 In the United 
States, there are reports of a resurgence in “ecstasy” use 
among 12th grade students, in particular;9 however, there 
is a declining trend in the use of “ecstasy” in Australia (from 
3.5 per cent in 2007 to 3.0 per cent in 2010).
Non-medical use of prescription drugs
Although global figures are not available for the non-med-
ical use of prescription drugs other than opioids, the use 
of such drugs, including tranquillizers and sedatives (such 
as the benzodiazepine family, diazepam, flunitrazepam or 
temazepam; methaquolone and barbiturates) is reportedly 
a growing health problem, with the prevalence of these 
substances reported to be higher than those of several con-
trolled substances in some population groups and countries 
where data are available. 
7 Among the European countries for which data on the prevalence of 
“ecstasy” use in night-life settings are available, last-year reported use 
ranges between 10 per cent to 75 per cent (European Monitoring 
Centre for Drugs and Drug Addiction, Annual Report 2011: The State 
of the Drugs Problem in Europe).
8 Amphetamines and Ecstasy: 2011 Global ATS Assessment (United 
Nations publication, Sales No. E.11.XI.13).
9 Lloyd D. Johnston and others, Monitoring the Future: National Results 
on Adolescent Drug Use—Overview of Key Findings, 2011 (Ann Arbor, 
Michigan, University of Michigan, Institute for Social Research, 
2012).
Map 6. Prevalence of “ecstasy” use in 2010 (or latest year)
Source: UNODC estimates based on annual report questionnaire data and other official sources. 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the 
United Nations. Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The 
final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined.
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In the United States, for example, lifetime, annual and 
monthly prevalence of the non-medical use of psychothera-
peutics (principally pain relievers) for persons aged 12 and 
over was reported to be 20.4 per cent, 6.3 per cent and 2.7 
per cent, respectively, for 2010,10 which are higher rates 
than for any other drug type other than cannabis. There 
was also a statistically significant increase in the use of 
pharmaceuticals for non-medical purposes in Australia, 
with annual prevalence for persons aged 14 and over rising 
from 3.7 per cent in 2007 to 4.2 per cent in 2010.11
Illicit use of tranquillizers and sedatives: 
an alarming pattern among females
In general, illicit drug use among males greatly exceeds 
that among females. A notable exception to this rule, how-
ever, in countries where data are available, is the use of 
tranquillizers and sedatives among females (see figure 2).
A survey on drug use in Afghanistan, conducted in 2009 
by UNODC and the Ministry of Counter Narcotics in 
Afghanistan,12 found that more than 10 per cent of drug 
users interviewed had used tranquillizers without a medi-
cal prescription at some point in their lives. Female drug 
users were twice as likely to have used tranquillizers than 
10 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Summary of 
National Findings.
11 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report, Drug Statistics Series, No. 25 (Canberra, 
July 2011).
12 United Nations Office on Drugs and Crime, “Drug use in Afghani-
stan: 2009 survey—executive summary”, June 2010.
males and most of the women were daily users, but the 
same could be said of only half of the men who reported 
the use of tranquillizers. 
Furthermore, according to available data covering the 
period 2005-2010, in 8 countries in South America and 
Central America and 14 countries in Europe, lifetime, 
annual and last-month prevalence of the use of tranquil-
lizers and sedatives among females far exceeded that of 
males (see figure 3). In South America and Central Amer-
ica, for example, lifetime prevalence is 6.6 per cent for 
females and 3.8 per cent for males, while the correspond-
ing prevalence rates in Europe were 13.0 per cent for 
females and 7.9 per cent for males.13 In fact, the annual 
and past-month prevalence for tranquillizer and sedative 
use among females in all these regions had the highest 
prevalence among illicit drugs, exceeding even 
cannabis.14
The situation with regard to illicit drug use among young 
people in Europe is similar. Based on data from school 
surveys in Europe,15 lifetime prevalence of the use of tran-
quillizers and sedatives without a doctor’s prescription is 
much higher among females than among males (8 per cent 
versus 5 per cent in 2007), in contrast to all other drug 
types. The use of tranquillizers and sedatives among female 
students far exceeds that of any other illicit drug, with the 
exception of cannabis. Particularly high rates for lifetime 
prevalence are noted among young people in Poland (11 
per cent among males; 24 per cent among females), Lithu-
ania (9 per cent among males; 21 per cent among females) 
and France (12 per cent among males; 18 per cent among 
females).16
Elsewhere, a school survey conducted in 2009/10 in 
Morocco17 found that lifetime, annual and past-month 
prevalence of the use of psychotropic substances without 
a prescription exceeded that of cannabis among females 
aged 15-17, while among young males cannabis, cocaine 
and “crack” were the most widely used drugs. Similarly, 
there is an evident preference for psychotropic drugs 
among females 15-16 years old in Algeria, which exceeds 
not only cannabis use but also alcohol and tobacco use.18
13 Similar differences exist for annual and past-month prevalence: in 
South America, annual and past-month prevalence of the use of tran-
quillizers and sedatives is 2.6 and 1.3 per cent among females and 1.7 
and 0.8 per cent among males; in Europe the corresponding prevalence 
rates are 5.8 and 4.2 per cent among females and 3.4 and 2.5 per cent 
among males.
14 Monthly prevalence of tranquillizer use among females in South 
America (1.3 per cent) and Europe (4.2 per cent) is greater than the 
corresponding annual prevalence of use of cannabis in South America 
(1.0 per cent) and Europe (3.5 per cent).
15 B. Hibell and others, The 2007 ESPAD Report: Substance Use among 
Students in 35 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and Other Drugs, 2009).
16 Ibid.
17 Council of Europe, Pompidou Group, MedNET Network, “Drug use 
in Moroccan schools: MedSPAD 2009-2010 report”, document PG/
Med (2011) 17, June 2011.
18 First results of the Mediterranean School Survey Project on Alcohol 
Fig. 2. Lifetime, annual and past-month preva-
lence of drug use by gender among 
adults, and lifetime prevalence among 
young people in Europe
Source: UNODC, data from the annual report questionnaire for 
adult prevalence; European School Survey Project on Alcohol and 
Other Drugs 2007 data (weighted by population) for lifetime use 
by young people.
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Once started, tranquillizer use is more 
likely to be maintained
In general, in the normal life cycle of drug use, there is a 
sharp decline in lifetime, annual and past-month preva-
lence of illicit drug use with increasing age, indicating that 
most people tend to stop using drugs as adults and that 
relatively few people who have used an illicit substance 
once progress to frequent or regular (i.e. monthly) use. 
However, data on the non-medical use of tranquillizers 
and sedatives in European countries, for example, suggest 
that the rate of attrition for such use is much lower than 
that of illicit drugs, particularly among females. Indeed, 
more than one third of females who have tried tranquil-
lizers and sedatives once (lifetime users) become regular 
(monthly) users, whereas in general less than 10 per cent 
and Other Drugs (MedSPAD) Algerian survey, December 2006.
of female lifetime users develop into regular (monthly) 
users of other drugs.
New psychoactive substances
New synthetic psychoactive substances that are chemically 
engineered to remain outside international control are 
being increasingly used, identified and reported. In 2010, 
many countries in all regions, particularly Europe, North 
America and Oceania, reported the use of such substances 
as an emerging trend. The most notable of these substances 
included the methcathinone analogue 4-methyl-meth-
cathinone (also known as mephedrone) and methylenedi-
oxypyrovalerone (MDPV), which are often sold as bath 
salts or plant food and used as substitutes for controlled 
stimulants such as amphetamines or “ecstasy”. Similarly, 
piperazine derivatives19 continue to be sold as substitutes 
for “ecstasy”, while several synthetic cannabinoids that 
emulate the effect of cannabis but contain products not 
under international control have also been detected since 
2008 in herbal smoking blends sold under brand names 
such as Spice. 
Other uncontrolled synthetic substances that are also being 
used to substitute or mimic the effects of controlled drugs 
have been reported. These substances include indanes, ben-
zodifuranyls, narcotic analgesics (such as codeine for con-
version into “krokodil” (desomorphine) in the Russian 
Federation), synthetic cocaine derivatives, Salvia divinorum 
(reported in Canada), ketamine (commonly reported in 
South-East Asia) and phencyclidine derivatives.  “Krokodil” 
represents a crude desomorphine preparation, made from 
codeine using easily obtainable chemicals such as hydro-
chloric acid, iodine and red phosphorus. The pure com-
pound has a potency some 10 times that of morphine; 
however, the process involved in making “krokodil” leads 
19 These include N-benzylpiperazine (BZP) and 1-3-trifluorometh-
ylphenylpiperazine.
Fig. 3. Regional population-weighted prevalence of the use of tranquillizers and sedatives and the 
use of cannabis, by gender, in South America and Europe, 2005-2010
Source: UNODC, data from the annual report questionnaire.
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to high concentrations of chemicals such as hydrochloric 
acid, iodine, phosphorous and heavy metals, which results 
in skin damage at the point of injection, disorders of the 
endocrine, nervous and muscular systems and inflamma-
tion of the liver and kidneys. 
The leaves of Salvia divinorum, a plant native to Mexico, 
produce hallucinogenic effects upon ingestion or smoking 
due to the active constituent salvinorin A. Salvia divinorum 
products include the dried leaves, extracts/tinctures and 
pre-rolled “joints”. “Kratom”, a product derived from 
Mitragyna speciosa Korth., a South-East Asian tree, has 
been used for centuries to treat opioid withdrawal. 
“Kratom” has dose-dependent effects, producing stimula-
tion at low doses and predominantly opioid-like effects at 
higher doses. Its use is most prevalent in Malaysia, Myan-
mar and the southern part of Thailand,20 but online sur-
veys conducted by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) show that 
“kratom” is one of the new psychoactive products that are 
most widely offered on the Internet.
Health consequences of  
illicit drug use
Problem and injecting drug users  
have remained stable
UNODC estimates that the number of problem drug 
users21 in 2010 was between 15.5 million and 38.6 mil-
lion, or about 10-13 per cent of the global estimate of all 
drug users, while in 2008, according to the Reference 
Group to the United Nations on HIV and Injecting Drug 
Use, there were an estimated 16 million people who 
injected drugs. Both of these estimates have remained 
essentially stable. 
Infectious diseases among  
injecting drug users
Injecting drugs carries a high risk of infection with blood-
borne viruses such as HIV, hepatitis C and hepatitis B, and 
the sharing of contaminated needles and syringes is an 
important mode of transmission for those viruses, which 
pose a major public health concern, incur considerable 
costs to health-care services and often lead to premature 
death.
Of the estimated 16 million people who inject drugs, about 
3 million are living with HIV. With the exception of sub-
Saharan Africa, injecting drug use accounted for approxi-
mately one third of all new HIV infections reported 
globally in 2010.22 The region with the highest HIV preva-
20 More than 2 tons of “kratom” were seized in Malaysia in 2010. In 
Thailand, 28 tons of “kratom” leaves were seized in 2010, the largest 
total amount of “kratom” seized during the past five years.
21 Those who regularly use opiates, cocaine and amphetamines, are 
injecting drugs or are diagnosed with dependence or substance use 
disorders.
22 UNAIDS World AIDS Day Report 2011 (Geneva, Joint United Nations 
lence among injecting drug users is Latin America (29 per 
cent), followed by Eastern Europe (27 per cent) and East 
and South-East Asia (17 per cent), according to the Refer-
ence Group to the United Nations on HIV and Injecting 
Drug Use. While the use of contaminated needles and 
syringes has long been the major cause of HIV infections 
among drug users, several studies have also indicated that 
the administration of cocaine, “crack” cocaine and ATS by 
means other than injection is associated with an increased 
risk of HIV infections23 as a result of unprotected sex.
UNODC also estimates that global prevalence of hepatitis 
C infection among injecting drug users in 2010 was 46.7 
per cent, or some 7.4 million injecting drug users infected 
with hepatitis C worldwide (based on data extrapolated 
from 54 countries), while global prevalence of hepatitis B 
infection was estimated at 14.6 per cent, or some 2.3 mil-
lion injecting drug users infected with hepatitis B (based 
on data extrapolated from 46 countries). Most of the infor-
mation compiled by UNODC regarding viral hepatitis 
relates to European countries where the rate of hepatitis C 
infection among injecting drug users is high in comparison 
with the global average. However, a prevalence rate in 
excess of 80 per cent is noted in Estonia, Sweden and Lux-
embourg, while Europe also reports a high hepatitis B 
infection rate among injecting drug users by global stand-
ards, with particularly high rates, in excess of 70 per cent, 
noted in Estonia, Lithuania and the former Yugoslav 
Republic of Macedonia. A high reported estimate of hepa-
titis B and hepatitis C infections among injecting drug 
users in Europe is partly attributable to better coverage and 
monitoring of infections in Europe compared with other 
regions where injecting drug use is also a common 
practice.
Treatment demand
It is estimated that 20 per cent of problem drug users in 
2010 received treatment for their drug dependence. Opi-
oids (largely heroin) continue to be the dominant drug 
type accounting for treatment demand in Asia and Europe 
(particularly in Eastern Europe and South-Eastern Europe, 
where they account for almost four out of every five drug 
users in treatment). Opioids also contribute considerably 
to demand for treatment in Africa, North America and 
Oceania. Only in South America is demand for treatment 
for opioid use negligible (accounting for 1 per cent of all 
demand for treatment for drug dependence in the region).
Cannabis, the most widely consumed illicit drug world-
wide, is considered to be the least harmful of the illicit 
drugs. Yet it is the dominant drug accounting for treatment 
demand in Africa, North America and Oceania, a major 
contributor to treatment demand in South America and 
the second most important contributor to such treatment 
in Europe. 
Programme on HIV/AIDS, 2011).
23 G. Colfax and others, “Amphetamine-group substances and HIV”, The 
Lancet, vol. 376, No. 9739 (7 August 2010).
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and care of female drug users and the stigma associated 
with being a female drug user can make accessibility to 
treatment even more difficult. In Afghanistan, for instance, 
10 per cent of all estimated drug users have access to treat-
ment services,26 whereas only 4 per cent of female drug 
users and their partners have access to treatment services 
and interventions.
Drug-related deaths
Deaths resulting from illicit drugs use, most of which are 
premature and preventable, are clearly the most extreme 
manifestation of the harm that can result from the illicit 
use of drugs. Definitions and methods of recording drug-
related deaths vary by country but comprise some or all of 
the following: unintentional overdose; suicide; HIV and 
AIDS acquired through the sharing of contaminated drug 
paraphernalia; and trauma (such as motor vehicle accidents 
caused by driving under the influence of illicit drugs).27
Globally, UNODC estimates that there were between 
99,000 and 253,000 deaths in 2010 as a result of illicit 
drug use, or between 22.0 and 55.9 deaths per million 
population aged 15-64 (see table 1). This is based on the 
reporting of numbers of drug-related deaths covering a 
substantial percentage of the population aged 15-64 in 
North America (100 per cent), Europe (100 per cent), 
South America (71 per cent) and Oceania (62 per cent), 
and to a much lesser extent in Asia (8 per cent) and Africa 
(less than 1 per cent). Indeed, data reported to UNODC 
by countries in Africa represented such a small percentage 
of the population that an alternative source of estimates 
for aggregated drug-related deaths has been used in those 
countries.28 The UNODC estimate of drug-related deaths 
is consistent with previously published estimates prepared 
by the World Health Organization (WHO), the latest of 
which refers to 2004 when the number of drug-related 
deaths from illicit drug use worldwide was estimated at 
245,000,29 a total that includes AIDS-related deaths and 
deaths caused by hepatitis B and hepatitis C resulting from 
illicit drug use, whereas UNODC estimates are based on 
country reports that, for the most part, report only deaths 
caused by drug overdose and trauma related to drug abuse.
26  United Nations Office on Drugs and Crime, “Drug use in Afghani-
stan: 2009 survey—executive summary”.
27 According to the International Statistical Classification of Diseases and 
Related Health Problems, tenth revision, drug-related deaths may be 
recorded under external causes of morbidity and mortality that may 
include accidents (V01-V99); differential behavioural disorders caused 
by use of psychoactive substances (F11, F12, F14-16, and F19). Other 
external causes of accidental injury (X40-X49): especially accidental 
poisoning by and exposure to noxious substances, intentional self-
harm (X60 to X84) and intentional self poisoning by and exposure to 
different psychoactive substances.
28 Louisa Degenhardt and others, “Illicit drug use”, in Comparative 
Quantification of Health Risks: Global and Regional Burden of Disease 
Attributable to Selected Major Risk Factors, vol. 1, Majid Ezaati and 
others, eds. (Geneva, World Health Organization, 2004).
29  World Health Organization, Global Health Risks: Mortality and 
Burden of Disease Attributable to Selected Major Risks (Geneva, 2009).
Treatment for cocaine use is largely associated with the 
Americas, particularly South America, where it accounts 
for nearly half of all treatment for illicit drug use, whereas 
in Asia, Eastern Europe, South-Eastern Europe and Oce-
ania, the share of demand for treatment for drug use 
accounted for by cocaine use is negligible (less than 1 per 
cent).
Demand for treatment for the use of ATS (mostly meth-
amphetamine), is most noticeable in Asia where such drugs 
are the second major contributor to treatment demand, 
and to a lesser extent in Oceania, Western and Central 
Europe and North America.
Females are underrepresented  
in treatment
To be equally represented in treatment, the ratio of males 
to females in treatment should be similar to the ratio of 
males to females in problem drug use. Using past-month 
prevalence as a proxy for problematic use,24 gender-disag-
gregated data from EMCDDA on past-month prevalence 
and outpatient clients in treatment suggest that in most 
countries in Europe females could be underrepresented in 
treatment for the problematic use of cannabis, cocaine and 
amphetamines (see figure 5). There are few studies that 
analyse gender differences in the accessibility of treatment 
services; however, the ratio of males and females reported 
in treatment in Europe was 4:1 — higher than the ratio 
between male and female drug users.25 In many develop-
ing countries, there are limited services for the treatment 
24 However, this does not reflect the frequency of use or the amounts of 
drugs consumed and that will no doubt have an impact on the need 
to seek treatment.
25 European Monitoring Centre for Drugs and Drug Addiction, “A 
gender perspective on drug use and responding to drug problems”, 
Annual Report 2006: Selected Issues, No. 2 (Luxembourg, Publica-
tions Office of the European Union, 2006).
Fig. 5. Ratio of male to female past-month 
prevalence against outpatient treat-
ment in Europe
Source: European Monitoring Centre for Drugs and Drug  
Addiction. 
Note: Prevalence is based on the most recent national general population 
survey available since 2000 and outpatient treatment is for 2009 or the 
most recent year available.
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The estimated number of drug-related deaths and mortal-
ity rates for 2010 reported here should be seen as a refine-
ment of the estimates given in the previous World Drug 
Report and not necessarily as a result of changes in the 
number of drug-related deaths that actually occurred from 
the previous year. Where ranges are presented, they reflect 
uncertainty in the level of drug-related deaths from coun-
tries within the region where no mortality data were avail-
able. Thus, a large range is presented for Asia as only 8 per 
cent of its population is covered.
Drug-related deaths account for between 0.5 per cent and 
1.3 per cent of all-cause mortality at the global level among 
persons aged 15-64,30 but they vary considerably by 
region. Accounting for approximately 1 in every 20 deaths 
among persons aged 15-64, drug-related deaths are high-
est in North America and Oceania. In Asia, they account 
for approximately 1 in 100 deaths, in Europe 1 in 110, in 
Africa 1 in 150 and in South America approximately 1 in 
every 200 deaths. There is a higher rate of drug-related 
deaths in North America and Oceania because those 
regions have a higher number of problem drug users and 
better monitoring and reporting of drug-related deaths; in 
contrast, in Asia and Africa there is limited capacity, and 
the monitoring of drug-related deaths is an infrequent 
practice.
Regional trends in illicit drug use
Africa
Notwithstanding the fact that recent data on illicit drug 
use in Africa are limited, the most commonly used drug 
in the region continues to be cannabis, followed by ATS. 
Annual prevalence of cannabis use in Africa, particularly 
West and Central Africa, is much higher than the global 
30 All-cause mortality among persons in the age group 15-64 is taken as 
18.74 million. (United Nations, Department of Economic and Social 
Affairs, Population Division, World Population Prospects: The 2010 
Revision.) 
average (5.2-13.5 per cent of the population aged 15-64). 
The estimated prevalence of the use of ATS and opioids 
in all African subregions remains comparable to the global 
average; however, cocaine use is reportedly high in West 
and Central Africa and Southern Africa.
It is speculated that increasing trafficking of cocaine 
through the coastal countries of West Africa is leading to 
an increase in cocaine use in that part of Africa.31 A survey 
conducted among secondary school students and street 
children in Liberia and Sierra Leone shows that cocaine is 
being used more often than heroin (see table 2). Other 
substances that were used by children and youth surveyed 
in Sierra Leone, included benzodiazepines such as diaze-
pam, chlorpromazine and different inhalants, while 3.7 
per cent were injecting drugs.
31 Given the forensic capacity in some African States to properly identify 
substances, it is debatable whether the actual chemical composition of 
the substance referred to is actually cocaine. The same applies to the 
other synthetic substances being reported.
Table 1. Estimated number of drug-related deaths and rates per million population  
aged 15-64
Source: UNODC, data from the annual report questionnaire; Inter-American Drug Abuse Control Commission; European Monitoring 
Centre for Drugs and Drug Addiction; Louisa Degenhardt and others, “Illicit drug use”, in Comparative Quantification of Health Risks: 
Global and Regional Burden of Disease Attributable to Selected Major Risk Factors, vol. 1, Majid Ezaati and others, eds. (Geneva, World 
Health Organization, 2004). 
Note: Data for South America include data from Central America and the Caribbean. Data for Oceania are based on data from Australia only and therefore 
no range is given.
Region
Number of all drug 
users (thousands)
Prevalence 
 (percentage)
Number of  
drug-related deaths
Mortality rate per  
million aged 15-64
Africa 22,000-72,000 3.8-12.5 13,000-41,700 22.9-73.5
North America 45,000-46,000 14.7-15.1 44,800 147.3
South America 10,000-13,000 3.2-4.2 3,800-9,700 12.2-31.1
Asia 38,000-127,000 1.4-4.6 14,900-133,700 5.4-48.6
Europe 36,000-37,000 6.4-6.8 19,900 35.8
Oceania 3,000-5,000 12.3-20.1 3,000 123.0
Global 153,000-300,000 3.4-6.6 99,000-253,000 22.0-55.9
Table 2. Percentage of young people currently 
using drugs in Liberia and Sierra 
Leone, based on studies with limited 
geographical coverage
Source: Campaign for Development and Solidarity (FORUT), “Sum-
mary of baseline surveys on alcohol, drugs, cigarettes and devel-
opment in Freetown” (Sierra Leone, 2011) (The school survey 
included 1,245 secondary school students); GOAL, “European 
Union substance use harm reduction programme: summary of 
results from main survey” (Sierra Leone, 2011) (Benjamin L. Harris 
and others, “Substance use behaviors of secondary school  
students in post-conflict Liberia: a pilot study”, International Jour-
nal of Culture and Mental Health, 2011, pp. 1-12.)
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In Africa, the increasing use of heroin and drug injecting 
is also emerging as an alarming trend, particularly in 
Kenya, Libya, Mauritius, Seychelles and the United Repub-
lic of Tanzania.32,33 In sub-Saharan Africa, 1.78 million 
drug users (range: 534,500-3,022,500) are estimated to be 
injecting drug users, and an estimated 221,000 injecting 
drug users (range: 26,000-572,000) are living with HIV.34 
In 2010, 7 out of 54 African States provided information 
to UNODC, and most of them reported an increasing 
trend in the use of cannabis and opioids (notably, Nigeria, 
Mozambique, South Africa (cannabis only) and Swaziland) 
but rather stable trends in the use of cocaine and ATS. 
Overall, experts from African States who reported to 
UNODC perceived a substantial increase in the use of all 
illicit drugs after 2005.
There are also indications that the use of ATS is spreading 
to other areas of Africa and has been reported in several 
countries, including Cape Verde, Egypt, Ghana, Nigeria 
and Kenya. Lifetime prevalence of the use of amphetamines 
and Mandrax (methaqualone) in secondary schools in Nai-
robi was reported to be 2.6 per cent, with 1.6 per cent of 
pupils reporting use of those drugs within the past 6 
months. The use of Miraa (a local variant of khat) was also 
quite high among those pupils: 31.5 per cent had used it 
in their lifetime and 15.7 per cent had used it in the pre
vious 6 months,35 which comes close to the average for 
amphetamine use among young people in Europe.
32 Chris Beyrer and others, “Time to act: a call for comprehensive 
responses to HIV in people who use drugs”, The Lancet, vol. 376, No. 
9740 (14 August 2010), pp. 551-563.
33 Reference Group to the United Nations on HIV and Injecting Drug 
Use (2011 estimates). 
34 Ibid.
35 Peter Koome and National Campaign against Drug Abuse Author-
ity, “Role of school environment in alcohol and drug abuse among 
students: evidence from public secondary school students in Nairobi”, 
in Promotion of Evidence-Based Campaign: National Alcohol and Drug 
Abuse Research Workshop—2011 Report  (National Campaign against 
Drug Abuse Authority, March 2011), pp. 28-30.
Cannabis and opioids are the two main substances con-
tributing to demand for treatment for illicit drug use in 
Africa, with 64 per cent of all treatment for drug use 
reportedly provided for disorders related to cannabis use.
The Americas
The Americas remain major consumers of illicit drugs. 
Annual prevalence of the use of cannabis (6.6-6.9 per cent), 
opioids (2.0-2.3 per cent), cocaine (1.1-1.2 per cent), ATS 
(0.9-1.1 per cent) and “ecstasy”-group substances (0.5-0.6 
per cent) all remain higher than the global average. In con-
trast to most other regions, in the Americas, prescription 
opioids are more commonly used than heroin.
In North America, the non-medical use of prescription 
drugs, especially pain relievers (narcotic analgesics) and 
stimulants, remains a major problem. While it is still a 
major cocaine market, North America recorded a decline 
in cocaine use, from an estimated annual prevalence of 1.9 
per cent in 2009 to 1.6 per cent in 2010.
In the United States, annual prevalence of cannabis use 
among the general population (persons 15-64 years of age) 
continued to increase in 2010 (to 14.1 per cent, compared 
with 13.7 per cent in 2009).36,37 Similarly, as reported in 
a recent school survey, there was a continued increase in 
the annual prevalence of cannabis use among teenagers: 
the combined annual prevalence of cannabis use among 
high school students was reported to be 25 per cent in 
36 The increase in cannabis use, however, is not statistically significant.
37 World Drug Report 2011 (United Nations publication, Sales No. E.11.
XI.10); Substance Abuse and Mental Health Services Administration, 
Results from the 2010 National Survey on Drug Use and Health: Sum-
mary of National Findings.
Fig. 6. Cumulative unweighted average of 
perceived trends in drug use in Africa, 
by drug type
Source: UNODC, data from the annual report questionnaire.
Fig. 7. Annual prevalence of illicit drug use 
among the population aged 12 and 
over in the United States, 2007-2010
(Percentage)
Source: United States of America, Department of Health and 
Human Services, Substance Abuse and Mental Health Services 
Administration, Results from the 2010 National Survey on Drug 
Use and Health: Detailed Tables (Rockville, Maryland, September 
2011).
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2011, compared with 24.5 per cent in 2010.38 Also, annual 
prevalence of the use of synthetic marijuana among school-
children was measured for the first time in 2011 and 
reported as 11.4 per cent.39,40
Having been reported as increasing in 2009, “ecstasy” use 
among the general population was stable in 2010, but its 
use among young people is considered to be on the way 
up again. Annual prevalence of “ecstasy” use among 8th 
and 10th grade pupils increased significantly from 2009 
to 2010 (from 1.3 to 2.4 per cent and from 3.7 per cent 
to 4.7 per cent, respectively) but declined in 2011 (to 1.7 
per cent and 4.5 per cent, respectively), while “ecstasy” use 
among 12th grade students increased in 2011 (to 5.3 per 
cent, compared with 4.5 per cent in 2010).41 
The estimates of past-year non-medical users of psycho-
therapeutic drugs, including prescription opioids, tranquil-
lizers and stimulants, as well as cocaine, remained stable 
in 2010. Annual prevalence of the use of psychotherapeutic 
drugs among the population aged 12 and over was 6.3 per 
cent in 2010 (4.8 per cent for prescription opioids, 2.2 per 
cent for tranquillizers and 1.1 per cent for stimulants), 
while for cocaine use it was 1.8 per cent.42 
38 The increase in cannabis use has been attributed to the falling per-
ceived risk of cannabis use, which has been declining for the past five 
years.
39 The Drug Enforcement Administration (DEA) scheduled synthetic 
marijuana in March 2011 making its possession and sale no longer 
legal. The authors (Johnson and others, Monitoring the Future: 
National Results on Adolescent Drug Use) report that the next year’s 
survey results should reflect any effects of scheduling by DEA.
40 Johnston and others, Monitoring the Future: National Results on 
Adolescent Drug Use.
41 Ibid.
42 United States of America, Department of Health and Human Services, 
Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables 
(Rockville, Maryland, September 2011).
Drugs that showed evidence of decline among high school 
students in the reporting year include inhalants, cocaine 
and “crack”, hydrocodone (a narcotic analgesic), prescrip-
tion stimulants, sedatives, tranquillizers and over-the-coun-
ter cough and cold medicines used for the purpose of 
“getting high”.43
In Canada, Salvia divinorum, a naturally occurring psy-
choactive plant not under international control, emerged 
as a substance of concern in 2009. In 2010, an estimated 
1.6 per cent of Canadians aged 15 years and over had used 
salvia in their lifetime and 0.3 per cent reported having 
used it in the past year. However, its use seems to be more 
popular among young people, with 6.6 per cent of persons 
in the age group 15-24 reporting lifetime use and statisti-
cally significantly higher rates of past-year use (0.6 per 
cent) than reported by adults.44 Trends in the use of most 
other drugs in Canada were reported as stable, while there 
was a further decline reported in past-year “ecstasy” use 
(from 0.9 per cent in 2009 to 0.7 per cent in 2010).45 
North America reported a large number of deaths from 
illicit drug use in 2010: an estimated 44,800 deaths, or 
(conservatively estimated) one in five of the global total. 
The number of deaths attributed to the non-medical use 
of prescription painkillers in the United States has risen 
steadily to a level that now exceeds the combined number 
of deaths due to heroin use (5,100 deaths) and cocaine use 
(3,000 deaths).46 As reported by the United States Centers 
for Disease Control and Prevention, “poisoning is the lead-
ing cause of death from injuries — higher than from motor 
vehicle traffic — with nearly 9 out of 10 poisoning deaths 
caused by drugs”.47
South America, Central America and  
the Caribbean
The prevalence of cocaine use in South America, Central 
America and the Caribbean remains high (0.7 per cent, 
0.5 per cent and 0.7 per cent, respectively). In Central 
America, annual prevalence of ATS use has been reported 
to be higher than the global average, particularly in El Sal-
vador (3.3 per cent), Belize (1.3 per cent), Costa Rica (1.3 
per cent) and Panama (1.2 per cent). The misuse of phar-
maceutical preparations containing opioids, stimulants and 
prescription stimulants also remains of concern in Central 
America and South America. 
43 Johnston and others, Monitoring the Future: National Results on Adoles-
cent Drug Use.
44 Canada, Health Canada, “Canadian Alcohol and Drug Use Monitor-
ing Survey: summary of results for 2010” (Ottawa, 2010).
45 Information provided by Canada in the annual report questionnaire 
(2009, 2010); Health Canada, “Canadian Alcohol and Drug Use 
Monitoring Survey”.
46 Margaret Warner and others, “Drug poisoning deaths in the United 
States, 1980-2008”, NCHS Data Brief, No. 81, December 2011.
47 “Vital signs: overdoses of prescription opioid pain relievers-United 
States, 1999-2008”, Morbidity and Mortality Weekly Report, vol. 60, 
No. 43 (4 November 2011), pp. 1487-1492.
Fig. 8.  Opioid analgesics involved in deaths 
from drug poisoning in the United 
States, 1999-2008
Source: Margaret Warner and others, “Drug poisoning deaths in 
the United States, 1980-2008”, NCHS Data Brief, No. 81, Decem-
ber 2011.
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Concern over rising levels of the use of synthetic drugs 
such as “ecstasy” among South American youth also con-
tinues to grow, with prevalence of the use of stimulants 
(cocaine, amphetamine and “ecstasy”) among young people 
reported to be high, particularly in Argentina, Chile, 
Colombia and Uruguay (see table 3).
Several countries in South America, such as Argentina, El 
Salvador, Peru and Uruguay, have also reported the use of 
ketamine. Lifetime prevalence of ketamine use in Argen-
tina and Uruguay is reported to be 0.3 per cent; however, 
many studies of drug use among the general population 
in the region do not include the use of ATS.48 According 
to information reported in Argentina and Chile in 2010, 
most drug use remained stable in Argentina, while in Chile 
there were declining trends in cocaine and cannabis use 
(see figure 9). In the Bolivarian Republic of Venezuela, 
data for 2011 show prevalence of cocaine use among the 
adult population to be 0.7 per cent, a small increase from 
the previous estimate of 0.6 per cent, while the prevalence 
of cannabis use is 1.7 per cent (an increase from the previ-
ous estimate of 0.9 per cent), opioid use is 0.03 per cent 
and ATS use is 0.5 per cent.49 While there are no recent 
data on illicit drug use in Brazil, experts perceived an 
increase in cocaine use in 2010.
In South America, the rate of drug-related deaths is esti-
mated to be between 12.2 and 31.1 deaths per million 
population aged 15-64, well below the global average. 
Throughout the region, cocaine continues to be ranked 
the most lethal drug; however, it appears that in some 
countries in Central America and the Caribbean, higher 
48 For instance, the 2008 subregional collaborative study on drug use 
among the general population reports only the use of alcohol, tobacco, 
cannabis, and cocaine (United Nations Office on Drugs and Crime 
and Inter-American Drug Abuse Control Commission (CICAD), 
Elementos Orientadores para las Políticas Públicas sobre Drogas en la Sub-
región: Primer Estudio Comparativo sobre Consumo de Drogas y Factores 
Asociados en Población de 15 a 64 Años (Lima, April 2008)).
49 Bolivarian Republic of Venezuela, Oficina Nacional Antidrogas and 
Observatorio Venezolano de Drogas “Estudio Nacional de Drogas en 
Población General 2011”.
homicide rates are, in part, linked to organized crime and 
conflicts related to cocaine trafficking flows and cocaine 
markets.50 
Asia
Apart from cannabis, the use of opioids (especially heroin) 
and ATS are of primary concern in Asia. Annual prevalence 
of the use of opiates (heroin and opium) in Asia is com-
parable to the global average. While experts in most coun-
50 United Nations Office on Drugs and Crime, 2011 Global Study on 
Homicide: Trends, Contexts, Data (2011).
Fig. 9. Annual prevalence of drug use  
in Argentina and Chile 
 
Source: Argentina, Secretaría de Programación para la Prevención 
de la Drogadicción y Lucha contra el Narcotráfico (SEDRONAR), 
Tendencia en el Consumo de Sustancias Psicoactivas en Argentina 
2004-2010: Población de 16 a 65 Años (June 2011); Chile, Con-
sejo Nacional para el Control de Estupefacientes (CONACE), 
Noveno Estudio Nacional de Drogas en Población General de 
Chile, 2010: Principales Resultados (2010).
Table 3. Annual prevalence of the use of 
stimulants among young people in 
selected South American countries
Source: UNODC, data from the annual report questionnaire 
(2010).
Stimulant Age 
group
Year of 
estimate“Ecstasy” Cocaine ATS
Argentina 2.0 2.9 2.0 15-16 2009
Chile 1.6 4.9 1.9 15-16 2009
Colombia 2.8 1.7 3.2 12-17 2005
Uruguay - 2.6 1.2 13-17 2009
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tries in Asia consider the use of cannabis and ATS to be 
increasing overall, the use of opioids and “ecstasy” is per-
ceived to be stable. In the Near and Middle East, the 
increased use of synthetic and prescription drugs has also 
been reported in a number of countries and territories. 
Ketamine use was perceived to have increased in 2010 in 
China (including Hong Kong, China), Malaysia and Viet 
Nam.
Experts in many countries in Central Asia and South-West 
Asia, such as Georgia, Kazakhstan, Tajikistan and Uzbeki-
stan, reported increasing trends in cannabis use in the last 
reporting year (2009-2010), while Georgia also reported 
increasing ATS use. With increasing reports of manufac-
turing and seizures of methamphetamine in some parts of 
Central Asia and Transcaucasia and South-West Asia, it is 
speculated that the use of ATS is likely to emerge in that 
region. Opiates, particularly heroin, remain the primary 
drug of concern there, although most countries in the 
region have reported stable or decreasing trends in opiate 
use. Afghanistan, Iran (the Islamic Republic of ), Pakistan 
and the Central Asian States continue to be the countries 
with opiate use higher than the global estimate. 
In Nepal, according to the study Mapping and Size Estima-
tion of Most at Risk Population, the number of injecting 
drug users has been estimated at 30,000-34,000 (nearly 
0.18 per cent of the adult population). This represents an 
increase from the previous estimate of 28,500 injecting 
drug users in 2009,51 most of whom are considered to be 
using synthetic opioids such as buprenorphine and pro-
poxyphene. In another study among female drug users52 
in Nepal, apart from cannabis, benzodiazepines, heroin 
and dextropropoxyphene were the main substances being 
used.53
In East and South-East Asia, annual prevalence of ATS use 
is estimated to be 0.2-1.3 per cent of the population aged 
15-64. The reported use of methamphetamine, particularly 
crystalline methamphetamine, is reported to be quite wide-
spread. Crystalline methamphetamine is now the most 
commonly used drug in Brunei Darussalam, Japan, Phil-
ippines and the Republic of Korea. Treatment demand 
relating to the use of crystalline methamphetamine has 
also increased considerably.54 Use of crystalline metham-
phetamine accounts for most of the demand for treatment 
for drug use in countries such as Brunei Darussalam and 
the Republic of Korea.
51 Nepal, National Centre for AIDS and STD Control, Mapping and Size 
Estimation of Most-at-Risk Population in Nepal–2011, vol. 2, Injecting 
Drug Users (2011).
52 Although national estimates of drug use in Nepal are not available, it 
is estimated that about 7 per cent of all drug users are women.
53 United Nations Office on Drugs and Crime and Nepal, Ministry of 
Home Affairs, Profile, Drug Use Pattern, Risk Behaviour and Selected 
Bio-Markers of Women Drug Users from Seven Sites in Nepal (2011).
54 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific, 
2011—A Report from the Global SMART Programme (November 
2011).
In China, opioids, mainly heroin, are the primary drug of 
concern, followed by ATS and tranquillizers. The propor-
tion of the total number of registered drug users who use 
heroin as a primary drug decreased from 83 per cent in 
2001 to 69.2 per cent in 2011. However, the total number 
of heroin users in the registry has continued to increase, 
together with the total number of registered drug users: 
the number of registered heroin users in 2010 increased 
by 43 per cent compared with the figure for 2007 (from 
746,000 in 2007 to over 1 million in 2010). Along with 
this, the proportion of synthetic drug users in China that 
are registered increased from 19 per cent of total drug users 
in the country in 2008 to 28 per cent in 2010.
Injecting drug use is also an increasing concern in East and 
South-East Asia, with an estimated 3.9 million (range: 
3,043,500-4,913,000) drug users injecting mostly opioids 
and, to a lesser extent, methamphetamine, while an esti-
mated 661,000 (range: 313,333-1,251,500) injecting drug 
users are living with HIV, according to the Reference 
Group to the United Nations on HIV and Injecting Drug 
Use. 
In South Asia, experts in Bhutan and Sri Lanka reported 
an increase in the use of cannabis and ATS and a stable 
trend or decrease in the use of opioids. In Bangladesh, the 
use of ATS has become quite widespread, especially in 
urban areas where methamphetamine tablets are widely 
available. In terms of treatment demand, opioids contin-
ued to be the primary drug for which the majority of drug 
users are treated in the region.
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Fig. 10. Trends in registered drug users and 
distribution of registered drug users 
in China, by drug type, 2000-2010
Source: China, National Narcotics Control Commission, Annual 
Report on Drug Control in China (n.p., n.d.). It should be noted 
that only starting from 2008 data on registered drug users could 
be disaggregated for synthetic drugs.
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Europe
With an annual prevalence of 5.2 per cent, cannabis 
remains the most commonly used substance in Europe, 
followed by cocaine, ATS and opioids (mostly heroin). 
After North America, Western and Central Europe remains 
a major illicit market for cocaine, with annual prevalence 
of cocaine use among the general population at about 1.3 
per cent. In most parts of Europe, there are stable or declin-
ing trends reported in the use of opioids, cannabis, cocaine 
and ATS; however, the rapid emergence of new synthetic 
drugs and the increasing interplay between legal “highs” 
and illicit drug markets pose a major challenge in the 
region. For instance, although mephedrone has been under 
national control in all European Union member States 
since 2010, it is still being sold both online as a legal 
“high”, as well as through the same illicit supply networks 
used for drugs such as “ecstasy” and cocaine. Nevertheless, 
opioids remain the most problematic drugs, are reported 
to be the primary substances responsible for demand for 
treatment for drug use and are a major cause of drug-
related deaths in Europe. 
In Western and Central Europe, while overall trends in 
“ecstasy” use have remained stable (annual prevalence of 
0.8 per cent), recent reports indicate increasing purity in 
the “ecstasy” available in the region and a possible resur-
gence in its use. Experts in numerous countries in Eastern 
and South-Eastern Europe have also reported an increasing 
trend in the use of cannabis and ATS, including “ecstasy”, 
while the use of opioids and cocaine is reported as stable. 
In 2011, a significant increase in new cases of HIV infec-
tion and increased HIV prevalence among injecting drug 
users was reported in Bulgaria (Sofia only), Greece and 
Romania, though the HIV prevalence has been low in 
Greece. Additionally, Lithuania and Luxembourg were the 
two countries that reported an increase in new cases of 
HIV infection among injecting drug users (in 2011 and 
2010).55 
Despite heroin being the main opioid used in Europe, 
there are reports that synthetic opioids such as fentanyl 
55 European Monitoring Centre for Drugs and Drug Addiction 
and European Centre for Disease Prevention and Control, “Joint 
EMCDDA and ECDC rapid risk assessment: HIV in injecting drug 
users in the EU/EEA, following a reported increase of cases in Greece 
and Romania” (2011).
and buprenorphine might have displaced its use in some 
countries, notably in Estonia and Finland. In Western and 
Central Europe, in about 5 per cent of all admissions for 
treatment for drug abuse, opioids other than heroin were 
reported as the primary drug of abuse. Fentanyl accounted 
for 75 per cent of such admissions in Estonia, and 
buprenorphine was reported as the primary drug of abuse 
among 58 per cent of admissions in Finland.56 Similarly, 
the Russian authorities have reported that, due to a heroin 
shortage, desomorphine and acetylated opium have been 
used as substitutes for heroin throughout the Russian Fed-
eration and fentanyl has been used as a substitute in some 
parts of the country.57
Amphetamine use remained at a significant level in Europe 
(annual prevalence estimated at 0.6 per cent in Western 
and Central Europe and 0.2-0.5 per cent in Eastern and 
South-Eastern Europe). While the use of methampheta-
mine had previously been restricted to the Czech Republic 
and Slovakia, there have been recent reports of metham-
phetamine being increasingly available in Finland, Latvia, 
Norway and Sweden, where it is thought to be replacing 
amphetamine.58 
Recent data from Western and Central Europe indicates a 
stable or decreasing trend in cannabis use, especially among 
young adults, which is also mirrored in school surveys (see 
table 4). The decline in cannabis use may be partly influ-
enced by the declining trends in tobacco smoking among 
young people. Changes in lifestyle and fashion, the replace-
ment of cannabis with other drugs and unfavourable per-
ceptions about cannabis use might also explain the 
decreasing trend in cannabis use in Europe.59 
Although current cocaine use in Western and Central 
Europe is still high (estimated at 1.3 per cent of the adult 
population), recent surveys in the region indicate some 
decline in past-year use of cocaine in countries with high 
prevalence rates, such as Denmark, Spain and the United 
Kingdom (see figure 11); a decline in cocaine use among 
young adults (age group 15-34) is also evident in those 
countries (see table 5). Nevertheless, in 2009 cocaine was 
reported to account for 17 per cent of all demand for treat-
56 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
57 Information provided by the Russian Federation in the annual report 
questionnaire (2010).
58 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
59 Ibid.
Table 4. Annual prevalence of cannabis use in Western and Central Europe, by age group,  
2010-2011
Source: European Monitoring Centre for Drugs and Drug Addiction, Annual Report 2010: The State of the Drugs Problem in Europe 
(Luxembourg, Publications Office of the European Union, 2010).
 
Age group
15-24 15-34 15-64
2010 16% (10 million) 12.6% (17 million) 6.8% (23 million)
2011 15.2% (9.5 million) 12.1% (16 million) 6.7% (22.5 million)
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ment for drug abuse — 23 per cent of persons entering 
treatment for the first time in their life — and cocaine use 
accounted for 900 drug-related deaths in countries in 
Western and Central Europe.60 
With an annual prevalence of 0.4 per cent, opioid use in 
Western and Central Europe shows a stable trend, yet 
opioid users account for nearly half of treatment demand, 
and the majority of the 7,600 drug-related deaths in the 
region were also attributed to opioid use. Opioid users in 
treatment are, on average, an older cohort, with a smaller 
proportion among them injecting, a higher proportion 
reporting the use of opioids other than heroin; and they 
are polydrug users. 
Revised data for the Russian Federation indicate annual 
prevalence of the use of opioids to be 2.3 per cent and the 
annual prevalence of heroin use: 1.4 per cent.61 Of the 
9,263 drug-related deaths reported in 2010, 6,324 were 
attributed to opioid use.
Oceania
The information from Oceania is primarily on the drug 
situation and trends in Australia and New Zealand. In 
60 Ibid.
61 Information provided by the Russian Federation in the annual report 
questionnaire (2010).
Oceania, annual prevalence of the use of all drugs except 
heroin (cannabis use: 9.1-14.6 per cent; use of opioids: 
2.3-3.4 per cent; cocaine use: 1.5-1.9 per cent; use of ATS: 
1.7-2.4 per cent; and “ecstasy” use: 2.9 per cent) remain 
much higher than the global average (see tables 6 and 7).
In Australia, the 2010 national survey showed, an increase 
in the use of cocaine and cannabis (from 1.6 per cent in 
2007 to 2.1 per cent in 2010 and from 9.1 per cent in 
2007 to 10.3 per cent in 2010, respectively), while the use 
of opioids is reported to be stable (heroin use: 0.2 per cent) 
and the use of ATS (methamphetamine, amphetamine and 
“ecstasy”) is reported to have decreased (methampheta-
mine/amphetamine use: from 2.3 per cent to 2.1 per cent 
in 2010; “ecstasy” use from 3.5 per cent in 2007 to 3 per 
cent in 2010). Cannabis remains the most prevalent drug 
in Australia, as well as the main substance accounting for 
demand for treatment for substance abuse (50 per cent), 
with heroin and amphetamines accounting for almost 20 
per cent of treatment demand. Of the 1,790 drug-related 
deaths reported in 2010, nearly 40 per cent were due to 
opioids and approximately a quarter attributed to benzo-
diazepines. The use of pharmaceuticals for non-medical 
purposes increased from 3.7 per cent in 2007 to 4.2 per 
cent in 2010.
In New Zealand, a decrease in the use of “ecstasy” is 
reported to have been offset by the use of other substances 
mimicking its effects, including many piperazines, 
cathinone and mephedrone.62,63 In the Pacific island 
States, there is only sketchy information available on the 
extent of illicit drug use. However, the use of kava (Piper 
methysticum) and cannabis is considered to be quite 
common and widespread. ATS use among secondary 
school students is now also reported in many Pacific 
islands, with lifetime prevalence of the use of 
methamphetamine reported to be high in the Marshall 
Islands (13.1 per cent) and Palau (7.1 per cent). There is 
also evidence of injecting methamphetamine in many 
Pacific island territories, and in Vanuatu, where 
methamphetamine is injected by 41 per cent of injecting 
drug users aged 15-24.64
62 4-Methylethcathinone, 3-trifluoromethylphenylpiperazine and BZP.
63 Information provided by New Zealand in the annual report 
questionnaire (2010).
64 J. Lippe and others, “Youth risk behavior surveillance: Pacific Islands 
United States territories, 2007”, MMWR Surveillance Summaries, vol. 
57, No. SS12 (21 November 2008), pp. 28-56.
Table 5. Annual prevalence of cocaine use 
among young adults (age group 15-
34) in Western and Central Europe, 
selected countries, 2010-2011
Source: European Monitoring Centre for Drugs and Drug  
Addiction, Annual Report 2010: The State of the Drugs Problem 
in Europe (Luxembourg, Publications Office of the European 
Union, 2010).
 
Denmark Spain United Kingdom
2010 3.4% 5.5% 6.2%
2011 2.5% 4.4% 4.8%
Fig. 11. Recent trends in annual prevalence  
of cocaine use in European countries 
with high prevalence rates
Source: World Drug Report (n.d.); UNODC, data from the annual 
report questionnaire.
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A. Extent of illicit drug use and health consequences
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
2
25
R
eg
io
n
 o
r 
 
su
b
re
g
io
n
C
o
ca
in
e
A
TS
 (
ex
cl
u
d
in
g
 "
ec
st
as
y"
)
“E
cs
ta
sy
”
N
um
be
r 
(t
ho
us
an
ds
)
Pr
ev
al
en
ce
  
(p
er
ce
nt
ag
e)
N
um
be
r 
(t
ho
us
an
ds
)
Pr
ev
al
en
ce
  
(p
er
ce
nt
ag
e)
N
um
be
r 
(t
ho
us
an
ds
)
Pr
ev
al
en
ce
  
(p
er
ce
nt
ag
e)
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
Be
st
  
es
tim
at
e
Lo
w
er
U
pp
er
A
fr
ic
a
2 
78
0
95
0
4 
61
0
0.
5
0.
2
0.
8
4 
73
0
1 
19
0
8 
27
0
0.
8
0.
2
1.
4
1 
16
0
40
0
1 
93
0
0.
2
0.
1
0.
3
Ea
st
 A
fr
ic
a
  
  
.. 
  
  
  
.. 
  
  
  
.. 
  
 .
.   
  
  
.. 
  
  
  
.. 
  
  
.. 
  
  
 .
.   
  
.. 
  
  
 .
.   
  
  
.. 
  
  
  
.. 
  
  
.. 
  
  
  
.. 
  
  
  
.. 
  
  
 .
.   
  
  
.. 
  
  
  
.. 
  
N
or
th
 A
fr
ic
a
40
30
50
0.
03
0.
03
0.
04
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
So
ut
he
rn
 A
fr
ic
a
63
0
27
0
85
0
0.
8
0.
3
1.
1
59
0
29
0
79
0
0.
7
0.
4
1.
0
30
0
19
0
30
0
0.
4
0.
2
0.
4
W
es
t 
an
d 
 
C
en
tr
al
 A
fr
ic
a
1 
53
0
56
0
2 
33
0
0.
7
0.
3
1.
1
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
A
m
er
ic
as
7 
15
0
6 
99
0
7 
38
0
1.
2
1.
1
1.
2
5 
79
0
5 
45
0
6 
55
0
0.
9
0.
9
1.
1
3 
23
0
3 
16
0
3 
40
0
0.
5
0.
5
0.
6
C
ar
ib
be
an
18
0
11
0
33
0
0.
7
0.
4
1.
2
22
0
30
53
0
0.
8
0.
1
1.
9
80
10
24
0
0.
3
0.
1
0.
9
C
en
tr
al
 A
m
er
ic
a
13
0
13
0
14
0
0.
5
0.
5
0.
6
33
0
33
0
33
0
1.
3
1.
3
1.
3
30
20
30
0.
1
0.
1
0.
1
N
or
th
 A
m
er
ic
a
5 
00
0
5 
00
0
5 
00
0
1.
6
1.
6
1.
6
3 
92
0
3 
92
0
3 
92
0
1.
3
1.
3
1.
3
2 
71
0
2 
71
0
2 
71
0
0.
9
0.
9
0.
9
So
ut
h 
A
m
er
ic
a
1 
84
0
1 
76
0
1 
91
0
0.
7
0.
7
0.
7
1 
31
0
1 
17
0
1 
77
0
0.
5
0.
4
0.
7
42
0
42
0
42
0
0.
2
0.
2
0.
2
A
si
a
1 
27
0
40
0
2 
20
0
0.
05
0.
01
0.
08
19
 5
70
4 
94
3
34
 2
01
0.
7
0.
2
1.
2
10
 3
80
2 
58
0
18
 1
80
0.
4
0.
1
0.
7
C
en
tr
al
 A
si
a
  
.. 
  
  
.. 
  
  
.. 
  
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
Ea
st
 a
nd
  
So
ut
h-
Ea
st
 A
si
a
42
0
31
0
1 
07
0
0.
03
0.
02
0.
07
8 
40
0
3 
74
0
19
 5
10
0.
6
0.
2
1.
3
2 
82
0
1 
59
0
6 
38
0
0.
2
0.
1
0.
4
N
ea
r 
an
d 
M
id
dl
e 
Ea
st
70
50
12
0
0.
03
0.
02
0.
05
57
0
31
0
1 
26
0
0.
2
0.
1
0.
5
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
So
ut
h 
A
si
a
  
.. 
  
  
.. 
  
  
.. 
  
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
 .
.   
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
  
.. 
  
Eu
ro
p
e
4 
65
0
4 
49
0
4 
87
0
0.
8
0.
8
0.
9
2 
64
0
2 
35
0
2 
95
0
0.
5
0.
4
0.
5
3 
74
0
3 
65
0
3 
90
0
0.
7
0.
7
0.
7
Ea
st
er
n 
an
d 
 
So
ut
h-
Ea
st
er
n 
Eu
ro
pe
48
0
32
0
67
0
0.
2
0.
1
0.
3
78
0
51
0
1 
06
0
0.
3
0.
2
0.
5
1 
28
0
1 
21
0
1 
39
0
0.
6
0.
5
0.
6
W
es
te
rn
 a
nd
  
C
en
tr
al
 E
ur
op
e
4 
16
0
4 
17
0
4 
20
0
1.
3
1.
3
1.
3
1 
87
0
1 
84
0
1 
90
0
0.
6
0.
6
0.
6
2 
46
0
2 
44
0
2 
51
0
0.
8
0.
8
0.
8
O
ce
an
ia
37
0
37
0
45
0
1.
5
1.
5
1.
9
51
0
41
0
57
0
2.
1
1.
7
2.
4
71
0
69
0
71
0
2.
9
2.
9
2.
9
G
lo
b
al
 e
st
im
at
e
16
 2
20
13
 2
00
19
 5
10
0.
4
0.
3
0.
4
33
 2
40
14
 3
43
52
 5
41
0.
7
0.
3
1.
2
19
 2
20
10
 4
80
28
 1
20
0.
4
0.
2
0.
6
Ta
b
le
 7
. 
A
n
n
u
al
 p
re
va
le
n
ce
 o
f 
th
e 
u
se
 o
f 
co
ca
in
e,
 a
m
p
h
et
am
in
es
 a
n
d
 “
ec
st
as
y”
, b
y 
re
g
io
n
So
ur
ce
: 
U
N
O
D
C
 e
st
im
at
es
 b
as
ed
 o
n 
an
nu
al
 r
ep
or
t 
qu
es
tio
nn
ai
re
 d
at
a 
an
d 
ot
he
r 
of
fic
ia
l s
ou
rc
es
.
1. RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS26
B. ILLICIT OPIATE MARKET 
Demand remains unaffected by  
a recovery in supply
In 2011, global potential opium production recovered after 
a significant decline in 2010, which was primarily attrib-
uted to a reduced opium yield caused by a disease of opium 
poppy plants in Afghanistan, the world’s principal opium 
producer. The latest (2011) data on opiate production indi-
cate a resurgence of opium and heroin production in two 
of the three regions in which opium poppy is cultivated 
— South-West Asia (primarily Afghanistan) and South-
East Asia (the Lao People’s Democratic Republic and 
Myanmar), 2011 data for the Americas (Mexico, Colombia 
and Guatemala) are not yet available. 
Despite the 2010 shortfall in production, the consump-
tion of opiates worldwide has remained stable at an esti-
mated annual prevalence range of 0.3-0.5 per cent (between 
12.9 million and 21 million opiate users), and the negative 
health consequences of opiate use in terms of drug-related 
deaths and HIV infection also remain undiminished. 
Average wholesale and retail prices in the most regularly 
monitored illicit markets for opiates, Western Europe and 
the Americas, have also shown little change since 2009 (24 
euros per gram and 52 euros per gram, respectively, for 
Europe in 2010). However, this does not reflect the situ-
ation seen in such major opium-producing countries as 
Afghanistan, Colombia and Myanmar, where, despite an 
increase in opium production, farm-gate prices have con-
tinued to rise. The latter implies that, despite the recent 
recovery of opium production, the demand for opium is 
continuing to increase. What exactly are the reasons for 
this apparent increase in demand? Is the 2010 crop failure 
in Afghanistan leading to some kind of shift in markets at 
source? And, if so, how will this impact on the major illicit 
markets for opiates further down the line? Those questions 
are discussed below.
Global opium production
Estimated potential opium production increased from 
4,700 tons in 2010 to 7,000 tons in 2011, reaching levels 
comparable to the levels of previous years. In Afghanistan 
itself, potential opium production fell to 3,600 tons in 
2010 but resurged to 5,800 tons in 2011. A considerable 
increase in potential opium production was also reported 
in South-East Asia in this period. In Myanmar, for exam-
ple, potential opium production increased from 580 tons 
in 2010 to 610 in 2011, while in the Lao People’s Demo-
cratic Republic it increased from 18 tons in 2010 to 25 
tons in 2011. A preliminary 2010 estimate for Mexico 
shows that, after the year-to-year increase observed since 
2005, opium production decreased from 2009.
When looking at how total potential production of opium 
in 2011 (7,000 tons) was utilized, it is estimated that 3,400 
tons were consumed or trafficked as raw opium while the 
rest was converted into heroin, resulting in 467 tons of 
potential heroin manufacture in 2011, an increase from 
the 384 tons estimated in 2010 (see table 8). It is estimated 
that, compared with previous years, a higher percentage 
of Afghan opium was not processed into heroin in 2011.
The total area under opium poppy cultivation globally also 
increased from 191,000 hectares (ha) in 2010 to some 
Fig. 12. Global potential opium production, 
1997-2011 (Tons)
Source: UNODC. 
Note: The 2011 estimate for the rest of the world is provisional.
Fig. 13. Global illicit cultivation of opium poppy, 
1997-2011 (Hectares)
Source: UNODC.
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Table 9. Areas of opium poppy cultivation reported to be eradicated in selected countries,  
2001-2011 (Hectares)
Source: UNODC, annual report questionnaire, Government reports, reports of regional bodies; International Narcotics Control Strategy 
Report.Note: Table covers only eradication reported in area units. Information on eradication reported as plant seizures can be found in the annex on sei-
zures in the electronic version of the World Drug Report.
a Although eradication took place in 2004, it was not officially reported to UNODC.
207,000 ha in 2011 (see table 10). Afghanistan remains 
the main country cultivating opium poppy, accounting for 
approximately 63 per cent of global opium poppy cultiva-
tion, while the Lao People’s Democratic Republic and 
Myanmar in South-East Asia account for over 20 per cent, 
and countries in Central America and South America 
(mainly Mexico and Colombia) account for almost 7 per 
cent. Reports of opium poppy eradication also indicate the 
existence of smaller areas under opium poppy cultivation 
in many other countries and regions, with at least 13,000 
ha of opium poppy cultivation estimated outside the main 
countries cultivating opium poppy.
For example, a considerable level of illicit opium poppy 
cultivation is estimated to occur in India, where the licit 
production of opium has taken place for decades. Eradica-
tion reports also suggest that illicit opium poppy cultiva-
tion is expanding in Guatemala, but there are no data 
available to estimate the exact size of the total area under 
cultivation.
Global opiate seizures 
With a slight increase of some 7 per cent, global seizures 
of heroin remained rather stable in 2010 (81 tons in 2010 
compared with 76 tons in 2009), though different trends 
were observed in different illicit markets. Heroin seizures 
increased in the trafficking routes that stem from the 
opium production areas in South-East Asia and Central 
and South America (Colombia, Guatemala and Mexico), 
Table 8. Potential illicit production of opium and manufacture of heroin of unknown purity,  
2004-2011 (Tons)
Note: The proportion of potential opium production not converted into heroin could be estimated only for Afghanistan. For the purpose of this table for all 
other countries it is assumed that all opium potentially produced is converted into heroin. If total potential opium production in Afghanistan in 2011 were 
converted into heroin, total potential heroin manufacture would be 829 tons (Afghanistan) and 948 tons (global). The 2011 estimate of “opium not pro-
cessed into heroin” in Afghanistan was based exclusively on regional seizure data, in contrast to previous years, when information from key informants was 
also taken into consideration. The 2011 estimate is not directly comparable with previous years.
2004 2005 2006 2007 2008 2009 2010 2011
Total potential opium production 4 850 4 620 6 610 8 890 8 641 7 853 4 736 6 995
Potential opium not processed into heroin 1 197 1 169 2 056 3 411 3 080 2 898 1 728 3 400
Potential opium processed into heroin 3 653 3 451 4 555 5 479 5 561 4 955 3 008 3 595
Total potential heroin manufacture 529 472 629 757 752 667 384 467
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Afghanistan  ..  21 430 a  5 103  15 300  19 047  5 480 5 351 2 316 3 810 
Colombia  3 577  3 266  3 866  2 121  1 929 375 381  546  711  .. 
Egypt 15 34 65 45 50 98 121  89  222  .. 
Guatemala  ..  ..  .. 489 720 449 536 1 345  918 1 490 
India 219 494 167 12 247  8 000 624 2 420 1 022  ..  
Lao People’s Demo-
cratic Republic
 ..  4 134  3 556  2 575  1 518 779 575  651  579  662 
Lebanon  .. 4 67 27  .. 8  ..  21  ..  4 
Mexico  19 157  20 034  15 926  21 609  16 890  11 046  13 095 14 753 15 484  .. 
Myanmar  7 469 638  2 820  3 907  3 970  3 598  4 820 4 087 8 268 7 058 
Nepal 19 19 4  .. 1  .. 21  35  ..  .. 
Pakistan  ..  4 185  5 200 391 354 614 0 105 68 1 053 
Peru 14 57 98 92 88 28 23  32  21  .. 
Thailand 989 767 122 110 153 220 285  201  278  208 
Ukraine  ..  ..  ..  ..  ..  .. 28  ..  436  .. 
Venezuela (Bolivarian 
Republic of)
0 0 87 154 0 0 0  ..  ..  .. 
Viet Nam 125 100 32  ..  .. 38 99  31  ..  ..
1. RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS28
Table 11. Potential production of oven-dry opium, 1997-2011 (Tons)
Table 10. Global illicit cultivation of opium poppy, 1997-2011 (Hectares)
Source: For Afghanistan: (a) 1997-2002: UNODC; (b) 2003-2011: National Illicit Crop Monitoring System supported by UNODC. For Paki-
stan: annual report questionnaire, Government of Pakistan, United States Department of State. For the Lao People’s Democratic Republic: 
(a) 1997-1999: UNODC; (b) 2000-2011: National Illicit Crop Monitoring System supported by UNODC. For Myanmar: (a) 1997-2000: 
United States Department of State; (b) 2001-2011: National Illicit Crop Monitoring System supported by UNODC. For Colombia: (a) 1997-
1999: various sources; (b) 2000-2010: Government of Colombia. Starting with 2008, production was calculated based on regional yield 
figures and conversion ratios from the United States Department of State/DEA. For Mexico: estimates derived from United States Govern-
ment surveys.
Note: Figures in italics are preliminary.
a May include areas which were eradicated after the date of the area survey. 
b Due to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category “Other”.
c The Government of Mexico does not validate the estimates provided by the United States of America, as they are not part of its official figures and it does 
not have information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in 
collaboration with UNODC to estimate illicit cultivation and production (2010 production: UNODC estimate). 
d Eradication and plant seizure reports from different sources indicate that illicit opium poppy cultivation also exists in the following subregions: North Africa, 
Central Asia and Transcaucasia, Near and Middle East/South-West Asia, South Asia, East and South-East Asia, Eastern Europe, South-Eastern Europe, Cen-
tral America and South America. Starting in 2008 a new methodology was introduced to estimate opium poppy cultivation and opium/heroin production 
in those countries. The estimates are higher than the previous figures but have a similar order of magnitude.
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
South-West Asia
 Afghanistan 2 804 2 693  4 565  3 276 185  3 400  3 600 4 200 4 100 6 100 8 200 7 700 6 900 3 600 5 800 
 Pakistan  24  26  9  8  5  5  52 40 36 39 43 48 44 43 9 
 Subtotal 2 828 2 719 4 574 3 284 190 3 405 3 652 4 240 4 136 6 139 8 243 7 748 6 944 3 643 5 809
South-East Asia
 Lao People’s  
 Democratic  
 Republic
147 124 124 167 134 112 120 43 14 20 9 10 11 18 25 
 Myanmar  1 676  1 303 895  1 087  1 097 828 810 370 312 315 460 410 330 580  610 
 Thailandb  4  8  8  6  6  9 .. .. .. .. .. .. .. .. ..
 Viet Namb  2  2  2 .. .. .. .. .. .. .. .. .. .. .. ..
 Subtotal  1 829  1 437  1 029  1 260  1 237 949 930 413 326 335 469 420 341 598 635
Latin America
 Colombia  90 100  88  88  80  52  50  49 24 13 14 10 9 9 ..
 Mexicoc  46  60  43  21  91  58 101  73 71 108 149 325 425 305 ..
 Subtotal 136 160 131 109 171 110 151 122 95 121 163 335 434 314 314 
Other regions
 Other  
 countriesd
 30  30  30  38 32 56  50 75 63 16 15 139 134 181 237 
Total 4 823 4 346 5 764 4 691 1 630 4 520 4 783 4 850 4 620 6 610 8 890 8 641 7 853 4 736 6 995
 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
South-West Asia
 Afghanistan 58 416 63 674   90 583 82 171 7 606 74 100 80 000 131 000 104 000 165 000 193 000 157 000 123 000 123 000 131 000
 Pakistan 874 950 284 260 213 622 2 500 1 500 2 438 1 545 1 701 1 909 1 779 1 721 362
 Subtotal 59 290 64 624 90 867 82 431 7 819 74 722 82 500 132 500 106 438 166 545 194 701 158 909 124 779 124 721 131 362
South-East Asia
 Lao People’s  
 Democratic        
 Republica
24 082 26 837 22 543 19 052 17 255 14 000 12 000 6 600 1 800 2 500 1 500 1 600 1 900 3 000 4 100
 Myanmara 155 150 130 300 89 500 108 700 105 000 81 400 62 200 44 200 32 800 21 500 27 700 28 500 31 700 38 100 43 600
 Thailandb 352 716 702 890 820 750  ..  ..  ..  ..  ..  ..  ..  ..  ..
 Viet Namb 340 442 442  ..  ..  ..  ..  ..  ..  ..  ..  .. ..  .. ..
 Subtotal 179 924 158 295 113 187 128 642 123 075 96 150 74 200 50 800 34 600 24 000 29 200 30 100 33 600 41 100 47 700
Latin America
 Colombia 6 584 7 350 6 500 6 500 4 300 4 153 4 026 3 950 1 950 1 023 715 394 356 341 ..
 Mexicoc 4 000 5 500 3 600 1 900 4 400 2 700 4 800 3 500 3 300 5 000 6 900 15 000 19 500 14 000 ..
 Subtotal 10 584 12 850 10 100 8 400 8 700 6 853 8 826 7 450 5 250 6 023 7 615 15 394 19 856 14 341 14 341
Other regions
 Other  
 countriesd
2 050 2 050 2 050 2 479 2 500 2 500 3 074 5 190 5 212 4 432 4 184 8 600 7 700 10 500 13 300
Total 251 848 237 819 216 204 221 952 142 094 180 225 168 600 195 940 151 500 201 000 235 700 213 003 185 935 190 662 206 703
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confirming an increase in the supply of heroin deriving 
from an increase in production in those areas in recent 
years. However, along the established trafficking routes for 
heroin manufactured from Afghan opium, leading to the 
Russian Federation and Western and Central Europe, a 
consistent decrease in heroin seizures was observed in 
2010. This most probably reflects falling levels of opium 
production in Afghanistan after 2007 and the shortage of 
opium observed in Afghanistan in 2010. 
The countries that seized the most heroin worldwide con-
tinued to be the Islamic Republic of Iran, with 27 tons 
(accounting for 33 per cent of global heroin seizures), and 
Turkey, with 13 tons (accounting for 16 per cent of global 
heroin seizures) (see figure 14). In 2010, significant quanti-
ties of heroin were also seized closer to the illicit heroin 
markets, most notably in China (accounting for 7 per cent 
of global seizures of heroin) and Pakistan, where seizures of 
heroin doubled to 4.2 tons in 2010. In the Islamic Republic 
of Iran, opposing trends were observed for heroin and mor-
phine seizures, with heroin seizures increasing slightly from 
25 tons in 2009 to 27 tons in 2010 and morphine seizures 
decreasing by 50 per cent during the same period; accord-
ing to preliminary data for 2011, however, heroin seizures 
in that country have now decreased to 23 tons. 
In China, seizures of heroin decreased slightly, from 5.8 
tons in 2009 to 5.4 tons in 2010, but China continues to 
be an important market for heroin. For several years the 
main source of heroin in China was illicit opium poppy 
cultivation and heroin manufacture in South-East Asia 
(particularly Myanmar), but it appears that significant 
quantities of heroin have been smuggled into China from 
Afghanistan via Pakistan and possibly other intermediate 
countries in recent years. Nevertheless, it is believed that 
large amounts of heroin have continued to enter China 
from northern Myanmar via Yunnan Province.
In North America, heroin seizures in the United States rose 
by almost one half, from 2.4 tons in 2009 to a record level 
of 3.5 tons in 2010. Heroin entering the United States 
from countries other than from Mexico originated in South 
America, notably Colombia. In 2010, heroin seizures 
reached 1.7 tons, a record level in Colombia, more than 
twice the level in 2009, while in Ecuador heroin seizures 
increased to 853 kg in 2010, almost five times the level in 
2009 (177 kg). The increase in heroin seizures was less 
pronounced in Mexico (from 283 kg in 2009 to 374 kg 
in 2010). In Canada, although there had been an increase 
in heroin seizures from 2008 to 2009, seizures decreased 
considerably, from 213 kg in 2009 to 98 kg in 2010.
In Asia, seizures of opium and morphine continued to be 
mainly concentrated in Afghanistan and in neighbouring 
Iran (Islamic Republic of ) and Pakistan. Iranian authori-
ties seized 8 tons of morphine, a 50 per cent reduction in 
comparison with the level of the previous year. Pakistan 
reported an increase in morphine seizures: 6.1 tons in 
2010. It is not clear if the morphine trafficked outside 
Afghanistan and seized in Iran (Islamic Republic of ) and 
Pakistan was meant for further processing into heroin or 
was intended for an as yet unmeasured demand for mor-
phine itself. 
An apparent imbalance in global 
supply and demand 
Despite an increase in opium production, farm-gate prices 
have continued to rise in major opium-producing coun-
Fig. 14. Heroin seizures worldwide and in  
selected countries, 2000-2010 (Tons)
Source: Annual report questionnaire supplemented by other  
official sources.
Fig. 15. Global opium seizures, 2000-2010
Source: Annual report questionnaire supplemented by other  
official sources.
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tries, especially Afghanistan, Colombia and Myanmar (see 
figure 16), which implies an apparent steady increase in 
the demand for opium. 
The steep rise in the price of opium observed in Afghani-
stan was, as mentioned earlier, a result of a decrease in 
opium production in 2010 caused by disease in the opium 
poppy. While production has returned to high levels in 
2011, the price of both opium and heroin has remained 
high, not only in Afghanistan but also in neighbouring 
countries. Only in the second half of 2011 did opium and 
heroin prices in Afghanistan stop going up and start to 
decrease. 
The apparent increase in opium demand at source, as wit-
nessed in increasing farm-gate prices, is not consistent with 
the recent increase in the production of opium and heroin 
or with the stabilization of heroin use in the major illicit 
heroin markets. In Europe, for example, there have been 
stable trends in countries with substantial opiate use. Most 
heroin users entering treatment in Europe are, on average, 
an older cohort, and an increasing proportion use opioids 
other than heroin.65 In North America, the steep rise in 
the use of synthetic opioids has also reduced the demand 
for heroin. 
Different hypotheses can be put forward to explain this 
apparent contradiction. One explanation could be an 
underestimation of the level of heroin consumption glob-
ally, particularly in major countries in Asia, as well as in 
possible emerging markets in Africa. Asia and Africa 
account for more than 70 per cent of the estimated number 
of global heroin and opium users, but most of the coun-
65 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
tries in those continents lack recent and reliable estimates 
on heroin and opium use; thus, changes in heroin and 
opium use may have gone undetected. There is, however, 
some sporadic information suggesting an increase in heroin 
and opium use in some Asian countries.66 
It is also possible that increasing prices at source may not 
reflect higher demand but rather an increased risk in cul-
tivation and trafficking resulting from the intensification 
of law enforcement activities. Alternatively, the high 
demand for opium may be driven by an expansion in the 
market for raw opium that is not processed into heroin. 
This could feed increased opium consumption or, more 
likely, a parallel illicit market for other opiates such as 
morphine. For example, in 2010, Pakistan saw a large 
increase in morphine seizures, despite the reduced supply 
of opium caused by the Afghan opium poppy disease in 
the same year.
There is no definitive evidence to back up any one of the 
particular hypotheses discussed above. The apparent imbal-
ance between increasing supply and decreasing demand 
may be attributable to a combination of different factors. 
But what remains to be seen is how, if at all, they will affect 
the major illicit markets in the coming years. 
Opiate consumer markets one year 
after the opium crop failure in 
Afghanistan
It is not known how long it takes opium produced in 
Afghanistan to reach the streets of consumer countries in 
the form of heroin, but trends in production and seizures 
suggest that it may take between one and two years. With 
information available only for 2010 and partially for 2011, 
it may be too early to fully understand the effect of the 
2010 crop failure in Afghanistan in all illicit markets; how-
ever, two major changes could be observed after 2010: a 
general decrease of seizures in 2010 in most of the coun-
tries supplied by Afghan opiates and a heroin shortage in 
some European countries between 2010 and 2011. While 
these changes may not reflect a uniform and rapid response 
to the reduced opium harvest in 2010, it is reasonable to 
assume that they reflect a rapid reaction in the markets of 
countries closer to Afghanistan or those supplied through 
direct routes leading from Afghanistan.  
Although large quantities of heroin continued to be traf-
ficked along the main Balkan route (leading from Afghani-
stan to Western and Central Europe via South-Eastern 
Europe), declining heroin seizures were reported in 2010 
in most countries on the route, with the exception of the 
Islamic Republic of Iran. 
66 For example, recently revised estimates for Singapore, Sri Lanka and 
Indonesia show a higher level of opiate use than did previous estimates. 
A 10-year-period survey of the number of registered drug users in 
China shows an increasing trend in the number of registered heroin 
users, particularly in the period 2007-2010, when the number of 
registered heroin users increased by 43 per cent. The “Drug use in 
Afghanistan: 2009 survey—executive summary” also showed a large 
increase in the number of heroin and opium users from 2005. 
Fig. 16. Farm-gate opium prices in the main 
countries producing opium, 2004-2011
Source: UNODC.
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All countries except Uzbekistan reported a decline in 
heroin seizures in Central Asia and Transcaucasia, 
which remains the major transit route used for smuggling 
heroin from Afghanistan into the Russian Federation. In 
the Russian Federation itself, heroin seizures also went 
down, from 3.2 tons in 2009 to 2.6 tons in 2010 (see fig-
ures 17 and 18). 
In 2010, opium seizures also declined globally and in the 
Islamic Republic of Iran, in particular, where they went 
down to 401 tons (from a high level of 580 tons in 2009). 
In China, heroin seizures showed a small decline, suggest-
ing that China was less affected by the shortage of heroin 
from Afghanistan because of an increase in heroin produc-
tion in Myanmar.
By the end of October 2010 and the beginning of 2011, 
there were definite indications of a shortage in the avail-
ability of heroin in Ireland and the United Kingdom and 
a similar, albeit less clear, situation in other countries in 
Europe. Bulgaria, Hungary, Italy, the Russian Federation, 
Slovakia, Slovenia and Switzerland reported some degree 
of shortage, whereas other countries, such as France, Ger-
many and Sweden, reported little or no reduction in the 
supply of heroin.67 The full extent of this shortage and its 
impact on heroin consumption, prices and purity levels 
may become clearer when data become available for 2011 
and later. 
Total seizures of heroin in the United Kingdom fell by 
more than half, from 1.7 tons in 2010 to 798 kg in 2009.68 
67 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
68 Estimates for 2009 and 2010 for the United Kingdom are based 
on incomplete data for some jurisdictions for the financial years 
2009/2010 and 2010/11, respectively, and adjusted for the missing 
jurisdictions using the distribution (based on more comprehensive 
data) in 2006/07.
Furthermore, the Serious Organised Crime Agency of the 
United Kingdom reported instances of heroin prices 
increasing by 50 per cent and heroin purity falling by one 
third.69 According to the United Kingdom authorities, the 
average purity of heroin seized by police forces and ana-
lysed by the United Kingdom Forensic Science Service fell 
from 46 per cent in the last quarter of 2009 to 16 per cent 
in the first quarter of 2011. It is likely that that is a reflec-
tion of the situation on the retail market more than on the 
wholesale market, but a similar (albeit slightly less pro-
nounced) decrease was also observed in the purity level of 
heroin seized by the United Kingdom Border Agency, 
which fell from 58 per cent in the third quarter of 2009 
to over 30 per cent in the last quarter of 201070 (see figure 
19). Similarly, Switzerland reported sporadic shortages of 
heroin in 2010, with the typical purity of heroin base fall-
ing both at the wholesale level (from 40 per cent in 2009 
to 23 per cent in 2010) and at retail level (from 21 per 
cent in 2009 to 16 per cent in 2010).
In the United Kingdom, the adulteration of street heroin 
with substances such as benzodiazepines and barbiturates 
also resulted in a number of drug-related deaths in England 
and Wales. While there was a slight decrease in drug-related 
deaths in England and Wales during 2009 and 2010, in 
nearly 40 per cent of those deaths heroin and morphine 
were the substances involved.71 There are also signs that 
69 “SOCA comments on reported UK heroin shortages”, Serious Organ-
ised Crime Agency news, 31 January 2011. Available from www.soca.
gov.uk/news/309-soca-comments-on-reported-uk-heroin-shortages 
(accessed March 2012).
70 Kathryn Coleman, “Seizures of drugs in England and Wales, 2010/11”, 
Home Office Statistical Bulletin No. 17/11 (London, Home Office 
November 2011).
71 United Kingdom, Office for National Statistics, “Deaths related to 
drug poisoning in England and Wales, 2010”, Statistical Bulletin, 23 
August 2011.
Fig. 17. Heroin seizures in Europe, selected 
countries, 2009-2010
Source: Annual report questionnaire supplemented by other  
official sources. Estimates for 2009 and 2010 for the United King-
dom are based on incomplete data for some jurisdictions for the 
financial years 2009/2010 and 2010/11, respectively, and adjusted 
for the missing jurisdictions using the distribution (based on more 
comprehensive data) in 2006/07.
Fig. 18. Heroin seizures in Central Asia, by 
country, 2009-2010
Source: UNODC Regional Office for Central Asia Drug Situation 
Report 2011.
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No data available for previous year
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the shortage of heroin has led users to replace it with other 
substances. In the Russian Federation, for example, there 
are reports of opiate users increasingly using desomorphine, 
acetylated opium and, in some parts of the country, fenta-
nyl. As a general trend, in many of the Scandinavian coun-
tries there has also been some displacement of heroin by 
synthetic opioids, mainly buprenorphine and fentanyl. 
It is not clear to what extent the decline in seizures in 2010 
and the shortage of heroin in some European countries 
were related to, or mirrored, the decline in production 
observed in Afghanistan in the same year. Changes in law 
enforcement activities and new trafficking routes leading 
to expanding markets in Asia and Africa may also have 
played a role in reducing the illicit supply of heroin and 
opium. In the case of the United Kingdom, the shortage 
of heroin has been attributed to increases in law enforce-
ment activities in Turkey and the dismantling of wholesale 
heroin networks operating between Turkey and the United 
Kingdom; to some extent, however, the supply of heroin 
reaching the United Kingdom has also been attributed to 
direct trafficking from South-West Asia. This explains the 
fact that there has been a more rapid and sharper response 
to developments in Afghanistan in the illicit market in the 
United Kingdom than in other European countries, but 
the extent to which this is true for other European coun-
tries is less clear. The fall in opium and heroin production 
in Afghanistan probably triggered a change in the market 
that translated into decreased supply in established mar-
kets. Other measures or circumstances may have made the 
shortage more severe in some countries. 
The drop in opium production in Afghanistan was partly 
reversed in 2011. Traffickers tend to be adept at finding 
alternative routes and networks in response to disruptions 
caused by law enforcement activities. Thus, on the one 
hand, the impact of such factors on the heroin supply may 
Map 7. Global seizures of heroin and morphine, 2010 (countries and territories reporting seizures* of 
more than 100 kg)
Source: UNODC annual report questionnaires data supplemented by other sources. 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. 
Final boundary between the Republic of Sudan and the Republic of South Sudan has not yet been determined.
Fig. 19. Purity of heroin seized in the United 
Kingdom (England and Wales only), by 
quarter, 2003-2011
Source: United Kingdom of Great Britain and Northern Ireland 
Home Office. 
Note: Data for the first quarter of 2006 were unavailable.
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be short-lived. On the other hand, the diversification of 
routes from Afghanistan to less well-established destina-
tions in Africa and in Asia and the Pacific is likely to con-
tinue and become more prominent. Developments in 2011 
may also shed light on the dynamics behind the observed 
shortages, whether they are sustained into 2011 or simply 
come to represent a “blip” in the supply of heroin reaching 
Europe. It will be important to observe heroin trends in 
Europe, Asia and Africa in the next few years in all their 
aspects — use, seizures, price and purity — to determine 
any short- or long-term impact and changes in heroin con-
sumption and trafficking in those regions.
Price trends in countries supplied by 
Afghan opiates
The effect of the decrease in heroin production in 2010 
and the subsequent rise in opium and heroin prices at 
source in Afghanistan is as yet unnoticeable outside 
Afghanistan. In those Central Asian countries neighbour-
ing Afghanistan, wholesale prices for opium and heroin 
have remained largely unaffected after the increase observed 
in 2009, although the most recent data available are only 
for 2009 and 2010 (see figure 20). The same can be said 
for prices and purity in Western Europe, where average 
wholesale and retail prices and retail purity in 2010 (24 
euros per gram and 52 euros per gram, respectively) showed 
little change from 2009 (see figures 21 and 22). 
Fig. 20. Wholesale heroin prices in Central 
Asia, by country, 2005-2010 
Source: UNODC Regional Office for Central Asia Drug Situation 
Report 2011. 
Note: Data for Tajikistan, which were reported separately for low- and 
high-purity heroin, are aggregated into one category for the purposes of 
comparability.
Fig. 21. Opium prices and opium production in Afghanistan compared with retail prices of heroin  
in Western and Central Europe, 1998-2011
Source: Estimates based on UNODC data from the illicit crop monitoring programme and from the annual report questionnaire; data 
from the European Police Office. 
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Emerging and expanding heroin  
markets in Africa and Asia 
Data on seizures and heroin use suggest that heroin mar-
kets are expanding in some parts of Africa and Asia. An 
increase in heroin seizures has been reported, for example, 
in the coastal areas of East Africa, West and Central Africa, 
and North Africa, suggesting that Afghan heroin is being 
diverted to those areas. In 2010, heroin seizures increased 
most notably in Egypt (from 159 kg in 2009 to 234 kg), 
in Kenya (from 8.5 to 35 kg in 2010), in Nigeria (from 
104 to 202 kg) and in the United Republic of Tanzania 
(from 7.9 to 191 kg). Mirroring the increase in seizures, 
there are reports of the emerging use of heroin and inject-
ing drug use, particularly in Kenya, Mauritius, Seychelles 
and the United Republic of Tanzania. 
Slight increases in heroin seizures have also been reported 
in many countries in East and South-East Asia, most nota-
bly in Indonesia, the Lao People’s Democratic Republic, 
Malaysia, Singapore and Sri Lanka, which may point to 
an increase in the heroin markets in that region. Reports 
from various countries confirm that the smuggling of 
heroin from South-West Asia has made inroads into the 
illicit markets of Asia-Pacific alongside opiates from South-
East Asia, a more established source area. Forensic profiling 
of heroin seized at the Australian border indicates that 
heroin originating in South-West Asia already accounted 
for a majority of the bulk weight of analysed seizures in 
2010, while heroin originating in South-East Asia still 
accounted for the majority in terms of number of seizure 
cases.72 In 2010, Australia reported seizures of 513 kg, the 
highest annual level of seized heroin since 2003, up from 
195 kg in 2009.
Reports of individual heroin seizure cases in Pakistan sug-
gest that of the heroin consignments with a known desti-
nation other than Pakistan, the proportion of heroin 
consignments intended for the Asia-Pacific region 
decreased from 42 per cent in 2009 to 34 per cent in 2010. 
The drop in 2010 was offset by an increase in heroin con-
signments intended for the major consumer markets of 
Europe and North America, notably the United Kingdom 
and Canada. Nevertheless, the proportion intended for the 
Asia-Pacific region remained significantly higher than that 
registered prior to 2006, which saw a marked shift in des-
tinations from West and Central Africa to countries in the 
Asia-Pacific region, notably China. The proportion 
intended for West and Central Africa continued to decline 
after that; it stood at 6 per cent in 2010 (see figure 23).
72 Australian Crime Commission, Illicit Drug Data Report 2009-10 (Can-
berra, June 2011).
Fig. 22. Heroin prices and purity in Europe, 
2003-2010
Source: Estimates based on UNODC data from the annual report 
questionnaire and data from the European Police Office.
Fig. 23. Destinations of heroin consignments 
seized in Pakistan, by region, 2002-
2010
Source: UNODC individual drug seizure database. 
Note: Based only on cases involving seized heroin consignments with an 
intended destination known to be outside of Pakistan.
0
50
100
150
200
250
300
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
Pr
ic
e
(e
ur
os
 p
er
 g
ra
m
)
0%
5%
10%
15%
20%
25%
30%
35%
Eq
u
iv
al
en
t 
av
er
ag
e 
p
u
ri
ty
 (
re
ta
il)
Purity-adjusted retail price, weighted average,  
12 countries (euros)
Bulk retail price, weighted average, 12 countries (euros)
Bulk retail price, weighted average, 17 countries (euros)
Bulk wholesale price, weighted average,  
17 countries (euros)
Equivalent retail average purity (12 countries)
0
10
20
30
40
50
60
70
80
90
100
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
Pe
rc
en
ta
g
e
Other
North America
Europe
Gulf States 
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates)
East Africa and Southern Africa
West and Central Africa
Asia-Pacific, excluding China
China
C. Cocaine market
W
O
R
L
D
 D
R
U
G
 R
E
P
O
R
T
 2
01
2
35
C. COCAINE MARKET
A decline in production but no fall  
in global consumption
Despite uncertainty in cocaine manufacture estimates, 
which do not allow a precise comparison of levels of poten-
tial manufacture between the three cocaine-manufacturing 
countries, Bolivia (Plurinational State of ), Colombia and 
Peru,73 available data on cultivation, yield and trafficking 
indicate that global cocaine manufacture declined in 2010 
from the high levels seen in the period 2005-2007. This 
is largely a result of a decrease in cocaine manufacture in 
Colombia in the five years up to and including 2010, 
73 A discussion of the challenges in estimating the quantities of cocaine 
manufactured can be found in the World Drug Report 2010 (United 
Nations publication, Sales No. E.10.XI.13), chap. 4.1.
which was partly offset by increases in both Bolivia (Pluri-
national State of ) and Peru. 
At the global level, cocaine use is generally stable, with the 
number of estimated annual cocaine users in 2010 ranging 
from 13.3 million to 19.7 million, corresponding to 0.3-
0.4 per cent of the global adult population (persons aged 
15-64). The negative health consequences of cocaine use 
therefore remain undiminished and violence related to 
cocaine trafficking continues to be an important contribu-
tory factor in the affected subregions, some of which are 
currently experiencing the highest homicide rates in the 
world.74 
74 See United Nations Office on Drugs and Crime, 2011 Global Study on 
Homicide: Trends, Contexts, Data.
Table 12. Global illicit cultivation of coca bush, 2001-2010 (Hectares)
Source: For Bolivia (Plurinational State of): 2001-2002: Inter-American Drug Abuse Control Commission (CICAD) and United States   
   Department of State, International Narcotics Control Strategy Report; 2003-2010: National Illicit Crop Monitoring System  
   supported by UNODC.  
   For Colombia: National Illicit Crop Monitoring System supported by UNODC.  
   For Peru: National Illicit Crop Monitoring System supported by UNODC. 
a For the calculation of the total area, the series Colombia (Area without adjustment for small fields) was used as the area with adjustment was not available  
 for all years presented.
 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Bolivia (Plurina-
tional State of) 19 900 21 600 23 600 27 700 25 400 27 500 28 900 30 500 30 900 31 000
Colombia
(Area without 
adjustment for  
small fields)
144 800 102 000 86 000 80 000 86 000 78 000 99 000 81 000 68 000 57 000
(Area with  
adjustment for  
small fields)
.. .. .. .. .. .. .. .. 73 000 62 000
Peru 46 200 46 700 44 200 50 300 48 200 51 400 53 700 56 100 59 900 61 200
Totala 210 900 170 300 153 800 158 000 159 600 156 900 181 600 167 600 158 800 149 200
Table 13. Potential production of sun-dried coca leaf in Bolivia (Plurinational State of) and Peru, 
2005-2010 (Tons)
Source: For Bolivian estimates: potential production of sun-dried coca leaf available for cocaine manufacture, estimated by the national 
illicit crop monitoring system supported by UNODC. For the coca leaf yield, UNODC studies (for the Yungas of La Paz). The estimated 
amount of coca leaf produced on 12,000 ha in the Yungas of La Paz, where coca bush cultivation is authorized under national law was 
deducted (range: upper and lower bounds of the 95 per cent confidence interval of the estimate of coca leaf yield).  
For Peruvian estimates: potential production of sun-dried coca leaf available for cocaine manufacture, estimated by the national illicit 
crop monitoring system supported by UNODC. A total of 9,000 tons of sun-dried coca leaf were deducted, which, according to Govern-
ment sources, is the amount used for traditional purposes. Range: upper and lower bounds of the 95 per cent confidence interval of the 
estimate of coca leaf yield.
2005 2006 2007 2008 2009 2010
Bolivia (Plurinational State of)
Best estimate 28 200 33 200 36 400 39 400 40 100 40 900
Range .. .. 34 200-38 300 37 300-41 800 37 900-42 300  38 600-43 100 
Peru
Best estimate 97 000 105 100 107 800 113 300 118 000 120 500 
Range 85 400-108 600 91 000-119 200 93 200-122 000 97 600-127 800 102 400-134 200 103 000-136 300
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Global cocaine seizures in  
comparison with manufacture
With 694 tons of cocaine of unknown purity seized in 
2010, compared with 732 tons in 2009, global cocaine 
seizures have remained relatively stable in recent years (see 
figure 24). Comparing trends in cocaine seizures and man-
ufacture, it can be noted that seizures increased signifi-
cantly, at a much faster pace than cocaine manufacture, 
between 2001 and 2005, when drug control efforts were 
intensified, particularly in the vicinity of cocaine-manu-
facturing countries such as Colombia, which was then by 
far the world’s largest producer. During that period, South 
America and Central America accounted for more than 
two thirds of the increase in global cocaine seizures. After 
2005, cocaine seizures decreased at a comparable rate to 
manufacture and drug control successes became increas-
ingly difficult to achieve, as traffickers adapted their strate-
gies and developed new methods. This could have 
contributed to the decrease in recent annual cocaine seizure 
totals, which failed to reach the peak level of 2005. While 
the total weight of seized cocaine remained rather stable 
from 2006 to 2010, the amount of pure cocaine removed 
from the illicit market was actually smaller because the 
purity of the cocaine on the market decreased. For exam-
ple, the average purity of the cocaine seized in the United 
States fell from 85 per cent in 2006, the highest annual 
average in the period 2001-2010, to only 73 per cent in 
2010, the lowest level in that period.75 
Comparing absolute numbers of total cocaine seizures and 
manufacture could be misleading. To understand the rela-
tionship between the amount of annual seizures reported 
by States (694 tons cocaine of unknown purity in 2010) 
and the estimated level of manufacture (788-1,060 tons 
of cocaine of 100 per cent purity), it would be necessary 
to take into account several factors, and the associated cal-
75 These results refer to cocaine originating in Colombia  seized mainly 
by United States authorities in the United States. Cocaine of Bolivian 
and Peruvian origin is seized much less often in the United States. The 
small number of samples  from these two countries analysed did not 
indicate a similar decrease in purity (unofficial communication from 
the Drug Enforcement Administration, Cocaine Signature Program, 
2011).
Table 14. Potential production of fresh coca leaf and coca leaf in oven-dried equivalent in Colombia, 
2005-2010 (Tons)
Source: National illicit crop monitoring system supported by UNODC. 
Note: Because of the introduction of an adjustment factor for small fields, 2010 estimates are not directly comparable with previous years. The ranges 
express the uncertainty associated with the estimates. The range represents the two approaches taken to calculate the productive area, with the lower limit 
being closer to the estimation used in previous years. The methodology used to calculate uncertainty ranges for production estimates is still under develop-
ment and figures may be revised when more information becomes available.
2005 2006 2007 2008 2009 2010
Fresh coca leaf
 Best estimate 555 400 528 300 525 300 389 600 343 600 305 300
 Range .. .. .. .. .. 305 300-349 600
Coca leaf in oven-dried equivalent
 Best estimate 164 280 154 130 154 000 116 900 103 100 91 600
 Range .. .. .. .. .. 91 600-104 880
Table 15. Potential manufacture of cocaine with a purity level of 100 per cent in Bolivia (Plurinational 
State of), Colombia and Peru, 2005-2010 (Tons)
Source: For Bolivian estimates: calculations based on UNODC studies (for the Yungas of La Paz) and studies of the Drug Enforcement 
Administration (DEA) of the United States (for Chapare). For Colombian estimates: national illicit crop monitoring system supported by 
UNODC and DEA studies. Due to the introduction of an adjustment factor for small fields, 2010 estimates are not directly comparable 
with previous years. For Peruvian studies: calculations based on coca leaf to cocaine conversion ratio from DEA studies.  
Note: Figures in italics are under review. 
a Due to the ongoing review of conversion factors, no point estimate of the level of cocaine manufacture could be provided for 2009 and 2010. Because  
 of the uncertainty about the level of total potential cocaine manufacture and about the comparability of the estimates between countries, the 2009 and  
 2010 figures were estimated as ranges (842-1,111 and 788-1,060 tons respectively).
2005 2006 2007 2008 2009 2010
Bolivia
 Best estimate 80 94 104 113 .. ..
Colombia
 Best estimate 680 660 630 450 410 350
 Range  ..  ..  ..  ..  .. 350-400
Peru
 Best estimate 260 280 290 302 .. ..
Total 1 020 1 034 1 024 865 .. a .. a
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culations would depend on a level of detail in seizure data 
that is often unavailable. Making purity adjustments for 
bulk seizures, which contain impurities, cutting agents and 
moisture, to make them directly comparable with the 
cocaine manufacture estimates, which refer to a theoretical 
purity of 100 per cent, is difficult, as in most cases the 
purity of seized cocaine is not known and varies signifi-
cantly from one consignment to another. The total amount 
of seized cocaine reported by States is also likely to be an 
overestimation. Large-scale maritime seizures, which 
account for a large part of the total amount of cocaine 
seized, often require the collaboration of several institu-
tions in a country or even in several countries. 76 Therefore, 
double counting of reported seizures of cocaine cannot be 
excluded. 
Main consumer market trends
North America, South America and Western and Central 
Europe continue to be the world’s largest cocaine markets. 
The United States experienced a decrease in the prevalence 
of cocaine use among adults (persons aged 15-64), from 
3.0 per cent in 2006 to 2.2 per cent in 2010,77 which can 
be linked to the decline of 47 per cent in cocaine manu-
76 For example, in Colombia, between 2002 and 2010, 41-62 per cent 
of annual seizures of cocaine were made at sea. In 2010, 58 per cent 
of all such seizures were joint operations involving more than one law 
enforcement agency from Colombia and/or other countries (United 
Nations Office on Drugs and Crime and Colombia, Colombia: Moni-
toreo de Cultivos de Coca 2010 (June 2011)).
77 In some age groups, the decline was much more drastic, e.g. from 5.7 
per cent in 2006 to 2.9 per cent in 2010 among 12th graders (United 
States, National Institute on Drug Abuse, Monitoring the Future 
survey, 2006-2010) or from 0.7 per cent in 2006 to 0.21 per cent in 
2010 among the workforce (Quest Diagnostics, Drug Testing Index, 
2010).
facture in Colombia, where most of the cocaine destined 
for North America was manufactured during that period. 
But the “turf wars” between drug trafficking organizations 
and drug control agencies disrupting the flow of cocaine 
through Mexico are also factors hampering the illicit supply 
of cocaine to the United States. 
While their decline began in 2005, cocaine seizures in the 
United States have followed a downward trend similar to 
the prevalence of cocaine itself, suggesting that falling sei-
zures reflect a decreasing supply of cocaine reaching the 
United States. One reason contributing to the time lag that 
emerges from these similar, but unsynchronized, trends, 
with changes in seizure data occurring earlier than changes 
in prevalence data, is that seizures usually occur relatively 
near to the start of the trafficking cycle, whereas consump-
tion usually takes place at its end.78 
Europe, on the other hand, has not experienced a decline 
in cocaine supply of the same magnitude, with prevalence 
of cocaine use starting to stabilize in some countries in 
2007, though it has declined in others. In the United 
States, the decrease in cocaine availability has been reflected 
in the increased price of cocaine in comparison with 2007 
and prior years. Purity-adjusted retail prices reveal signifi-
cantly more than bulk prices about the recent develop-
ments in the United States market; the purity-adjusted 
price in the period 2008-2010 was significantly higher 
than the stable levels prior to 2007, reflecting a sustained 
decreased availability of cocaine in the United States (see 
78 Ehleringer and others report a time lag of about two years between 
coca leaf production and sale to the end-user (J. R. Ehleringer and 
others, “14C analyses quantify time lag between coca leaf harvest and 
street-level seizure of cocaine”, Forensic Science International, vol. 214, 
Nos. 1-3 (2012), pp. 7-12).
Fig. 24. Seized cocaine of unknown purity, by 
region, 2001-2010
Source: Annual report questionnaire supplemented by other 
official sources.
Fig. 25. Global trends in potential cocaine  
manufacture and seizures, 2001-2010
Source: UNODC (manufacture) and ARQ supplemented by other 
official sources (seizures). 
Note: The potential cocaine production trend was calculated using new 
conversion factors as described in the World Drug Report 2011 (United 
Nations publication Sales No. E.11.XI.10 p. 264). A one-year time lag 
between production and seizure was chosen because it provides a better 
correlation than two years or no time lag.
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figure 26). In Europe, however, no dramatic changes in 
prices have been observed since 2007. On the whole, nomi-
nal prices (i.e. prices not adjusted for purity or inflation) 
remained at the same level in dollar terms between 2007 
and 2010. In some countries, cocaine prices have even 
decreased, although some nominal price decreases have 
gone hand in hand with lower levels of purity. 
The purity of cocaine in Europe may have decreased 
slightly since 2007. The German authorities have reported 
a relatively stable purity level of about 70 per cent in whole-
sale seizures in the past decade and an even higher level of 
purity at the retail level between 2008 and 2010 than in 
2007.79 Seizures by the police in the United Kingdom have 
indicated a rather drastic decrease in purity, from 32 per 
cent in the first quarter of 2008 to only 16 per cent in the 
second quarter of 2009, which then increased to 30 per 
cent in the first quarter of 2011.80 By contrast, the purity 
of cocaine seizures made by the United Kingdom Border 
Agency, which are considered to reflect the purity of 
cocaine of mainly wholesale quality at the point of entry 
into the country, remained above 60 per cent until the last 
quarter of 2010.81 The average purity-adjusted retail price 
(weighted average of 14 countries), however, rose slightly 
in 2010, with a corresponding drop in the equivalent aver-
age purity.
79 Tim Pfeiffer-Gerschel and others, 2011 National Report to the 
EMCDDA by the Reitox National Focal Point: Germany—New Devel-
opments, Trends and In-Depth Information on Selected Issues, Drug 
Situation 2010/2011 (European Monitoring Centre for Drugs and 
Drug Addiction  and Deutsche Referenzstelle für die Europäische 
Beobachtungsstelle für Drogen und Drogensucht, 2011), p. 198.
80 Coleman, “Seizures of drugs in England and Wales, 2010/11”.
81 Ibid.
In contrast to North America, where prevalence of cocaine 
use and cocaine seizures have fallen in parallel, the stability 
of the prevalence of cocaine use in Western and Central 
Europe has not coincided with stable seizure levels, as the 
seizure levels have fallen by some 50 per cent since 2006. 
A report of the European Police Office (Europol) on mari-
time seizures of cocaine suggests that a change in traffick-
ing modes could have contributed to this apparent 
mismatch.82 While overall seizures have decreased, the 
amount of cocaine seized in containers has actually 
increased in countries covered by the study, such as Ger-
many, Spain and the United Kingdom. Seizures of cocaine 
found on vessels (but not inside containers) have decreased 
over the same period, implying that traffickers are increas-
ingly making use of containers on the European route by 
taking advantage of the large volume of container ship-
ments between South America and Europe.83 Semi-sub-
mersible boats, which are known to be used on the Pacific 
route, do not yet play a role in transatlantic trafficking.84 
Meanwhile, the West African route, which became more 
and more popular up until 2007, has since become less 
important. 
82 European Police Office, Project COLA, “Cocaine trafficking to Europe 
by sea” (The Hague, n.d.).
83 Germany reported its largest ever cocaine seizure in 2010: 1.3 tons of 
cocaine hidden in a container originating in Paraguay (Gerschel and 
others, 2011 National Report to the EMCDDA by the Reitox National 
Focal Point: Germany, p. 191).
84 European Police Office, Project COLA, “Semisubmersibles: the immi-
nent threat to Europe?” (The Hague, 27 September 2011).
Fig. 26. Purity-adjusted prices in the United States and Western and Central Europe, 2003-2010
Source: Estimates based on UNODC data from the annual report questionnaire the European Police Office and data from the United 
States of America Office of National Drug Control Policy. 
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The European cocaine market:  
a shift in supply
The relative stability in the price and purity of cocaine in 
the main European markets suggests that Europe has not 
experienced a cocaine shortage resulting from a decreasing 
supply of cocaine originating in Colombia, as observed in 
the United States, because this was, at least partially, com-
pensated by an increasing supply of cocaine originating 
elsewhere. Indeed, there is some evidence that, while the 
United States market continued to be almost exclusively 
supplied by cocaine manufactured in Colombia,85 starting 
in 2006 there was something of a shift in the European 
markets towards Bolivian and Peruvian cocaine.
Since 2006, for example, in individual cocaine seizures 
reported in European countries, Bolivia (Plurinational 
State of ) and Peru have been mentioned more often than 
Colombia as countries where cocaine shipments originated. 
The analysis of the same datasets by seizure size also points 
to the growing importance of those two countries, but the 
trend is less obvious as the seizure peaks originating in 
Colombia in the period 2004-2006 and in 2008 all 
reflected one multi-ton seizure in each of those years. 
Although this provides some evidence of the shift that may 
have occurred in the European market, more investigation 
is necessary. Above all, European seizures should be ana-
lysed through a cocaine signature programme to verify the 
producing country, while routes should be more carefully 
recorded and reported since most shipments follow com-
plex routes and may change hands frequently, resulting in 
the loss of information relating to the producing country.
85 United States, Drug Enforcement Administration, “Cocaine Signature 
Program report”, January 2011.
Growth in the European market and other expanding mar-
kets for Bolivian and Peruvian cocaine can also be regis-
tered in the increased demand for coca paste and cocaine 
in Bolivia (Plurinational State of ) and Peru, as observed 
in the rising prices of those substances. Yearly average prices 
for coca paste and cocaine in cocaine-producing areas in 
Peru were higher by 28 per cent and 13 per cent, respec-
tively, in the period 2008-2010 compared with the period 
2005-2010 (see figure 29); as local demand for cocaine is 
reported to be rather stable, this increase is likely to be 
export-driven. In the Plurinational State of Bolivia, nomi-
nal prices of cocaine in producing areas also increased con-
Fig. 27. Cases involving seizures in Europe of cocaine originating in countries cultivating coca bush, 
by number of cases and amount, 2001-2010
  
Source: UNODC individual drug seizure database based on data from 14 European countries. The database includes cocaine seizure of 
100 g or more. 
Fig. 28. Trends in cocaine seizures in North 
America and Western and Central  
Europe (Two-year moving averages)
Source: UNODC data from the annual report questionnaire.
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siderably between 2005 and 2010. As cocaine manufacture 
in both countries increased over the same period, because 
of the expansion of the area under coca bush cultivation 
and, perhaps also because of improved cocaine extraction 
methods, prices of coca derivates should have decreased 
rather than increased. The increase could be a sign of 
increased, possibly export-driven, demand for cocaine by 
traffickers supplying the European market or other mar-
kets, such as Brazil, to compensate for a decrease in pro-
duction in Colombia, which may have caused a change in 
trafficking patterns. 
Emerging and expanding markets
An additional factor influencing the availability of, and 
overall demand for, cocaine in different regions is the emer-
gence of new cocaine markets outside the main markets, 
North America, Western and Central Europe, and South 
America. Seizure amounts in these emerging markets are 
typically low in absolute terms and only a fraction of sei-
zures made in producing regions or the main markets. 
However, as cocaine is not one of the typical drugs con-
sumed in regions where, for example, opiates or ATS are 
more common, it may not always be identified as cocaine 
by law enforcement authorities. Since no recent studies on 
prevalence are available for these emerging markets, the 
upward trend in cocaine seizures in such markets could 
highlight an emerging problem that is not yet visible in 
demand data.
Some data suggest that emerging and expanding markets 
for cocaine exist in subregions such as Eastern Europe, 
South-East Asia and Oceania; while those markets are still 
small, they have growth potential and/or risk factors that 
favour an increase in cocaine use. Seizure trends in subre-
gions not known to have sizable cocaine consumer popu-
lations could indicate that the smuggling of cocaine into 
or through those subregions has gained in importance. For 
example, while seizures in Western and Central Europe 
practically halved between 2005/06 and 2009/10, cocaine 
seizures in Eastern Europe and South-Eastern Europe tri-
pled. Increased demand could be one factor; a diversifica-
tion in trafficking patterns could be another.
An even greater increase in cocaine seizures can be seen in 
East Africa and Oceania, where the 2009/2010 levels were 
about four times higher than in 2005/2006, and in East 
and South-East Asia. In Oceania (2.6 per cent and increas-
ing in Australia and 0.6 per cent in New Zealand), annual 
prevalence of cocaine use is high compared with South-
East Asian countries (Indonesia, Philippines and Thai-
land), where less than 0.1 per cent of the adult population 
use cocaine. However, for many Asian countries, including 
China and India, no recent information on cocaine use is 
available. Limited information from Africa suggests that 
cocaine trafficking via West Africa may be having a spillo-
ver effect on countries in that region, with cocaine use 
possibly emerging alongside heroin use as a major problem 
among drug users.
Seizure data and limited information on demand for treat-
ment services also point to a possible increase in illicit 
demand for cocaine in countries with an already significant 
population of cocaine users. In Brazil, federal seizures have 
more than tripled since 2004, reaching 27 tons in 2010 
(see figure 30). According to experts, Brazil also experi-
enced some increase in cocaine use in 2010. Recent survey 
data for Brazil are unavailable, but the concern over the 
Fig. 29. Yearly average wholesale prices of co-
caine of unknown quality in producing 
areas of Peru, 2005-2010
Source: UNODC and Government of Peru, Coca Cultivation Survey 
reports 2005-2010. 
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Fig. 30. Cocaine seizures in selected South 
American countries, 2000-2010
Source: Annual report questionnaire supplemented by other  
official sources. 
Note: For Argentina, available data for 2010 were not directly comparable 
with data for previous years, as coverage does not include seizures by fed-
eral security forces in Argentina. Hence, total seizures for 2010 (for Argen-
tina and consequently for all five of the countries) may be higher than 
shown in the figure.
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increase in cocaine use in Brazil is reflected in the country’s 
national programme launched in December 2011. The 
increase in seizures could also reflect the role of Brazil as a 
country of departure for cocaine smuggled across the 
Atlantic Ocean.
In Argentina, cocaine seizures rose almost eightfold 
between 2002 and 2009.86 Seizures in Chile peaked in 
2007 and remained relatively high until 2010, and seizures 
more than doubled in Paraguay in 2010. However, survey 
data indicate that cocaine use in Argentina remained stable 
in 2010 in comparison with 2008, and cocaine use 
decreased in Chile over the same period. Nevertheless, 
prevalence of cocaine use remains relatively high in both 
of those countries. 
Improving the comparability of  
data from countries with coca bush 
cultivation
The comparison and aggregation of estimates of the area 
under coca bush cultivation in the three countries cultivat-
ing coca bush remains challenging. Numerous efforts have 
been made by UNODC and the Bolivian, Colombian and 
Peruvian Governments and to ensure the comparability of 
the estimates of their respective areas under coca bush cul-
tivation. The monitoring systems in the three countries 
are all based on remote-sensing technology covering the 
entire area under coca bush cultivation (census). They all 
follow standard scientific practices to maximize data qual-
ity; however, differences in the size of the monitored area, 
86 Data available for 2010 were not comparable, as coverage does not 
include seizures by federal security forces in Argentina. 
the concept used for the area under coca bush cultivation, 
climatic conditions, the availability of secondary informa-
tion and security risks impeding access to growing areas 
have led the systems to use different implementation 
modalities, technologies and data sources.87 
In Colombia, for example, virtually the entire country has 
to be covered by the survey each year as coca bush cultiva-
tion is very dynamic and is spread over a large area, shifting 
frequently and necessitating the use of larger but lower-
resolution satellite images, such as images taken by the 
Landsat ETM sensor. In Bolivia (Plurinational State of ) 
and Peru coca bush cultivation is restricted to particular 
growing areas that tend to be well known and relatively 
stable; because of the smaller area more costly images with 
higher resolution can be purchased (e.g. SPOT 5, Rapi-
deye, Ikonos). The dynamics of coca bush cultivation are 
different in Colombia than in the other two countries. The 
high eradication pressure in Colombia, through airborne 
spraying of coca bush cultivation sites, as well as intense 
manual eradication activities, has led to a highly dynamic 
situation. Cultivation sites are frequently shifted, they 
change in size, they are abandoned, reactivated and aban-
doned again within relatively short periods. By contrast, 
in the other two countries eradication, which is exclusively 
manual, is restricted to certain growing areas, because out-
side those areas there are fields where coca bush cultivation 
may be allowed by the Government for nationally author-
ized markets. 
While the adjustment of each monitoring system to coun-
try-specific conditions and needs has contributed to the 
continued production of annual estimates of coca bush 
cultivation, it has also put into question the comparability 
of those countries. The main element affecting the compa-
rability of estimates of coca bush cultivation in the three 
countries is the definition of area under coca bush cultiva-
tion. While in Bolivia (Plurinational State of ) and Peru the 
concept relates to the extent of coca bush cultivation as 
observed on satellite imagery taken between September of 
the reporting year and February of the following year, in 
Colombia the estimates refer to 31 December of each year. 
Therefore, the results from satellite imagery collected from 
September to February in Colombia undergo a number of 
adjustments in order to represent the net area under coca 
bush cultivation on 31 December of the reporting year, 
while in the other two countries no adjustments are usually 
made to the area interpreted in satellite images as being 
under such cultivation. Adjustments made to meet the ref-
erence date such as these, for example, take into account 
the effect of spraying and manual eradication that happened 
after the image was taken but before 31 December, and the 
adjustment of the results to a reference date improves the 
year-on-year comparability in a very dynamic situation. 
Other adjustments applied in Colombia address issues 
common to all three surveys, such as data gaps on the 
87 See World Drug Report 2011, p. 100. 
Fig. 31. Subregions with increasing cocaine 
seizures (Two-year moving averages)
Source: Annual report questionnaire supplemented by other  
official sources.
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images due to cloud cover or technical problems related 
to the satellite sensor, but which are a more severe problem 
in Colombia due to climatic conditions and the image 
types used. In addition, based on evidence gathered using 
images with very high resolution, an adjustment is made 
for small coca bush cultivation sites that the image resolu-
tion is not able to identify in Colombia but which are 
picked up by the images used for the other two countries. 
These adjustments improve the comparability of the three 
surveys. Thus, some adjustments directed at addressing 
country-specific needs and conditions limit the compara-
bility while others contribute to improving it. However, 
each adjustment factor also has its own uncertainty. 
The effect of eradication on  
comparability
In Colombia, the total geographical area affected by coca 
bush cultivation in the course of 12 months is significantly 
higher than the figure calculated on the 31 December.88 
In 2010, 145,000 ha were fumigated and eradicated, 
including a double counting of some areas, which were 
covered more than once due to replanting or recovery of 
the coca fields. In total, 140,000 ha were affected by coca 
cultivation in Colombia in 2010, including fields that 
remained active throughout the whole year, fields that were 
active only part of the year because they were sprayed or 
eradicated, and fields that only came into existence in the 
course of the year. Thus, the gross area affected by coca 
cultivation in 2010 was over two and a half times the net 
area estimated for 31 December 2010 (62,000 ha). 
The large difference between gross area and net area in 
Colombia demonstrates that a large part of the area affected 
88 The area affected by coca bush cultivation in this report refers to the 
geographical area fumigated, manually eradicated or found to have 
coca bush that was neither fumigated nor manually eradicated. It was 
assumed that all areas sprayed with herbicides were “affected” by coca 
bush cultivation. Independent confirmation that the totality of the 
fumigated area corresponds to coca bush fields is not available.
by coca cultivation is subject to continued law enforcement 
pressure. Given the nature of the coca plant, which can be 
harvested a number of times in a year and can be replanted 
at any time of year, eradication activities may have less of 
an effect on the extent of coca bush cultivation in a given 
year but more of an impact on the productivity of coca 
bush fields because it is thought to reduce the annual coca 
leaf yield. 
In Bolivia and Peru, there is no attempt to adjust the data 
to a particular date in the year and data on coca cultivation 
are estimated as interpreted through satellite images 
acquired from September to February. Manual eradication 
also plays a role in these countries, as does the abandon-
ment or new establishment of coca fields. However, satel-
lite imagery that is collected in the last quarter of the year 
only reflects the impact of eradication that happened 
before but not after the image date. 
Data for the three countries can be compared by making 
use of various methods for comparison. Due to eradication 
pressure influencing coca monitoring in different coun-
tries, the area observed in satellite images at a certain point 
in time may hide very different dynamics and extents of 
coca cultivation. 
The gross area was estimated by adding fields eradicated 
or fumigated before the imagery was taken and which 
would therefore not show as coca on the satellite images. 
Comparing the gross area or total area affected by coca 
cultivation in a year with other area concepts demonstrates 
the dynamics of coca cultivation differ a great deal between 
the three countries. 
Table 16. Comparing concepts of the area under coca bush cultivation, 2010 (Hectares)
Sources: UNODC and Governments of Bolivia (Plurinational State of), Colombia and Peru, Coca Cultivation Surveys (2010) as well as infor-
mation from spraying and eradication records provided by the Governments.   
a There was not sufficient information available on the timing and location of eradication activities to provide a point estimate of the area on 31 December  
 and the gross area affected by coca bush cultivation. For the calculation of the area on 31 December, the effect of eradication conducted between the   
 satellite image date and 31 December could be estimated but not the effect of potential replanting and new plantations, which could potentially offset   
 eradication. 
Area
Bolivia  
(Plurinational State of)
Colombia Perua
Area on 31 December 2010 .. 62 000
(adjusted for small fields, clouds 
and other information gaps, date 
of image and spraying)
59 800–61 200
Area interpreted on satellite imagery 31 000 60 553 
(adjusted for small fields, clouds 
and other information gaps)
61 200
Gross area affected by coca bush cultivation 
between 1 January and 31 December including 
areas that were eradicated and productive only 
part of the year
.. 140 000 61 200–71 800
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D. CANNABIS MARKET
The two faces of cannabis 
Cannabis is a truly global phenomenon. Reports on cul-
tivation and seizures of cannabis and on sources of cannabis 
products89 illustrate that cannabis is not only consumed 
in all countries in the form of cannabis herb (marijuana), 
it is also grown in most of them. Cannabis herb refers to 
the flower buds of the plant, which contain the highest 
concentration of the drug’s main active ingredient, tetrahy-
drocannabinol (THC), while the other most common of 
its variations, cannabis resin (hashish), is produced from 
the compressed resin glands of the cannabis plant. 
The cannabis plant can be easily cultivated both indoors 
and outdoors, and the relatively simple production of can-
nabis herb, in particular, has led to it being produced and 
traded almost everywhere in the world, often in local mar-
kets. In this way, much of the demand for cannabis can be 
covered by local production, which producers may also 
consider to be safer since it involves less trafficking and 
subsequently reduces the risk of seizure, though many 
countries continue to report that a significant proportion 
of cannabis comes from intraregional trafficking. 
The more protracted processing of the cannabis plant into 
cannabis resin is confined to far fewer countries, most of 
which are located in North Africa, the Near and Middle 
East, and South-West Asia. There are, however, only frag-
mented new data available on global cannabis resin 
production,90 an exception being data from the cannabis 
survey conducted by UNODC in Afghanistan in 2011. 
The localized and often small-scale nature of cannabis cul-
tivation and production also makes it very difficult to 
89 See World Drug Report 2010 (United Nations publication, Sales No. 
E.10.XI.13).
90 In the World Drug Report 2009 (United Nations publication, Sales No. 
E.09.XI.12), it was estimated that the production of cannabis herb 
ranged from 13,300 to 66,100 tons and the production of cannabis 
resin from 2,200 to 9,900 tons. The calculations were based on the 
minimum and maximum levels from reported cultivation and produc-
tion, seizures and prevalence rates. In 2011, these indicators did not 
show significant changes that would justify an update of the produc-
tion estimates, taking into account the large minimum and maximum 
levels.
measure the extent of global cannabis cultivation and 
production. 
Global cannabis production
Few countries estimate the extent of cannabis cultivation 
and production, but the Governments of the following 
countries reported estimations of their areas under cultiva-
tion in 2010 (see table 18): India (552 ha); Indonesia (422 
ha of harvestable areas); Morocco (47,400 ha ); Sri Lanka 
(500 ha); Swaziland (633 ha); and Ukraine (920 ha), which 
also recently reported a large increase in cannabis cultiva-
tion. According to estimates made by the United States, 
the extent of cannabis cultivation in Mexico has decreased.91 
However, area figures for all countries are rarely accompa-
nied by a description of the estimation methods used and 
are frequently identical to eradication figures. UNODC is 
currently preparing to assist both Mexico and Ukraine in 
monitoring the extent of cannabis cultivation.
Data on cannabis production may be limited but differ-
ences in the geographical distribution of cannabis herb and 
resin production are actually reflected in the regional mar-
kets for cannabis. Map 8 shows the relative importance of 
the number of cannabis resin seizure cases in comparison 
with the number of cannabis herb seizure cases by subre-
gion from 2006 to 2010; the different geographical con-
centrations of the markets for cannabis herb and resin. In 
the Near and Middle East and South-West Asia, cannabis 
resin is by far the most prominent of the two, in North 
Africa and Europe, the proportion of herb and cannabis 
resin seizure cases, estimated at between 40 and 60 per 
cent, respectively, show that the two markets are similar in 
size, whereas the rest of the world is dominated by can-
nabis herb. In terms of the weight of cannabis seizures, 
cannabis resin was the most dominant (90 per cent) of the 
two products in the European market in 2010. Data for 
most parts of Africa are scarce but it seems that cannabis 
herb is also the more commonly seized of the two in that 
region. 
91 United States, Department of State, Bureau for International Narcotics 
and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. I, Drug and Chemical Control (March 2012).
Table 17. Reported eradication of coca bush, 2005-2011 (Hectares)
Source: Governments of Bolivia (Plurinational State of), Colombia and Peru. UNODC data from the annual report questionnaire. 
a Voluntary and forced eradication since 2006.  
b Including voluntary and forced eradication.
Country
Eradication 
method useda 2005 2006 2007 2008 2009 2010 2011
Bolivia Manual 6 073 5 070 6 269 5 484 6 341 8 200 10 460
Colombia Manual 31 980 43 051 66 805 95 634 60 544 43 690 35 203
Spraying 138 775 172 026 153 134 133 496 104 771 101 939 103 302
Ecuador Manual 18 9 12 12 6 3 ..
Perub Manual 7 605 9 153 10 188 11 102 10 091 12 239 ..
Venezuela Manual 40 0 0 0 0 .. ..
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Ç
ÇÇÇÇÇ
Ç
ÇÇ
ÇÇ
Ç
Ç
Ç
Dominant number of
seizure cases
Mainly cannabis herb (>80%)
Predominance of 
cannabis herb (60-80%)
Cannabis herb and resin (40-60%)
Predominance of cannabis resin (60-80%)
Mainly cannabis resin (>80%)
No data available or no ARQ received
Table 18. Update of information available on the extent of cannabis cultivation and production in ma-
jor producing countries, 2010
Source: UNODC data from the annual report questionnaire (2010), if not mentioned otherwise. Only areas reporting more than 100 ha 
are mentioned. 
a Information from the cannabis survey conducted by UNODC in Afghanistan in 2010 and 2011. 
b The Government of Mexico does not validate the estimates provided by the United States, as they are not part of its official figures and it does not  
 have information on the methodology used to calculate them. The Government of Mexico is in the process of implementing a monitoring system in  
 collaboration with UNODC to estimate illicit cultivation and production. 
c Information from the Government of Mexico.
Country
Area under cultivation area 
(hectares)
Eradication area 
(hectares)
Harvestable area  
(hectares)
Production (tons )
Cannabis resin Cannabis herb
Afghanistana 9 000-24 000 .. .. 1 200-3 700 ..
Egypt .. 129.8 .. .. ..
India 552.0 552.0 .. .. ..
Indonesia 600.0 178.0 422.0 .. ..
Jamaica .. 447.0 .. .. ..
Mexico 16 500 (INCSR 2012)b 18 581c .. .. ..
Morocco .. 9 400.0 47 500 760 38 000
Nigeria .. 593.2 .. .. ..
Sri Lanka 500.0 .. .. .. ..
Swaziland 632.5 632.5 .. .. ..
Ukraine 920.0 920.0 .. .. ..
Map 8. Importance of cannabis herb and resin products, by subregion, 2006-2010
Source: UNODC data from the annual report questionnaire (2006-2010). 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. 
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties.
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Is there a shift in the supply of  
cannabis resin from Morocco to 
Afghanistan?
Production of cannabis resin in Europe is assumed to be 
very small, yet Europe is the world’s largest market for can-
nabis resin and North Africa has long been its predominant 
supplier. The majority of North African cannabis resin 
consumed in Europe traditionally comes from Morocco 
but recent data show that the relative importance of that 
source country could be on the decline, whereas the rela-
tive importance of other countries, such as Afghanistan 
and India, is on the increase. 
Figure 32 shows the main countries producing cannabis 
resin in terms of the number of times they were mentioned 
as a source country by countries in which seizures of can-
nabis resin took place. Such data must be treated carefully 
as it does not distinguish between transit countries and 
countries of origin, but it does suggest that there might 
have been a shift in the importance of the two countries 
most often cited for producing cannabis resin: Afghanistan 
and Morocco. 
Data reported by the Government of Morocco point to a 
decrease in the production of cannabis resin in that coun-
try, with lower cannabis cultivation figures compared with 
the figures for the period 2003-2005, when UNODC and 
the Government conducted joint surveys. Seizures of can-
nabis in all its forms also decreased; while “kif ”, (a dried 
form of cannabis that can be processed into cannabis resin), 
is still seized in large quantities, seizures of “kif ” fell from 
223 tons in 2009 to 187 tons in 2010.
UNODC and the Government of Afghanistan jointly car-
ried out a survey on cannabis cultivation in Afghanistan 
in 2009, 2010 and 2011. The extent of cannabis cultiva-
tion and production could only be estimated as ranges with 
a high level of uncertainty at between 9,000 and 29,000 
ha in 2010, which is lower than earlier estimates from 
Morocco. However, the large yield of the Afghan cannabis 
crop (128 kg of cannabis resin per hectare, compared with 
about 40 kg per hectare in Morocco), which led to the 
production of between 1,200 and 3,700 tons of cannabis 
resin in 2010, makes Afghanistan a very important — if 
not the most important — producer of cannabis resin 
worldwide.
The latest results of UNODC price monitoring have 
shown that, as the price of cannabis largely developed in 
parallel with the opium price hike caused by the 2010 
opium crop failure (see figure 33), cannabis continues to 
be an attractive cash crop in Afghanistan. The rise in the 
farm-gate price of cannabis in Afghanistan was, to some 
extent, echoed in its neighbouring countries, particularly 
Pakistan, where the wholesale price increased from $200 
per kilogram in December 2009 to $630 per kilogram in 
February 2012. 
Cannabis: Afghanistan’s most lucrative 
cash crop
Production and price data collected for the 2010 survey 
of cannabis cultivation in Afghanistan showed that can-
nabis cultivation has become very lucrative, with reve-
nues even surpassing those earned from the cultivation 
of opium poppy: the average gross income of a cannabis-
growing household was about $9,000 in 2010, com-
pared with $4,900 for a household growing opium 
poppy. The income of the latter increased in 2011 to 
$10,700. However the results of the 2011 cannabis 
survey are not yet available, and comparisons cannot be 
made for 2011. 
Fig. 32. Main source countries of cannabis resin, 2002-2010
Source: UNODC data from the annual report questionnaire (2002-2010).
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Seizure data show that an increase in seizures of cannabis 
resin in South-West Asia as a whole could be observed in 
2010; and although seizures in Afghanistan dropped after 
reaching a record level in 2008 (271 tons, mainly as a result 
of one very large seizure), seizures in its neighbouring 
countries increased. In Pakistan, seizures of cannabis resin 
increased sharply from 2008, with 212 tons being seized 
in 2010, almost twice the 2007 level (see figure 34). Paki-
stan assessed that all of the cannabis resin seized on its ter-
ritory in 2010 originated in Afghanistan, and identified 
Canada and Sri Lanka as being among the intended coun-
tries of destination. Seizures of cannabis resin also increased 
in the countries in the Middle East with the largest amount 
of seized cannabis resin (Egypt, Saudi Arabia and the 
Syrian Arab Republic).
Cannabis resin seizures in Turkey, an important transit 
country for opiates from Afghanistan, also showed an 
increasing trend, from 10 tons in 2009 to 29 tons in 2010 
(see figure 35). Since heroin seizures decreased in Turkey 
in 2010, it seems plausible that there has been a shift from 
smuggling heroin to smuggling consignments of cannabis 
resin, which is more common, possibly destined for other 
European countries. However, since seizure data may 
simply reflect improved law enforcement efforts, it is not 
entirely clear whether the decrease in heroin seizures gave 
security forces more opportunity to seize cannabis or 
whether this actually reflected an increase in trafficking 
from, or illicit production in, Afghanistan. 
The continuous increasing trend in seizures of cannabis 
herb in Kazakhstan, where cannabis grows wild in large 
areas, is also remarkable. Since 2010, Kazakhstan has devel-
oped new approaches to counteracting drug trafficking 
and illicit drug use, focusing on supply reduction, strength-
ening its southern border and treatment programmes for 
drug users.92 Therefore, increased seizures may also reflect 
an increase in law enforcement activities and not simply 
increased illicit drug production and trafficking in that 
country. 
92 United States, Department of State, Bureau for International Narcotics 
and Law Enforcement Affairs, International Narcotics Control Strategy 
Report, vol. I, Drug and Chemical Control (March 2011).
Fig. 33. Average farm-gate prices for opium 
and cannabis resin (first “garda”) in  
Afghanistan, 2005-2011
Source: UNODC and Afghanistan, Ministry of Counter-Narcotics. 
Note: “Garda” is the local term used in Afghanistan for the powder 
obtained by threshing and sieving harvested and dried cannabis plants. This 
process is repeated several times, resulting in different quality levels of 
“garda” (first, second, third). “Garda” is further processed into hashish, 
which is the traded product.
Fig. 34. Cannabis resin seized in Afghanistan 
and its neighbouring countries,  
2002-2011
Source: UNODC and Afghanistan, Ministry of Counter-Narcotics, 
Afghanistan: Cannabis Survey 2010 (2011).
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2001-2010
Source: Annual report questionnaire supplemented by other  
official sources.
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Europe: a market in transition?
Europe may be the world’s largest market for imported 
cannabis resin, but there is evidence that cannabis herb 
actually produced in the region itself93 is playing an 
increasingly important role in the European cannabis 
market. As discussed above, cannabis resin consumed in 
Europe is traditionally from Morocco but cannabis culti-
vation and production in that country seem to be on the 
decline. From the late 1990s to the mid-2000s, cannabis 
resin seizures increased with a sudden drop in 2006 fol-
lowing a 2005 crop failure in Morocco (see figure 36), 
whereas cannabis herb seizures decreased in the same 
period. Cannabis herb seizures started increasing in 2006 
and stabilized at about 170 tons per year in 2009 and 2010, 
whereas seizures of cannabis resin have significantly 
decreased since 2008, and the 2010 seizure total of 566 
tons is even lower than the total in 2006.
Spain, which has long been a gateway for cannabis resin 
from North Africa, reports that seizures fell for the second 
consecutive year to their lowest registered level since 1997 
(384 tons). If this trend continues, it may be an indication 
of the increasing relative importance of cannabis herb over 
cannabis resin in Europe, though assessing how trends in 
European production of cannabis herb influence the can-
nabis market and the consumption of cannabis continues 
to be difficult. European price data show that, while the 
price of cannabis herb increased between 2004 and 2010, 
the price of cannabis resin remained stable (see figure 37), 
lending weight to this argument. However, the prices are 
adjusted for inflation but not for purity/potency, which is 
93 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe. EMCDDA is 
to review developments in the European cannabis market in detail in 
a forthcoming issue of the EMCDDA Insights series.
particularly significant in the case of cannabis herb, as the 
potent “sinsemilla” (a high-grade form of cannabis that is 
produced without seeds and that consists of the unfertilized 
flowers of the female plant) is reportedly more expensive 
than less potent forms of cannabis. 
The term “import substitution” is increasingly being used 
in reference to increases in cannabis cultivation in Europe. 
In recent scientific literature94 on cannabis markets, as well 
as in reports published by individual countries such as 
France,95 increasing local production of cannabis is related 
to tougher competition in the European market for 
imported products such as cannabis resin. 
A shift in cannabis herb production 
in Europe
The Netherlands continues to be one of the main Euro-
pean countries producing cannabis herb; however, tougher 
policies towards cannabis production in the past few years 
have been implemented there, which can be observed in 
the country’s large number of dismantled “grow-ops”, or 
indoor cultivation sites. In the past five years, between 
5,000 and 6,000 sites have been dismantled annually,96 
94 A comprehensive overview is given by T. Decorte, G. R. Potter and M. 
Bouchard, eds., World Wide Weed: Global Trends in Cannabis Cultiva-
tion and its Control (Ashgate, 2011).
95 C. Ben Lakhdar and D. Weinberger, “Cannabis markets and produc-
tion: the cannabis market in France—between resin imports and home 
grown herbal cannabis”, in 2009 National Report (2008 Data) to the 
EMCDDA by the Reitox National Focal Point: France—New Develop-
ments, Trends and In-Depth Information on Selected Issues (European 
Monitoring Centre for Drugs and Drug Addiction and Observatoire 
français des drogues et des toxicomanies, 2009).
96 Wouters estimates 6,000 sites after adjusting for possible errors (M. 
Wouters, “Controlling cannabis cultivation in the Netherlands”, in 
Cannabis in Europe: Dynamics in Perception, Policy and Markets, Dirk 
J. Korf, ed. (Lengerich, Germany, Pabst Science Publishers, 2008).
Fig. 36. Cannabis herb and cannabis resin 
seized in Europe, 1998-2010
Source: Annual report questionnaire supplemented by other  
official sources.
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Change in seizure weight
and restrictive policies have resulted in a decline in the 
number of so-called “coffee shops”, where cannabis is sold 
for personal consumption. In addition, continued actions 
targeting growing sites have led to a reduction in the avail-
ability of cannabis.97
These decreases in production in Western Europe may 
have triggered an increase in the production of cannabis 
herb in countries in Central, Eastern and Northern Europe, 
as well as in Portugal and Spain. Several countries (Austria, 
Belarus, Poland, Slovakia and Sweden) in those parts of 
Europe reported increases in the period 2009-2010, and 
others (Iceland, Lithuania, Poland and Romania) have 
reported the appearance of indoor cultivation sites. Ukraine 
has reported the appearance and eradication of large can-
nabis fields in its border area with the Republic of Mol-
dova, made more seizures and also reported recent large 
increases in cultivation, estimating the area under illicit 
cannabis cultivation at 920 ha in 2010. Albania, another 
important country producing cannabis herb, has imple-
mented tough law enforcement actions against cannabis 
growers and traffickers and reported a lower estimate of 
the production capacity for the region.98 
97 Ibid.
98 UNODC, data from the annual report questionnaire (2010); Bureau 
for International Narcotics and Law Enforcement Affairs, Interna-
tional Narcotics Control Strategy Report (March 2011).
When comparing cannabis herb seizures99 between 2001-
2005 and 2006-2010 (see map 9), a pattern appears that 
confirms the reported production trends mentioned above. 
Traditional producers of cannabis herb such as Albania, 
the Netherlands and the United Kingdom show decreases 
in herb seizures whereas increases are shown in Bulgaria 
and Turkey, Central Europe, the Iberian Peninsula and 
parts of Scandinavia. 
Indoor herb production
The proliferation of indoor cultivation sites used for sup-
plying cannabis herb for the domestic market is another 
noticeable trend in Europe, with most European Union 
member States reporting the indoor cultivation of cannabis 
to be on the increase.100 This is mirrored in the existence 
of “grow shops” (also called “head shops”), specializing in 
supplying equipment for indoor cannabis cultivation; 
while they usually operate on a small scale, they may also 
be part of major production sites run by organized crimi-
nal groups.
99 Cannabis herb seizures refer to the total amount of retail and wholesale 
product seized. They do not include cannabis plants seized, for exam-
ple, at production sites.
100 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
Map 9. Change in cannabis herb seizures occurring between the periods 2001-2005 and 2006-2010
Source: Annual report questionnaire supplemented by other official sources. 
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. 
Dashed lines represent undetermined boundaries. Dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties.
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The increased access to the know-how and equipment 
needed for cultivating cannabis (seeds, growing lamps, 
hydroponic installations etc.), both in “grow shops” and 
on the Internet, means that starting a cannabis production 
unit has become relatively easy, and that has led to the 
further dispersion of cannabis production. The ready avail-
ability of cannabis seeds on the Internet, which are shipped 
in inconspicuous packages worldwide by post and courier 
services, requires further attention, as it has greatly 
increased access to high-yielding and highly potent can-
nabis varieties. UNODC is currently conducting in-depth 
research into this market, identifying 100-200 seed banks 
on the Internet in 2011 (see the box on page 50). 
Japan, a high-income country with limited options for 
outdoor cultivation, has also reported an increase in indoor 
cannabis cultivation as a result of the increasing availability 
of cannabis production paraphernalia and know-how. The 
number of arrests for cannabis-related crime has increased 
greatly since 2001 while the number of arrests for crime 
involving cannabis cultivation has increased, the number 
of persons arrested for importing cannabis has actually 
decreased (see figure 38), suggesting that cannabis culti-
vated in Japan is replacing cannabis imports. 
Potency
The rise in indoor cannabis cultivation is often related to 
an increase in cannabis potency, which is only reflected in 
the data to a limited extent. In 2009, the mean THC con-
tent of cannabis in European countries ranged from 3 to 
17 per cent, but it is more relevant to compare trends for 
different cannabis products. For example, the potency of 
cannabis herb remained relatively stable or decreased in 10 
reporting countries but increased in the Czech Republic, 
Estonia, the Netherlands and Slovakia, while the potency 
of locally produced “nederwiet” in the Netherlands 
declined from a peak of 20 per cent in 2004 to 15 per cent 
in 2009.101 However, there is no clear recent overall trend 
for THC potency in Europe.
Nor can the reported increase in domestic indoor cannabis 
cultivation be easily linked to changes in prevalence. 
Recent data for Europe indicate that cannabis use has 
increased in a small number of countries (Bulgaria, Esto-
nia, Finland, Sweden),102 while in others it has stabilized 
(e.g. in countries in Eastern Europe and South-Eastern 
Europe) or decreased (e.g. in countries in Western and 
Central Europe), especially among young adults (persons 
aged 15-34). Thus, cannabis production and use have 
increased in some countries whereas in others, despite a 
reported increase in production, there has been no increase 
in the prevalence of cannabis use. It is not clear whether 
there have been changes in the amount consumed or if 
imported cannabis is being replaced by locally produced 
cannabis. Furthermore, other factors, such as the decline 
in tobacco smoking among young people, changes in life-
style and fashion or replacement by other drugs, may have 
influenced cannabis use. 103 
Cannabis herb: a look at main  
markets in the Americas
Most countries in North America and South America have 
registered increases in cannabis herb seizures in recent 
years. The most noticeable increases were in South Amer-
ica, where several countries reported large quantities of 
seized cannabis herb in 2009 and 2010. In Colombia, for 
example, seizures rose from 209 tons in 2009 to 255 tons 
in 2010; Brazil registered cannabis herb seizures of 155 
tons in 2010; and in Paraguay, where extensive cultivation 
of cannabis has been reported, seizures reached 84 tons in 
2009. Seizures in the Bolivarian Republic of Venezuela 
rose from 33 tons in 2009 to 39 tons in 2010. The Pluri-
national State of Bolivia reported the eradication of 1,069 
tons of cannabis plant in 2010; that amount represents a 
notable long-term increase, as it is more than eight times 
the amount eradicated in 2006.104
The United States reported that the increasing level of can-
nabis cultivation in Mexico until 2009, in combination 
with high and increasing levels of such cultivation in the 
United States in 2010, resulted in the increased availability 
of cannabis herb in 2010.105 The United States seized simi-
lar amounts of cannabis herb in 2009 and 2010, with 
annual totals reaching 2 049 tons in 2009 and 1 931 tons 
in 2010. In the same period, cannabis herb seizures in 
101 Ibid.; World Drug Report 2011.
102 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2011: The State of the Drugs Problem in Europe.
103 Ibid.
104 An official breakdown of cannabis seizures in 2006 was not available.
105 Bureau for International Narcotics and Law Enforcement Affairs, 
International Narcotics Control Strategy Report (March 2011).
Fig. 38. Number of persons arrested for  
cannabis-related crime in Japan,  
2001-2010
Source: Japan Ministry of Health, Labour and Welfare.
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Cannabis seeds 
UNODC is currently undertaking research, to be concluded in 2012, into cannabis seeds purchasable online. Some 
of the findings are presented below.
In recent years, the trade in highly potent cannabis strains has become a subject of increasing concern in the inter-
national community. The cultivation of cannabis is illegal in almost all countries but the sale of cannabis seeds, which 
are openly marketed online directly by producers or through resellers and shipped worldwide in stealth packages, is 
often legal or semi-legal and only some countries restrict it. 
The cannabis seed business
The cannabis seed market has grown significantly in the past few years. To date between 100 and 200 cannabis seed 
brands can be found on the Internet. Those brands are produced by companies the majority of which are based in 
the Netherlands and Spain, but also in other European countries, Canada and the United States. However, the seeds 
produced by those companies are sold by a much greater number of resellers in a large number of countries.
The role of cannabis seeds in cannabis production
Cannabis can be grown not only outdoors but also in houses, garages, trucks or any other space provided that water 
and artificial lighting are on hand. The use of (purchased) seeds is an easy way for the home grower to start cultivat-
ing cannabis, but since cannabis plants can also be propagated by clones taken from an adult (“mother”) plant, seeds 
are not necessary for continuing cannabis cultivation once it has commenced. Cloning is a more sophisticated 
procedure, mostly practised by commercial cultivators, whereas home growers may prefer using seeds, which is an 
easier and more reliable method.
Distribution of cannabis seeds
The cannabis seed market is dominated by a number of large companies that successfully breed popular varieties of 
cannabis plants. Seeds may be sold online, directly by the breeder or by specialized online stores. However, the 
Internet is not the only source of cannabis: seeds are also distributed through social networks or via the sale of can-
nabis herb, when found among the flower heads of cannabis herb used for smoking. 
Cannabis varieties sold
The large number of cannabis varieties developed over the years provides the user with a wide palette of potencies 
and tastes to choose from, which are specified on dealers’ websites and in their brochures. The varieties are the 
product of decades of cross-breeding the three major cannabis species,a Cannabis sativa, Cannabis indica and Can-
nabis ruderalis, and the resulting strains are marketed under imaginative names such as Northern Lights, Thai Tanic, 
Lemon Chunk and White Widow. 
Several types of specially bred cannabis seeds, such as seeds of “feminized” and “auto-flowering” strains, are available. 
Normal cannabis seeds produce both male and female plants, but seeds of “feminized” cannabis are specially treated 
so that only female cannabis plants, which are in demand because of their high THCb content, are produced. “Auto-
flowering” strains can produce more than one harvest per year when grown outdoors.
Cannabis seed vendors usually provide information on the expected yield of each variety, the flowering period (time 
until harvest), the expected size of the plant and — less frequently — the THC level. Specifications on websites 
typically promise a THC level of 15-18 per cent, but sometimes up to 25 per cent, while some breeders also specify 
the level of cannabidiol (CBD), another psychoactive ingredient. These strain properties (yield, time until harvest, 
THC content) probably reflect some of the breeding goals of seed producers.
In 2011, the price for 10 cannabis seeds ranged from 15 to 180 euros, with most prices being between 50 and 70 
euros. Seeds of “feminized” cannabis are considerably more expensive than regular seeds because “feminized” seeds 
produce only female plants, whereas normal seeds also result in some male plants, which are not used for consump-
tion.
a Whether these are species or varieties is the subject of scientific debate.
b Cannabis growers harvest the flowers of the female plants, which has the highest THC levels. Except for “auto-flowering” plants, cannabis 
starts to flower when the hours of light are reduced.
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Mexico increased from 2,105 to 2,313 tons and seizures 
in Canada increased substantially (from 34 to 51 tons). 
The United States assessed that only 7 per cent of the can-
nabis herb seized in 2010 originated on its own territory; 
it also reported that a large percentage of the seized can-
nabis herb was of unknown origin, though Canada and 
Mexico are known to be source countries of cannabis herb 
in the United States. Canada seized 51 tons of cannabis 
herb and 1.9 million cannabis plants in 2010; however, 
the smuggling of cannabis herb from Canada into the 
United States appears to be decreasing and cannabis pro-
duction seems to be shifting to the United States side of 
that country’s border with Canada.106 The Sinaloa cartel, 
which manages highly sophisticated transportation and 
distribution networks107 is one of the most prominent 
organizations involved in trafficking cannabis herb in the 
United States.
Although estimates of the actual magnitude of cannabis 
production in the United States are lacking, eradication 
data point to continuing extensive cannabis cultivation in 
the country. The total number of eradicated cannabis 
plants continued to increase in 2010, with fewer of the 
eradicated plants having been cultivated outdoors (almost 
10 million plants) and more cultivated indoors (almost 
half a million plants).108 In the United States, cannabis is 
principally and increasingly cultivated on public land 
(national forests), particularly in California, as indicated 
by the large share (about 70 per cent) of cannabis seizures 
in that state. Most of the destroyed indoor growing sites 
were in Florida; however, of the eradicated cannabis plants 
that had been cultivated indoors, the majority were eradi-
cated in California.
E. ILLICIT MARKET FOR AMPHETA-
MINE-TYPE STIMULANTS
A picture of stability 
While global ATS seizures remained largely stable in 2010, 
the year was marked by a significant increase in metham-
phetamine seizures, which surpassed amphetamine seizures 
for the first time since 2006. Methamphetamine seizures 
totalled 45 tons, a 44 per cent increase over 2009 (31 tons) 
and more than double the amount seized in 2008 (22 tons) 
(see figure 39). That was mainly attributed to a significant 
increase in seizures in Mexico, as well as in East and South-
East Asia. 
By contrast, global amphetamine seizures declined by 42 
per cent to 19 tons (compared with 33 tons in 2009) 
106 United States, Department of Justice, National Drug Intelligence 
Center, National Drug Threat Assessment 2011 (August 2011).
107 Ibid.
108 Kathleen Maguire, ed., Sourcebook of Criminal Justice Statistics (United 
States, Department of Justice, Bureau of Justice Statistics). Available 
from www.albany.edu/sourcebook/index.html (accessed March 2012).
largely as a result of a decrease in such seizures in the Near 
and Middle East and South-West Asia. The downward 
trend in amphetamine seizures in Europe that began in 
2008 continued in 2010, yet there was a significant rise in 
the number of amphetamine laboratories seized in Europe 
and, as in previous years, Europe accounted for the major-
ity of the laboratories seized worldwide for illicitly manu-
facturing substances in the amphetamine group.
There are signs that the “ecstasy” market began to recover 
in 2010. For, example, the availability109 and use of 
“ecstasy” appears to be on the increase in the United States 
110 while Europol has also reported a resurgence of the 
drug in Europe since mid-2010. A 31 per cent increase in 
“ecstasy” seizures was observed in East and South-East Asia, 
and seizures also increased in Oceania.
In the past few years, the market for new psychoactive 
substances that mimic the effects of illicit stimulants such 
as “ecstasy” and amphetamines has evolved rapidly, while 
plant-based products have also emerged on the illicit ATS 
market. In order to avoid detection, drug trafficking organ-
izations have continued to adapt their manufacturing strat-
egies, and continuing change in the illicit manufacturing 
process of synthetic substances presents a myriad of new 
challenges to drug control authorities worldwide. 
Increased methamphetamine seizures 
in North America
North America accounted for roughly half of global meth-
amphetamine seizures in 2010, reporting 22 tons of seized 
methamphetamine. The biggest increase in methampheta-
mine seizures was reported in Mexico, where seizures dou-
bled from 6 tons in 2009 to almost 13 tons in 2010, but 
methamphetamine seizures also rose significantly in the 
United States, from 7.5 to 8.7 tons in that period.111 The 
increase in average purity, in tandem with a decline in aver-
age prices (see figure 40), indicates that the supply of meth-
amphetamine has been increasing in every part of the 
United States. The illicit manufacture of methampheta-
mine continues on a large scale in Mexico, where large 
amounts of precursors of ATS have been seized.112 
109 Particularly in the Great Lakes, New York/New Jersey, Southwest, 
and Pacific Organized Crime Drug Enforcement Task Forces regions 
(National Drug Intelligence Center, National Drug Threat Assessment 
2011).
110 In 2010, 52.3 per cent of National Drug Threat Survey respondents 
indicated a moderate to high level of MDMA availability in their 
jurisdiction, compared with 51.5 percent in 2009 (National Drug 
Intelligence Center, National Drug Threat Assessment 2011).
111 The year refers to the United States Government’s fiscal year beginning 
on October 1 of the previous calendar year and ending on September 
30 of the year in which it is numbered.
112 About 787 tons of phenylacetamide, a precursor of phenyl acetic acid, 
which is used in the illicit manufacture of methamphetamine, were 
found in the 2,500 m2 warehouse. Some 53 tons of tartaric acid, 
which is used in purifying d-/l-methamphetamine, were found in 
addition to 340,000 litres of benzyl chloride. In addition isobutyl 
phenylacetate and methyl phenylacetate were discovered, all of which 
can be broken down to phenylacetic acid (United Nations Office on 
Drugs and Crime, Global SMART Update, vol. 6, November 2011).
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The methamphetamine market 
expands in Europe
Although it remains a comparatively small market in global 
terms, the methamphetamine market in Europe is also 
expanding, where some countries (particularly in the north 
of Europe) have begun to report the increased presence of 
methamphetamine on their illicit markets. Indications of 
the increased use of methamphetamine were found in 
Norway, other Scandinavian countries and Germany;113 
113 Amphetamines and Ecstasy—2011 Global ATS Assessment.
and while methamphetamine seizures in Europe fell from 
696 kg in 2009 to 576 kg in 2010, they remained higher 
than seizures recorded prior to 2009. Increases were also 
registered by the Czech Republic, Finland, France, Ger-
many, the Netherlands, the Russian Federation and Swit-
zerland. By far the highest seizure levels were reported in 
Sweden (124 kg) and Turkey (126 kg), which together 
accounted for almost half (43 per cent) of total metham-
phetamine seizures in Europe. 
Despite signs of an expansion of the methamphetamine 
market in Europe, the number of illicit methamphetamine 
laboratories seized in the region has been in decline since 
2008, falling from 361 in 2009 to 328 in 2010. As in pre-
vious years, the Czech Republic accounted for the vast 
majority (307) of the laboratories seized in Europe, while 
there was an increase in the number of such laboratories 
reported to have been seized in Austria (five facilities, com-
pared with three in 2008 and two in 2009) and Bulgaria 
(two mobile laboratories in 2010, the first reported manu-
facture of methamphetamine there in a decade). 
Methamphetamine seizures in  
South-East Asia
As in previous years, the vast majority (96 per cent) of ATS 
seizures made in East and South-East Asia in 2010 involved 
methamphetamine. Methamphetamine seizures in 2010 
represented an increase of more than one quarter (28 per 
cent; from 16 to 20 tons) over 2009 and 74 per cent over 
2008, with methamphetamine seizures in East and South-
East Asia accounting for almost half of the global total in 
2010. 
Nearly 136 million methamphetamine tablets were seized 
in 2010, representing a 44 per cent increase compared with 
the number of tablets seized in 2009 (94 million) and a 
more than fourfold increase compared with the 2008 figure 
Fig. 39. Amphetamine-type stimulants seized worldwide, by weight, 2002-2010
Source: Annual report questionnaire supplemented by other official sources. 
a Including seized amphetamine, “ecstasy”-type substances, methamphetamine, non-specified amphetamine-type stimulants, other stimulants and  
 prescription stimulants. For the categories of other stimulants and prescription stimulants, seizures reported by weight or volume only are included.
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(32 million) (see figure 41). Most of the tablets were seized 
in China (58.4 million), Thailand (50.4 million) and the 
Lao People’s Democratic Republic (24.5 million), which 
together accounted for 98 per cent of the regional total.114 
Significant quantities of ATS continue to be illicitly manu-
factured in Myanmar in the form of methamphetamine 
tablets, most of which are manufactured in Shan State, in 
the eastern part of the country. Malaysia, where crystalline 
methamphetamine is predominantly used, also reported 
significant seizures of methamphetamine in the form of 
tablets (108,000) in 2010.115
Several countries and territories registered considerable 
fluctuations in methamphetamine seizures. Myanmar and 
the Philippines reported a significant decline; China, the 
Lao People’s Democratic Republic and Thailand reported 
large increases, as did Hong Kong, China. Reports for 2011 
from Cambodia show a significant increase in metham-
phetamine seizures, with seizures in 2011 more than tri-
pling to some 264,000 methamphetamine tablets, 
compared with a total of 83,000 tablets in 2010.116 Sei-
zures of crystalline methamphetamine also increased, from 
10 kg in 2010 to 19 kg in the first half of 2011;117 large 
amounts of precursor chemicals were also seized in 2010 
and almost 20 million tablets of pharmaceutical prepara-
114 Statistics based on data reported on number of tablets and collated by 
the UNODC global Synthetics Monitoring: Analysis, Reporting and 
Trends (SMART) programme. Data submitted through the annual 
report questionnaires by some countries was quantified by weight.
115 Ibid.
116 Information provided by Cambodia at the seventeenth Asia-Pacific 
Operational Drug Enforcement Conference, Tokyo, February 2012, 
p. 5.
117 Ibid.
tions containing pseudoephedrine were seized by Cambo-
dian authorities in 2010.118
In contrast to the trends reported in most countries in East 
and South-East Asia, methamphetamine seizures in Japan 
have been in declining steadily since 2008. This trend con-
tinued in 2010, with the country recording methampheta-
mine seizures of 311 kg compared with 368 kg in 2009.
A global drop in amphetamine seizures 
Global amphetamine seizures declined by 42 per cent to 
19 tons in 2010 from 33 tons in 2009, largely as a result 
of the decrease in amphetamine seizures in the Near and 
Middle East and South-West Asia. These subregions, which 
accounted for some 70 per cent of global amphetamine 
seizures, recorded a sizeable decline in seizures of ampheta-
mine (mostly Captagon119 tablets), from almost 24 tons 
in 2009 to 13 tons in 2010. This represented the lowest 
total amount of seized amphetamine reported in the region 
since 2006 and the first significant decline since 2000 (see 
figure 42). 
Amphetamine seizures in Europe 
continue to fall while the number of 
detected laboratories rises
The amount of amphetamine seized in Europe, which had 
been on the decline since 2008, continued its downward 
trend, from 8.9 tons in 2009 to 5.4 tons in 2010, the lowest 
seizure total for amphetamine in the region since 2002. 
118 Information provided by Cambodia at the sixteenth Asia-Pacific 
Operational Drug Enforcement Conference, Tokyo, February 2011, 
p. 2.
119 Captagon, a proprietary product containing the stimulant fenetylline, 
was discontinued in the 1980s. However, counterfeit versions contain-
ing primarily amphetamine continue to be available.
Fig. 41. Methamphetamine tablets seized in 
east and South-east Asia, 2008-2010
Source: Based on data collected by the Drug Abuse Information 
Network for Asia and the Pacific, including data for Brunei Darus-
salam, Cambodia, China, Indonesia, Japan, the Lao’s People Dem-
ocratic Republic, Malaysia, Myanmar, the Philippines, the Republic 
of Korea, Singapore, Thailand and Viet Nam.
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However, there was a 44 per cent increase in the number 
of amphetamine laboratories seized in Europe, with 62 
seized in 2010 as opposed to 43 in 2009. As in previous 
years, amphetamine laboratories accounted for the major-
ity of the laboratories seized worldwide for illicitly manu-
facturing substances in the amphetamine group. Estonia 
reported a significant increase in the number of ampheta-
mine laboratories detected, from two laboratories in 2009 
to seven in 2010. 
EMCDDA reported that the use of industrial equipment 
may have increased the production capacity and subse-
quent yield in the “north-west hub’’ (the Netherlands and 
Belgium) from 5-8 kg of amphetamine per production 
batch to up to 30-40 kg, while the capacity of illicit manu-
facturing facilities in Poland is reported to have risen from 
about 3 kg per batch to 4-8 kg per batch.
“Ecstasy” markets show signs  
of recovery 
Although many countries reported a continued low avail-
ability of MDMA in the “ecstasy” market in 2010 (often 
compensated by the increasing availability of new psycho-
active substances), there are signs that the “ecstasy” market 
began to recover in the period 2010/2011.
The significant decline in the total amount of “ecstasy”-
group substances seized in Canada between 2007 and 
2009120 was reversed in 2010, when “ecstasy” seizures 
increased to 529 kg from 405 kg in 2009. Destinations for 
“ecstasy” shipments seized in, or en route from, Canada 
120 “Ecstasy” seizures fell from 1 ton in 2007 to 715 kg in 2008 and 405 
kg in 2009.
included the United States and, to a lesser extent, Australia, 
Malaysia and Peru.121 
Although overall “ecstasy” seizures declined in 2010, the 
availability of “ecstasy” in the United States also appears 
to be on the increase.122 The prevalence of “ecstasy” use 
among the general population still declined marginally in 
2010 (from 1.1 to 1 per cent of the population aged 12 
and over);123 in contrast, data collected from 12th grade 
students showed increases in the availability of “ecstasy”124 
in parallel to increases in the prevalence of “ecstasy” use in 
both 2010 and 2011.125
The quantity of “ecstasy” seized along the border between 
Canada and the United States increased from more than 
1.9 million tablets in 2006 to more than 3.9 million tab-
lets in 2010, the largest amount seized in half a decade and 
an indication of the rising importance of Canada as a 
source for the manufacture of “ecstasy”.126 In addition, 
the average load size of such seizures continued to increase.
After several years of decline, most notably in 2009, there 
are also signs of a recovery in the European “ecstasy” market, 
with Europol reporting a resurgence of the drug since mid-
2010 (see figure 44). This is also reflected in an overall 
increase in seizures of “ecstasy”-group substances reported 
to UNODC, which more than doubled (from 595 kg in 
2009 to 1.3 tons in 2010). This recovery seems to be largely 
linked to the discovery of slightly modified precursor chem-
icals that are not controlled at international level. 
While Eastern European countries experienced a slight 
decrease in “ecstasy” seizures, South-Eastern Europe and 
Western and Central Europe registered significant increases 
in seizures (82 per cent and 136 per cent, respectively). 
Seven countries (France, Germany, the Netherlands, 
Poland, Spain, Turkey and the United Kingdom) account 
for 90 per cent of reported seizures, including particularly 
large increases in the Netherlands, where seizures rose 
almost seven-fold but are still not comparable to seizures 
made before 2009. The increased supply of “ecstasy” in the 
121 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire (2010).
122 Particularly in the Great Lakes, New York/New Jersey, Southwest, 
and Pacific Organized Crime Drug Enforcement Task Forces regions 
(National Drug Intelligence Center, National Drug Threat Assessment 
2011).
123 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Summary of 
National Findings.
124 The proportion of 12th grade students finding it very easy or fairly 
easy to obtain MDMA declined from a peak of 61.5 per cent in 2001 
to 41.9 per cent in 2008 and 35.1 per cent in 2009 before recovering 
again to 36.4 per cent in 2010 and 37.1 per cent in 2011 (United 
States, National Institute on Drug Abuse, Monitoring the Future 
survey, December 2011).
125 In line with availability, annual prevalence of MDMA use among 12th 
grade students fell from a peak of 9.2 per cent in 2001 to 4.3 per cent 
in 2009 before rising again to 4.5 per cent in 2010 and 5.3 per cent in 
2011. (United States, National Institute on Drug Abuse, Monitoring 
the Future survey, December 2011).
126 National Drug Intelligence Center, National Drug Threat Assessment 
2011, p. 30.
Fig. 43. Amphetamine seizures in selected  
European countries, 2009-2010
Source: Annual report questionnaire supplemented by other  
official sources. Estimates for 2009 and 2010 for the United King-
dom are based on incomplete data for some jurisdictions for the 
financial years 2009/2010 and 2010/11, respectively, and adjusted 
for the missing jurisdictions using the distribution (based on more 
comprehensive data) in 2006/07.
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European market is confirmed by the increasing purity of 
“ecstasy” observed in some European countries such as the 
Netherlands and the United Kingdom. 
A 31 per cent increase in “ecstasy” seizures was observed 
in 2010 in East and South-East Asia, where China (382 
kg), Malaysia (130 kg) and Indonesia (127 kg) reported 
significant seizures of “ecstasy”-group substances. In Oce-
ania, seizures also continued to increase in Australia, where 
112 kg of “ecstasy”-group substances were seized in 2010, 
compared with 54 kg in 2008 and 59 kg in 2009. In New 
Zealand, “ecstasy” seizures tripled to 12 kg, matching the 
level reported in 2004. 
A decline in the number of “ecstasy”  
laboratories seized in 2010
The number of “ecstasy” laboratories seized worldwide 
declined from 52 in 2009 to 44 laboratories in 2010. 
Countries reporting “ecstasy” manufacture in 2010 (by 
number of laboratories seized) were Australia (17), Canada 
(13), Indonesia (12), Malaysia (1) and Argentina (1). 
Despite a decline in reported “ecstasy” manufacture, it is 
worth noting that some countries, such as Australia and 
Indonesia, reported an increase in the manufacturing capa-
bility or size of laboratories. Also of note is the fact that 
some countries, such as Canada, New Zealand and Turkey, 
reported incidences of possible polydrug manufacture, in 
which “ecstasy” was also being manufactured in illicit 
methamphetamine laboratories. In Europe, despite 
increased seizures of the drug, no “ecstasy” laboratories 
were reported to UNODC as having been seized in 2010 
(see figure 46). However, several “ecstasy” laboratories were 
discovered in 2011. 
The continuing emergence of new  
psychoactive substances 
The ATS market has always been characterized by a large 
variety of substances and, in recent years, the market for 
new psychoactive substances has evolved rapidly. Unprec-
edented numbers and varieties of new psychoactive sub-
stances, often sold as “bath salts”, “legal highs” or “plant 
food”, are appearing on the market. These psychoactive 
substances, which include piperazines such as BZP or 
m-chlorophenylpiperazine (mCPP), as well as analogues of 
methcathinone such as 4-methylmethcathinone (4-MMC, 
known as mephedrone) or MDPV, mimic the effects of 
stimulants such as “ecstasy” and amphetamines. 
Mephedrone is accounting for an increasingly significant 
share of illicit drug markets in some European countries. 
Hungary, for example, reported that mephedrone was the 
Fig. 44. “Ecstasy” seizures, by region,  
2001-2010
Source: Annual report questionnaire supplemented by other  
official sources.
Fig. 45. MDMA content of tablets sold as 
“ecstasy” in the Netherlands and the 
United Kingdom (based on laboratory 
analysis), 2006-2010
Source: Charlotte Davies and others, eds., United Kingdom Drug 
Situation: Annual Report to the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) 2010 (United Kingdom, 
Department of Health, and UK Focal Point on Drugs, 2010).
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most frequently seized synthetic substance in 2010;127 and 
in the United Kingdom a recent government report showed 
that 286 of the 3,564 drug seizures made in Northern Ire-
land in the period 2010-2011 were mephedrone seizures, 
which was considerably more than the number of seizures 
for amphetamines (128 seizures) and “ecstasy” (150 sei-
zures), and only slightly fewer than the number of seizures 
of cocaine (304 seizures).128 
The synthetic cathinone MDPV has also become more 
widespread in illicit ATS markets around the world, 
notably in the United States. However, as the substance is 
not under international control, seizures are not routinely 
reported to UNODC via the annual report questionnaire.
The use of piperazines has been reported in various regions, 
including Asia,129,130 Europe and Oceania. BZP has been 
identified as a threat in the Philippines; and in Viet Nam, 
seizures of mCPP have been reported, and the use of 
1-(3-trifluoromethylphenyl)piperazine and BZP is also 
reportedly widespread. In Europe, several countries 
(Cyprus, Finland, Hungary, the Netherlands and Slovakia) 
reported seizures of mCPP tablets in 2010 (see figure 47), 
and Cyprus also reported seizures of BZP. 
127 Information provided by Hungary in the annual report questionnaire 
(2010).
128 Charlotte Davies and others, eds., United Kingdom Drug Situation: 
Annual Report to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 2010 (United Kingdom, Department of 
Health, and United Kingdom Focal Point on Drugs,  2010).
129 Information provided by Viet Nam at the seventeenth Asia-Pacific 
Operational Drug Enforcement Conference, Tokyo, February 2012, 
p. 3.
130 Global SMART Drug Control Brief, Viet Nam (March 2011); coun-
try report by Viet Nam, Standing Office on Drugs and Crime, pre-
sented at the Thirty-fourth Meeting of Heads of National Drug Law 
Enforcement Agencies, Asia and the Pacific, Bangkok, 30 November-3 
December 2010, p. 2.
Increasing flexibility in  
ATS manufacture
Drug trafficking organizations have always shown an 
extraordinary degree of flexibility in adapting their manu-
facturing strategies to avoid detection. Some of these strat-
egies include the use of substitute chemicals, the extraction 
of precursors from pharmaceutical preparations and, most 
recently, the masking of precursors and development of 
alternative methods of synthesis. The continued change in 
the illicit manufacturing process of synthetic substances 
presents a myriad of new challenges to drug control author-
ities worldwide. 
Ephedrine and pseudoephedrine have traditionally been 
the main precursors used in the illicit manufacture of 
methamphetamine but control over the substances, both 
in bulk form and in the form of pharmaceutical prepara-
tions, has increased considerably in recent years, particu-
larly in North America. As a result, traffickers have resorted 
to manufacturing methamphetamine using the substitute 
chemical 1-phenyl-2-propanone (P-2-P) and its precursors, 
including phenylacetic acid and phenyl acetate esters.131 
Global seizures of precursors reflect the increasing impor-
tance of P-2-P and phenylacetic acid in illicit ATS manu-
facture (see figure 48). 
Pseudoephedrine extracted from pharmaceutical prepara-
tions continues to be used as a precursor in the illicit manu-
facture of ATS. Large quantities of pseudoephedrine 
preparations intended for this purpose have been seized in 
131 The product obtained from the use of phenylacetic acid or P-2-P is a 
less potent racemic mixture, d- and l-methamphetamine. Laboratory 
operators compensate for the loss in potency of this product by higher 
purity levels or by adding an additional purification step to obtain the 
traditional d-methamphetamine. 
Fig. 47. Seizures of mCPP tablets reported in 
selected European countries, 2010
Source: Annual report questionnaire. 
Note: Finland also reported the seizure of 56 kg of mCPP.
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Asia (particularly in Myanmar and Thailand) and Oceania 
(in Australia and New Zealand). Similarly, the extraction 
of ephedrine and pseudoephedrine from ephedra plant 
material was reported in New Zealand132 and Kyrgyzstan. 
In the case of “ecstasy” manufacture, the extraction of saf-
role from camphor oil was noted in Australia in 2010. 
The masking of a precursor to avoid detection and/or con-
trols, followed by facile recovery to the original material 
prior to use in illicit ATS manufacture, presents a growing 
challenge to law enforcement authorities. For example, 
P-2-P, which exists as a liquid, has been seized in several 
countries in Europe in the form of a white powder (the 
non-scheduled bisulfite adduct) that can be converted into 
liquid form with relative ease. In 2010, the European 
market also saw the emergence of the non-controlled gly-
cidate derivative of 3,4-methylenedioxyphenyl-2-pro-
panone (3,4-MDP-2-P), the precursor used in the illicit 
manufacture of MDMA. Such masked precursors have 
little known legitimate use and share the common feature 
of being easy to convert to the related ATS precursor. 
New methods for illicitly manufacturing synthetic drugs 
continue to be developed. The “quick” or “volcano” 
method for manufacturing methamphetamine, discovered 
in the United States in 2010, seems capable of reducing 
the length of the entire synthesis to less than 10 min-
utes.133  The so-called “one-pot method” of manufacturing 
methamphetamine has also increased in popularity in com-
parison to previous years when the “red phosphorous” and/
or “anhydrous ammonia” manufacturing methods were 
predominant.134 An alternate method for manufacturing 
amphetamine involving the use of the non-controlled sub-
stances benzaldehyde135 and nitroethane136 as precur-
sors137 was also detected in a clandestine laboratory in 
Hungary in 2009.
132 A clandestine methamphetamine laboratory dismantled in July 
2010 revealed that the offender had been extracting ephedrine/pseu-
doephedrine from ephedra plant material and from pharmaceutical 
preparations (information provided by New Zealand in the annual 
report questionnaire).
133 Annual report questionnaire replies submitted by the United States for 
2010.
134 United States authorities attribute the popularity of the “one pot 
method” to the simplicity of the process and ease of acquiring “recipes" 
and/or videos containing step-by-step instructions via the Internet. 
Readily available ingredients are combined in a plastic two-litre bottle; 
no heat is required, and processing is completed in approximately 30 
minutes (information provided by the United States in the annual 
report questionnaire).
135 Benzaldehyde is a colourless liquid aldehyde with a characteristic 
almond odour used chiefly as a precursor for other organic com-
pounds, ranging from pharmaceuticals to plastic additives. It is formed 
by partial oxidation of benzyl alcohol and readily oxidized to benzoic 
acid and is converted to additional products by hydrocyanic acid or 
sodium bisulfite.
136 Nitroethane is a chemical used mainly as an industrial solvent, fuel 
additive and propellant in the manufacture of pharmaceutical products 
and in artificial nail removers. It is a colourless oily liquid with an 
unpleasant odour.
137 Amphetamines and Ecstasy: 2011 Global ATS Assessment.
Emerging markets and  
trafficking routes
West Africa
There is growing evidence to suggest that criminal organi-
zations involved in trafficking in ATS are exploiting West 
Africa in a similar way to the one used by cocaine traffick-
ers, by looking to avoid effective law enforcement in order 
to smuggle ATS, mostly methamphetamine, to other parts 
of the world (primarily East Asia) by courier. Seizures 
started to increase in West Africa in 2008, with metham-
phetamine being smuggled into countries in East Asia, 
predominantly Japan and the Republic of Korea. Seizures 
continued to be reported throughout 2009 and 2010. 
Near and Middle East 
Increasing annual legitimate requirements for precursor 
chemicals of ATS such as ephedrine and pseudoephedrine 
in the Near and Middle East could indicate the diversion 
of those chemicals for use in illicit drug manufacture. The 
countries reporting very high requirements for the precur-
sors include the Islamic Republic of Iran (55 tons), the 
Syrian Arab Republic (50 tons) and Pakistan (48 tons). 
Pakistan currently has the world’s fourth highest legitimate 
requirements for ephedrine (22 tons), behind China, the 
United States and the Republic of Korea. Seizures of 
ephedrine were reported in 2010 and 2011 in Iran (Islamic 
Republic of ) and Pakistan.138  
In contrast to the decline in amphetamine seizures in many 
countries in the region, the amphetamine market may be 
expanding in Iraq, as 2010 saw record seizures of almost 
1.6 tons of amphetamine in the form of Captagon tab-
lets.139 Seizures of methamphetamine in the region also 
suggest that this market is emerging and expanding in Iran 
(Islamic Republic of ) (where reported seizures of meth-
amphetamine continued to be high, amounting to almost 
1.4 tons in 2010), Israel (a record-high methamphetamine 
seizure in 2010) and Jordan (its first seizure being reported 
in 2010).140
138 Precursors and Chemicals Frequently Used in the Illicit Manufacture of 
Narcotic Drugs and Psychotropic Substances: Report of the International 
Narcotics Control Board for 2011 on the Implementation of Article 12 of 
the United Nations Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988 (United Nations publication, Sales 
No. E.12.XI.4), p. 70.
139 Country report of Iraq presented to the Subcommission on Illicit Drug 
Traffic and Related Matters in the Near and Middle East, at its forty-
sixth session held in Vienna from 19 to 22 December 2011.
140 Country report of Jordan presented to the Subcommission on Illicit 
Drug Traffic and Related Matters in the Near and Middle East at its 
forty-sixth session, held in Vienna from 19 to 22 December 2011.
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592THE CONTEMPORARY DRUG PROBLEM:CHARACTERISTICS, PATTERNS AND DRIVING FACTORS
The use of psychoactive substances is not a new pheno-
menon. They have been consumed throughout history, in 
different forms. Yet the contemporary drug problem, char-
acterized by a concentration of illicit drug use among 
youth, notably young males living in urban settings, and 
an expanding number of psychoactive substances, appears 
to have taken a distinctive shape over the past half 
century. 
Rapid socio-economic changes in recent history have cre-
ated the environment in which the drug problem as we 
know it has taken shape and started to exhibit the charac-
teristics mentioned above. Over the past decade, estab-
lished illicit drug markets in the industrialized countries 
have shown signs of stabilization, while the growth of illicit 
drug use has continued to accompany socio-economic 
transitions in developing countries. 
Chapter II presents and discusses the contemporary drug 
problem and explains how it has been shaped by the fun-
damental and enduring factors that define its nature, as 
well as by shorter-term developments that have contributed 
to modifying its patterns over time. This distinction will 
help, in turn, to inform a discussion of what constitute the 
risk factors and predictable drivers of the illicit drug econ-
omy and what remains largely unforeseeable. 
A. WHAT ARE THE FUNDAMENTAL 
CHARACTERISTICS OF THE  
CONTEMPORARY ILLICIT DRUG 
PROBLEM
The main dimensions of the  
contemporary drug problem 
Prevalence, age distribution, gender gap 
and market value 
The world population has reached 7 billion people. Of 
these, the United Nations Office on Drugs and Crime 
estimates1 that about 230 million2 use an illegal drug at 
least once a year. This represents about 1 in 20 persons 
between the ages of 15 and 64. In the same age group, 
approximately 1 in 40 people use drugs more regularly, at 
least once a month, and fewer than 1 in 160, that is, about 
1 The subsequent estimates are based on the findings contained in the 
World Drug Report 2011 (United Nations publication, Sales No. E.11.
XI.10). Many countries are still not in a position to conduct regular 
scientific household surveys. The estimates must thus be interpreted 
with caution. In order to reflect the uncertainty around these figures, 
ranges are presented in several parts of this report, either in the text or 
as footnotes.
2 Range: 153-300 million in 2010/11.
27 million people,3 use drugs in a manner that exposes 
them to very severe health problems. 
The large majority of illicit drug users consume cannabis. 
Some 170 million people consumed the substance at least 
once a year in the recent period. This is equivalent to 
some 3.8 per cent of the world’s adult population.4 Far 
behind cannabis, the second most commonly used group 
of illicit substances are the amphetamine-type stimulants 
(ATS), with some 33 million adults who used ampheta-
mines, including methamphetamine, amphetamine and 
methcathinone, and about 20 million who used sub-
stances sold as “ecstasy” (MDMA). Cocaine and opiates 
were used by some 16 million and 17 million people 
respectively. Most of the opiate users, about 12 to 13 
million, consumed heroin. Even if one adds to opiates 
synthetic opioids (many of which are prescription drugs 
not under international control), the rate of annual 
opioid use for non-medical purposes remained below 0.8 
per cent of the adult population.5 
The region with the world’s largest illicit drug market is 
North America, though no region is spared. Concentra-
tions in terms of drug production can be found in Africa 
and the Americas for cannabis (although cannabis is pro-
duced in almost all countries), Asia for opiates, South 
America for cocaine and Europe, Asia and North America 
for synthetic drugs. In terms of cannabis use, the highest 
levels have been reported in Oceania, North America and 
Africa. Cocaine use is highest in North and South America 
and Western Europe and, in recent years, Oceania. Rela-
tively high levels of opiate use are found primarily in the 
Near and Middle East, Central Asia, Europe and North 
America, and for ATS use in Oceania, East and South-East 
Asia, North America and Europe. 
Today, illicit drug use is largely a youth phenomenon in 
most countries. Prevalence rates gradually increase through 
the teens and peak among persons aged 18-25. Then the 
rates gradually decline to negligible levels for people aged 
65 and above. When it comes to people receiving treat-
ment for illicit drug use, the typical age is the late 20s-early 
30s, whereas for drug-related deaths the average age is often 
the mid-30s. 
Another key characteristic of illicit drug use throughout 
the world is that more males than females6 consume such 
drugs,7 though some studies indicate that women show a 
3 Range: 15.5-38.6 million.
4 Range: 2.6-5.0 per cent.
5 UNODC estimates.
6 L. Degenhardt and W. Hall, “Extent of illicit drug use and depend-
ence, and their contribution to the global burden of disease”, The 
Lancet, vol. 379, No. 9810 (7 January 2012), pp. 55-70.
7 There is an ongoing debate regarding the extent of hidden drug use 
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relatively high level of licit substance misuse. In the United 
States of America, 18.2 per cent of males and 12.5 per cent 
of females aged 12 and above had used an illicit drug at 
least once in 2010, which means that the proportion of 
female drug use was almost a third smaller than that of 
male drug use. For the potentially more problematic cat-
egory of illicit drug use over the past month (often referred 
to as “current drug use”), the difference was more pro-
nounced, as current drug use among females in the United 
States was some 40 per cent lower than such drug use 
among males.8 
Most other developed countries have larger gender gaps 
with regard to illicit drug use. In most of Europe, includ-
ing France, Germany and the United Kingdom of Great 
Britain and Northern Ireland (England and Wales only), 
female drug use is half, or less, than that of males. Calcu-
lating female versus male annual cannabis use in the Euro-
pean Union and Norway, based on surveys conducted 
between 2004 and 2010, gives a cannabis use level of 4.4 
per cent for females versus 9.1 per cent for males among 
the population aged 15-64. In the 28 countries analysed, 
relatively small gender gaps were only reported in three 
countries: Italy, with females accounting for 67 per cent 
of male cannabis use in 2008, Bulgaria (69 per cent in 
2008) and Norway (90 per cent in 2010).9
In most developing countries, the gender gaps are even 
more pronounced. Surveys conducted in Brazil in 200510 
and Argentina in 2010, for instance, showed prevalence 
rates of female drug use that were some two thirds lower 
than the corresponding male rates among the general pop-
ulation. In Indonesia, female drug use was equivalent to 
just 11 per cent of male drug use in 201011 and, similarly, 
13 per cent in the Philippines in 2008.12 A rapid assess-
ment in India in 200013 as well as national assessments in 
and addiction among females. Stigma and lack of services as well as 
specific behavioural characteristics tend to make female drug use less 
visible and may also affect reporting by women on their drug use 
habits in household surveys. Nonetheless, overall illicit drug use and 
addiction among females worldwide are still far less widespread than 
among males. Household surveys, drug tests among the workforce 
(based on urine and hair analyses), treatment data, emergency depart-
ment visits, arrest statistics and mortality statistics all show the same 
pattern: illicit drug use is much more common among males than 
among females.
8 L. Degenhardt and W. Hall, “Extent of illicit drug use and depend-
ence, and their contribution to the global burden of disease”, The 
Lancet, vol. 379, No. 9810 (7 January 2012), pp. 55-70.
9 European Monitoring Centre for Drugs and Drug Addiction, Statisti-
cal Bulletin 2011 (Lisbon, August 2011). Available from www.emcdda.
europa.eu/stats11.
10 F. I. Bastos, N. Bertoni and M. A. Hacker, “Drug and alcohol use: 
main findings of a national survey, Brazil 2005”, Revista de Saúde 
Pública, vol. 42, Suppl. 1 (2008), pp. 109-117.
11 United Nations Office on Drugs and Crime, data from the annual 
report questionnaire. 
12 Philippines, Dangerous Drugs Board, Study on the Current Nature and 
Extent of Drug Abuse in the Philippines (Manila, 2008).
13 United Nations Office on Drugs and Crime, The Extent, Pattern and 
Trends of Drug Abuse in India: National Survey (2004).
Pakistan in 200014 and 2006,15 found that females 
accounted for less than 10 per cent of the drug users who 
were identified and interviewed. 
School surveys, on the other hand, show far smaller gender 
gaps. This may suggest that women more readily give up 
illicit drug use than men. Women also tend to be more 
risk-averse and thus use smaller amounts of drugs than 
males, which may make it easier for women to stop using 
drugs. The school surveys conducted in 35 European coun-
tries in 2007 by the European School Survey Project on 
Alcohol and Other Drugs found that among 15 and 
16-year-old students 23 per cent of the male and 17 per 
cent of the female students had tried drugs at least once 
(lifetime prevalence). This means that the female preva-
lence rate was 74 per cent of the male rate at that age.16 
Comparable data from school surveys in the United States 
showed that the gap among high school students of the 
same age group (10th grade students) was even smaller, 
with female lifetime prevalence rates equivalent to 92 per 
cent of the male rates in 2007.17
The economic dimension of the international markets for 
opiates and cocaine is relatively well-studied. UNODC 
estimates suggest that the total retail market for cocaine 
amounts to some $85 billion18 and the opiate market 
amounts to some $68 billion (figures for 2009).19 The 
overall value of the illicit drug market was estimated at 
about $320 billion for the year 2003, equivalent to 0.9 per 
cent of global GDP.20 The 2003 estimates suggested that 
the largest markets — in value terms, calculated on the 
basis of retail sales — were North America (44 per cent of 
the total) and Europe (33 per cent), followed by Asia, Oce-
ania, Africa and South America. Though no new break-
down has been established since, partial data suggest that 
the proportions may have declined for North America and 
increased for the other regions.
14 United Nations Office for Drug Control and Crime Prevention and 
Pakistan, Anti-Narcotics Force, Drug Abuse in Pakistan: Results from the 
Year 2000 National Assessment (Vienna, 2002). 
15 United Nations Office on Drugs and Crime and Pakistan, Ministry of 
Narcotics Control, Problem Drug Use in Pakistan: Results from the Year 
2006 National Assessment (Tashkent, 2007); see also United Nations 
Office on Drugs and Crime, Female Drug Use in Pakistan: Mapping 
Estimates, Ethnographic Results and Behavioural Assessment (Islamabad, 
2010).
16 B. Hibell and others, The 2007 ESPAD Report: Substance Use among 
Students in 35 European Countries (Stockholm, Swedish Council for 
Information on Alcohol and other Drugs, 2009).
17 L. D. Johnston and others, Monitoring the Future: National Survey 
Results on Drug Use, 1975-2007, vol. I, Secondary School Students 2007, 
National Institutes of Health publication No. 08-6418A (Bethesda, 
Maryland, National Institute on Drug Abuse, September 2008).
18 World Drug Report 2011.
19 The Global Afghan Opium Trade: A Threat Assessment, 2011 (United 
Nations publication, Sales No. E.11.XI.11).
20 World Drug Report 2005, vol. 1, Analysis (United Nations publication, 
Sales No. E.05.XI.10).
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Prevalence rates compared
A comparison with consumption rates for legal psychoac-
tive substances suggests that the introduction of interna-
tional controls has contributed to maintaining lower 
consumption rates for illicit drugs. Global estimates show 
that current tobacco use (25 per cent of the population 
aged 15 and above) is 10 times more widespread than cur-
rent illegal drug use (see figure 1). Alcohol, which is legal 
in most countries, has an annual prevalence rate of 42 per 
cent, which is eight times larger than that of illicit drug 
use. Heavy episodic weekly drinking is eight times more 
prevalent than problem drug use.
Annual prevalence of alcohol use is clearly above the global 
average in Europe (69 per cent), the Americas (58 per cent) 
and in the WHO Western Pacific region (56 per cent). It 
is below average in areas where alcohol use is prohibited21 
or where it is considered inappropriate for religious reasons. 
Based on WHO regional groupings, below average rates 
of alcohol use are found in the Eastern Mediterranean (3.5 
per cent), in South-East Asia, which includes India (11 per 
cent) and, to a lesser extent, in Africa (29 per cent). Average 
per capita consumption figures reflect this pattern, the 
highest totals being reported in Europe and the Americas.22
Use of tobacco is clearly above average in Eastern Europe, 
East and South-East Asia and, to a lesser extent, in South 
Asia, the Southern Cone countries of South America, the 
Maghreb countries and Western and Central Europe. 
Below average rates are found in sub-Saharan Africa, Oce-
21 Such as Afghanistan, Brunei Darussalam, India (Gujarat), the Islamic 
Republic of Iran, Kuwait, Libya, Saudi Arabia, the Sudan, the United 
Arab Emirates (Sharjah) and Yemen.
22 World Health Organization, Global Status Report on Alcohol and Health 
(Geneva, 2011).
ania and North America.23 While tobacco use seems to 
have continued to increase in developing countries, it has 
been declining in the developed countries, notably in 
North America and Oceania. In the United States, for 
example, current tobacco use fell from a peak of 42 per 
cent of adults in 1965 to 19 per cent in 2011.24
The use of illicit drugs, alcohol and tobacco constitutes a 
significant health risk. A WHO study in 2002 suggested 
that deaths related to drug use affected some 200,000 per-
sons per year. As a result, 11.2 million life-years were lost 
(“disability-adjusted life-years”) due to of the use of opi-
ates, cocaine and amphetamines. The absolute numbers of 
both deaths and life-years lost are far larger for users of 
legal substances.25 Expressing the life-years lost as a pro-
portion of the number of users changes the picture dra-
matically, however, as there are far fewer illegal drug users: 
on average 19 life-years per 100 users were lost for users 
of illicit drugs (opiates, cocaine and amphetamines), in 
contrast to 5 years per 100 users of tobacco and 2 years 
per 100 users of alcohol. This clearly indicates that the use 
of opiates, cocaine and amphetamines is more problematic 
than the use of legal substances.
Subsequent studies have confirmed that the relative health 
risks linked to illicit drug use are significantly higher than 
those linked to alcohol use. A 2008 WHO study found 
that some 40.5 million people worldwide suffered a mod-
23 World Health Organization, WHO Report on the Global Tobacco Epi-
demic: Implementing Smoke-free Environments (Geneva, 2009).
24 Centers for Disease Control and Prevention, National Health Inter-
view Survey, 2011 and previous years. Available from www.cdc.gov/
nchs/nhis.htm.
25 World Health Organization, The World Health Report 2002: Reducing 
Risks, Promoting Healthy Life (Geneva, 2002). 
Fig. 1. Use of licit versus illicit psychoactive substances among youth and the adult population  
(Percentage)
Source: Estimates for illicit drugs based on UNODC data from the annual report questionnaire; alcohol statistics: World Health Organiza-
tion, Global Status Report on Alcohol and Health (Geneva, 2011); and Global Health Risks: Mortality and Burden of Disease Attributable 
to Selected Major Risks (Geneva 2009); tobacco statistics: World Health Organization, World Health Statistics 2010 (Geneva 2010). 
aTentative estimate.
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erate or severe disability due to alcohol dependence,26 com-
pared with some 11.8 million for the far lower number of 
illicit drug users (one ninth).27
If the health risk calculation is based on disability-adjusted 
life-years, illicit drugs were responsible for 13.2 million 
such years, or one tenth of all life-years lost due to sub-
stance abuse (see table 1). The higher proportion of drugs 
in life-years lost compared with deaths reflects the fact that 
drug users tend to die at a younger age than users of alco-
hol and, in particular, users of tobacco.
The application of public health 
policy and its regulatory approach  
to drugs
The State’s role in safeguarding public health has steadily 
increased over time, including through a regulatory 
approach that entails the implementation of an elaborate 
system of authorizations and quality controls. The control 
of psychoactive substances developed in that framework.
While the use of psychoactive substances has existed for 
several thousand years in many parts of the world, it is a 
relatively new public health concern. Opium and cannabis, 
for example, have long been used in Asia and, later, in 
Africa and Europe; the same is true for coca leaf in the 
Andean subregion and khat in the countries in the area of 
the Gulf of Aden. Moreover, a number of hallucinogenic 
plants have also long been consumed by humans. Tradi-
tional drug use was limited largely to special religious and 
social events, as well as some medical use. This changed in 
the nineteenth century, when opium became a big busi-
ness. Opium dens became popular throughout East and 
South-East Asia and large-scale drug addiction developed 
as a result.
China tried to ban opium imports in 1839, but came into 
open conflict with the traders and in 1858 had to give in 
to their demands for free trade in opium. As a result of this 
de facto legalization, opium use continued to rise una-
bated. According to some estimates, about a quarter of the 
adult male population in China used opium at the begin-
26 Defined as the WHO global burden of disease (GBD) disability classes 
III and above.
27 World Health Organization, The Global Burden of Disease: 2004 
Update (Geneva, 2008). 
ning of the twentieth century.28 It soon became apparent 
that attempts to control drugs exclusively at the national 
level would be insufficient. 
Cocaine use started to rise rapidly in the 1890s and the 
first decade of the twentieth century in the United States, 
causing serious problems in several cities and leading vari-
ous states to put controls in place. Those state-level efforts 
largely failed, however, as drugs were brought in from 
neighbouring states instead. That prompted a long battle 
to move drug control from the state to the federal level. 
Similarly, attempts by Egypt to ban all hashish imports in 
the first part of the twentieth century failed as long as trad-
ers could purchase hashish legally in other countries and 
smuggle it into the country.
That led to calls for a multilateral drug control system. 
The first conference of the International Opium Commis-
sion, held in Shanghai, China, in 1909, was followed by 
the adoption of the International Opium Convention, 
signed at The Hague on 23 January 1912,29 three drug 
control conventions adopted under the auspices of the 
League of Nations in the inter-war period and finally the 
three United Nations drug control conventions adopted 
in 1961, 1971 and 1988. The three United Nations con-
ventions are still the bedrock of today’s international drug 
control system, enjoying near-universal adherence.
Public health is a key dimension of the United Nations 
drug control system. This is illustrated by the paragraph 
of the preamble to the first United Nations convention 
related to drugs, the Single Convention on Narcotic Drugs 
of 1961 as amended by the 1972 Protocol,30 which reads 
“Concerned with the health and welfare of mankind”. 
Under that Convention, WHO plays a key role in con-
ducting medical, scientific and public health evaluations 
of psychoactive substances in order to make recommenda-
tions regarding their potential international control. The 
1961 Convention as amended by the 1972 Protocol estab-
lishes that drug production and use are to be limited to 
medical and scientific purposes (article 4, subparagraph 
(c)) and requires parties to give special attention to and 
28 Report of the International Opium Commission, Shanghai, China, Febru-
ary 1 to February 26, 1909, vol. II, Reports of the Delegations (Shanghai, 
North-China Daily News and Herald Limited, 1909).
29 League of Nations, Treaty Series, vol. VIII, No. 222.
30 United Nations, Treaty Series, vol. 976, No. 14152.
Table 1. Deaths and disability-adjusted life-years attributable to the use of illicit drugs, alcohol 
and tobacco
source: World health organization, Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks 
(geneva, 2009).
Illicit drugs Alcohol Tobacco Total
deaths related to substance abuse (millions) 0.245 2.3 5.1 7.6
global deaths (percentage) 0.4 3.6 8.7 12.6
lost disability-adjusted life-years (millions) 13.2 69.4 56.9 139.5
global lost disability-adjusted life-years (percentage) 0.9 4.4 3.7 9.0
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take all practicable measures to prevent the abuse of drugs 
and to pursue the early identification, treatment, educa-
tion, aftercare, rehabilitation and social reintegration of 
drug abusers (article 38, paragraph 1). The Convention 
on Psychotropic Substances of 1971,31 which expanded 
the range of substances under international control, main-
tained the same health focus.
The third United Nations drug control convention, the 
United Nations Convention against Illicit Traffic in Nar-
cotic Drugs and Psychotropic Substances of 1988,32 
requires States parties to establish as criminal offences the 
production, manufacture, sale, importation and exporta-
tion of drugs. Moreover, unlike the first two United Nations 
conventions, the 1988 Convention also requires parties to 
establish as criminal offences the possession and purchase 
or cultivation of drugs for personal consumption, with the 
rationale that demand also fuels trafficking (article 3). 
At the same time, the 1988 Convention — like the 1961 
Convention as amended by the 1972 Protocol — kept the 
door open for alternative interpretations with regard to 
sanctions for illicit drug use. For example, article 3, para-
graph 2, makes drug control subject to constitutional prin-
ciples and basic concepts of the legal system of each party, 
which provides some leeway for national variations in 
terms of implementation. Secondly, article 3, subparagraph 
4 (c), states: 
“Notwithstanding the preceding subparagraphs, in 
appropriate cases of a minor nature, the Parties may 
provide, as alternatives to conviction or punish-
ment, measures such as education, rehabilitation or 
social reintegration, as well as, when the offender 
is a drug abuser, treatment and aftercare.”
This means that countries may apply a range of alterna-
tives to criminal sanctions in dealing with illicit drug use 
and still be in line with the international drug control 
system. 
In the Political Declaration adopted by the General Assem-
bly at its twentieth special session,33 Member States rec-
ognized that demand reduction was an indispensable pillar 
in global drug control efforts. In the Declaration on the 
Guiding Principles of Drug Demand Reduction,34 which 
also emanated from the twentieth special session, it was set 
forth that demand reduction policies should aim at pre-
venting the use of drugs and at reducing the adverse con-
sequences of drug abuse. In addition to prevention, which 
had been part of the system from its very beginning, reduc-
tion of the adverse consequences of drug abuse became an 
integral part of the international drug control system. 
Member States made this even more explicit in the Politi-
cal Declaration and Plan of Action on International Coop-
31 Ibid., vol. 1019, No. 14956.
32 Ibid., vol. 1582, No. 27627.
33 General Assembly resolution S-20/2, annex.
34 General Assembly resolution S-20/3, annex.
eration towards an Integrated and Balanced Strategy to 
Counter the World Drug Problem,35 adopted in 2009 
during the high-level segment of the fifty-second session 
of the Commission on Narcotic Drugs and by the General 
Assembly in its resolution 64/182, in which Member States 
undertook to strengthen their efforts aimed at reducing 
the adverse consequences of drug abuse for individuals and 
society as a whole.
The unfolding of today’s drug  
problem in changing societies
The expansion of today’s illicit drug problem started with 
youth in North America in the 1960s, spread to Western 
Europe and, eventually, to the rest of the world. Illicit drug 
use was then part of a broad counter-culture, a youth pro-
test movement against the establishment, notably politi-
cians, the military and the war in Viet Nam. A significant 
number of drug users regarded themselves as progressive 
citizens who rejected materialism, consumerism and con-
formist behaviour. This movement was composed mainly 
of young people, and cannabis use grew alongside it. 
Though cannabis use in the United States had been linked 
to the jazz era of the 1920s,36 in the 1960s it spread to far 
larger sections of the population. Moreover, drug use in 
North America and Western Europe was increasingly seen 
as a way to explore altered states of consciousness. The use 
of hallucinogenic drugs such as lysergic acid diethylamide 
(LSD) became more widespread in the 1960s, often linked 
to psychedelic music. The late 1960s also saw the emer-
gence of heroin use in North America, notably among 
young American soldiers in Viet Nam. Soon afterwards, 
widespread heroin use also appeared in Europe.
After the end of the war in Viet Nam and the social reforms 
introduced in the 1970s in many countries, this broad 
youth protest movement largely faded away and with it 
the “ideological” basis for illicit drug use. Nonetheless, 
illicit drug use continued to grow in many parts of the 
world and it continued to be associated with certain aspects 
of youth culture.
While cocaine use has existed in the United States since 
the late nineteenth century, the market was relatively small 
until the 1960s, when it started to expand. Until the late 
1970s, cocaine was considered a relatively benign sub-
stance, used mainly by the upper class. The image of 
cocaine changed, however, following the invention of 
“crack”, a cheaper form of cocaine, in the early 1980s. A 
subculture developed around the marketing and use of 
“crack”, which became associated with gang-related crime, 
violent crime and prostitution.
Illicit drug use is also associated with nightlife, where 
young people are generally overrepresented. In the 1970s 
35 See Official Records of the Economic and Social Council, 2009, Supple-
ment No. 8 (E/2009/28), chap. I, sect. C.
36 See, for example, H. Shapiro, Waiting for the Man: The Story of Drugs 
and Popular Music (London, Helter Skelter Publishing, 1999).
2. THE CONTEMPORARY DRUG PROBLEM: CHARACTERISTICS, PATTERNS AND DRIVING FACTORS64
and 1980s, discos were popular, whereas in the late 1980s 
“rave” parties became more commonplace. Surveys among 
attendees have repeatedly shown very high prevalence rates 
for the illicit use of drugs, notably “ecstasy”, but also 
amphetamines, cannabis and cocaine. Youth in all sections 
of society are affected.
Though most drug-related youth cultures started in North 
America, one well-known exception is the Jamaican Ras-
tafarian movement. The Rasta culture, chiefly associated 
with reggae music and the use of cannabis, spread from 
Jamaica to many other countries in the 1980s. While there 
are still small communities of Rastafarians in a number of 
countries, it is nowadays a marginal phenomenon.
Drugs, in particular stimulants, have a history of being 
used to enhance performance in the workplace. This also 
takes place in today’s competitive, individualistic societies, 
where some workers may feel pressured to use drugs to 
increase their output. The lack of data makes it difficult 
to establish any trend for such use, however.
In addition, a number of vulnerable groups have become 
increasingly affected by illicit drug use. In that context, 
drug use may be linked to such factors as poverty, instabil-
ity, exposure to violence, difficult job conditions, work 
overload, post-traumatic stress disorders, neglect and 
abuse, and household dysfunction. 
An age group containment effect? 
Society and authorities are legitimately concerned about 
the impact of illicit drug use on young people, as it can 
affect their future and that of society. But why is illicit drug 
use found essentially among young people? The concen-
tration of drug use among youth, a fundamental charac-
teristic of the contemporary drug problem, may actually 
be less the result of a higher propensity among young 
people to take drugs than the effect of the lower propensity 
of adults to transgress laws and social norms. Comparisons 
of age distribution patterns of use for legal recreational 
psychoactive substances seem to support the hypothesis 
that the drug control system acts as a powerful brake 
against the extension of illicit drug use from adolescence 
to maturity.
The use of psychoactive substances is more homogeneously 
distributed across age groups for legal substances than for 
illegal drugs. While the initiation of use of all substances 
typically occurs during the teens or early years of adult-
hood, the use of legal substances such as tobacco and alco-
hol continues in much larger proportions with age in the 
same population groups, while the use of illegal drugs 
declines far more significantly.
In most countries, the use of psychoactive substances 
increases during adolescence and then falls again. Data for 
the United States, for example, suggest that the peak for 
illicit drug use is reached at about age 18-20, while the 
peak in alcohol and tobacco use occurs a few years later 
(between the ages of 20 and 25). Thereafter, consumption 
declines (see figure 2). 
Taking use of such substances among persons aged 18-25 
as a baseline, data confirm that the subsequent declines are 
far more pronounced for the use of illegal drugs than for 
the use of legal substances. Among persons in the so-called 
Woodstock generation, that is, persons who were aged 
18-25 in 1969 and who are now largely in the age group 
60-64, illicit drug use is now 87 per cent lower than among 
the current population aged 18-25. The corresponding 
rate for tobacco use is 50 per cent lower and for alcohol 
use 16 per cent lower. 
Similarly, data for Germany (2009) show that alcohol use 
is some 19 per cent lower among those aged 60-64 com-
pared with those aged 18-24, whereas tobacco use is some 
50 per cent lower (see figure 3). The age differences are 
again more pronounced for the use of illicit drugs. Cocaine 
use is 95 per cent lower, cannabis use almost 99 per cent 
lower and heroin, LSD and ATS use almost 100 per cent 
lower in the older age cohort.37
Given the significant changes in psychoactive substance use 
over time, this analysis is a credible indication — though 
not proof — of an age containment effect of the drug con-
trol system at work. The hypothesis of a stronger age con-
tainment effect for illegal drugs than for legal substances 
finds support in a comparison of prevalence rates for past-
month and lifetime use in each age cohort. The smaller the 
proportion, the more people were able to cease using sub-
37 A. Pabst and others, “Substanzkonsum und substanzbezogene Störun-
gen: Ergebnisse des Epidemiologischen Suchtsurveys 2009” (Substance 
use and substance use disorders: results of the 2009 Epidemiological 
Survey of Substance Abuse), Sucht – Zeitschrift für Wissenschaft und 
Praxis, vol. 56, No. 5 (2010), pp. 327-336.
Fig. 2. Age distribution prevalence of past-
month use of alcohol, tobacco and il-
licit drugs in the United States, 2010 
Source: United States, Department of Health and Human Services, 
Substance Abuse and Mental Health Services Administration 
Results from the 2010 National Survey on Drug Use and Health: 
Detailed Tables (Rockville, Maryland, September 2011).
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stances. Despite some of the substances being more addic-
tive, data from the United States show that, in each age 
group, more illicit drug users had given up their habit than 
users of legal substances (see figure 4). Thus only 7 per cent 
of the lifetime illicit drug users aged 60-64 were still using 
drugs in 2010, while 28 per cent of lifetime smokers in that 
group were smoking cigarettes and 58 per cent of the life-
time alcohol consumers were still drinking.
The hypothesis of a stronger age containment effect for 
illegal drugs than for legal substances also finds empirical 
support in cases where currently controlled substances have 
been de facto legal, such as opium in nineteenth-century 
China, or where psychoactive substances other than 
tobacco or alcohol are still legal, such as khat in Yemen and 
some countries of East Africa. A World Bank study under-
taken in Yemen in 2006 revealed that on average 72 per 
cent of males and 33 per cent of females reported having 
chewed khat in 2006.38 The age distribution showed the 
overall highest levels of khat use among persons aged 41-50 
(about 57 per cent), whereas for those aged 61 and above 
it was some 47 per cent. This was only 13 per cent lower 
than among the age group 21-30. Comparing the same 
two age groups in the United States, cannabis use was 93 
per cent lower in the older age cohort (see figure 5). 
38 World Bank, “Yemen toward qat demand reduction”, report No. 
39738-YE (June 2007).
Fig. 3. Prevalence of alcohol, tobacco and 
cannabis use in Germany, by age 
group,a 2009 (Index: age 18-24=100)
Source: Based on data from A. Pabst and others, “Substanzkon-
sum und substanzbezogene Störungen: Ergebnisse des Epidemi-
ologischen Suchtsurveys 2009”, Sucht – Zeitschrift für 
Wissenschaft und Praxis, vol. 56, No. 5 (2010). 
aData for prevalence of alcohol and tobacco use based on past-month use; 
data for prevalence of cannabis use based on annual use. 
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Fig. 4. Lifetime users of alcohol, tobacco and 
illicit drugs in the United States who 
continued using those psychoactive 
substances in the past months, 2010 
(Percentage)
Source: United States, Department of Health and Human Services, 
Substance Abuse and Mental Health Services Administration, 
Results from the 2010 National Survey on Drug Use and Health: 
Detailed Tables (Rockville, Maryland, September 2011).
Fig. 5. Age distribution of khat users in Yemena and cannabis users in the United States
Source: World Bank, “Yemen towards qat demand reduction”, report No. 39738-YE (June 2007); United States, Department of Health 
and Human Services, Substance Abuse and Mental Health Services Administration, Results from the 2010 National Survey on Drug Use 
and Health: Detailed Tables (Rockville, Maryland, September 2011).  
aSome 72 per cent of men and 32.6 per cent of women used khat in Yemen in 2006. Most was current khat use: less than 2 per cent of men and less than 
5 per cent of women used khat less than once a month. Some 42 per cent of men chewed khat every day and some 12 per cent chewed it 3-4 days per 
week. Some 13 per cent of women chewed it every day, some 7 per cent 3-4 times per week and 4 per cent reported chewing it 1-2 days per week.
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Fig. 6. Illicit drug use at the global level, late 1990s-2010/11 
Source: Estimates based on UNODC annual report questionnaire data.
The geographical spread of the  
contemporary drug problem 
While illicit drug use has increased at the global level since 
the 1960s, it has stabilized in recent years (see figure 6). 
The prevalence rates have remained largely stable over the 
past decade, at close to 5 per cent of those aged 15-64. In 
geographical terms, however, drug use continues to spread.
Although the paucity of data prevents a detailed analysis, 
it seems that countries with economies in transition and 
developing countries have become increasingly affected by 
illicit drug use, as they have experienced a range of socio-
economic changes. In absolute numbers, there are almost 
twice as many illicit drug users in countries not members 
of the Organisation for Economic Co-operation and 
Development (OECD) as in OECD countries (see figure 
7). The larger population in developing countries is one 
reason, but the shift in drug use towards developing coun-
tries is also reflected in annual reports sent by Governments 
to UNODC. While the reported trends in illicit drug use 
have been moving towards stabilization in the OECD 
countries in recent years, other countries tend to perceive 
it as increasing (see figure 8). The traditional distinction 
between drug-producing countries in the poorer South 
and consuming countries in the more affluent North is 
thus becoming increasingly blurred.
As with many other social phenomena, globalization has 
been accelerating the diffusion and a certain homogeniza-
tion of the contemporary drug problem. Thus cocaine use 
has been declining in North America, where rates were 
particularly high, while increasing over the past decade in 
South America, Western Europe and Africa, where they 
used to be much lower. Heroin abuse, which used to be 
particularly high in Western Europe, has shown signs of 
stabilization or decline in recent years there, while it con-
tinues to increase in some transit countries. “Ecstasy” use 
was originally confined to North America and Western 
Europe, but has been spreading to many other parts of the 
world, including Oceania, South-East Asia, South Amer-
ica, the Caribbean and Central America.
The black market economy  
for illegal drugs 
The development of the black market  
economy for illegal drugs 
After the ratification of the Hague Convention of 1912 in 
the wake of the peace treaties signed after the First World-
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Fig. 7. Number of cannabis users and  
prevalence of cannabis use in OECD 
and non-OECD countries, 2010
Source: Estimates based on UNODC annual report  
questionnaire data.
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War — peace treaties included a provision according to 
which their signatories automatically ratified the Hague 
Convention — global drug production and misuse 
declined markedly over the next few decades.39 At the same 
time, several countries reported signs of budding black 
markets for illegal drugs. 
The problem was most acute in the United States: organ-
ized criminal groups became involved in smuggling heroin 
from China and Turkey into that country. American organ-
ized criminal groups also had international linkages. For 
example, Italian criminal groups based in the United States 
were closely involved in drug trafficking, as were Jewish 
groups with links to others operating both domestically 
and abroad.40 Moreover, the 1930s witnessed the origins 
of the “French Connection”, a scheme by which opium 
was purchased in Turkey, processed into heroin in labora-
tories operated by Corsicans in Marseilles, France, and 
smuggled into the United States. At its peak in the late 
1960s and early 1970s, the French Connection supplied 
the bulk of the heroin used in the United States.
Concerned about the increase in drug trafficking activities, 
States responded by passing the Convention of 1936 for 
the Suppression of the Illicit Traffic in Dangerous Drugs.41 
39 United Nations Office on Drugs and Crime, A Century of International 
Drug Control (2009). Available from www.unodc.org/documents/data-
and-analysis/Studies/100_Years_of_Drug_Control.pdf.
40 Observatoire géopolitique des drogues, Atlas mondial des drogues (Paris, 
Presses Universitaires de France, 1996).
41 League of Nations, Treaty Series, vol. CXCVIII, No. 4648.
As a result of the difficult political situation in the late 
1930s and the outbreak of the Second World War, a lim-
ited number of States signed and ratified the Convention, 
rendering it largely insignificant. More than 50 years 
passed until drug trafficking was comprehensively 
addressed in the Convention against Illicit Traffic in Nar-
cotic Drugs and Psychotropic Substances of 1988.
A core objective of the 1988 Convention was to disrupt 
the large drug cartels that had emerged in the 1980s. It 
included provisions encouraging improved international 
cooperation, criminalization of drug trafficking, extradi-
tion of drug traffickers, mutual legal assistance, controlled 
deliveries, cooperation against illicit traffic by sea, control 
of precursors of illicit drugs, and a call for countries to 
fight money-laundering. A few years later, the world’s larg-
est drug cartels were dismantled in Colombia.
The dismantling of the large cocaine cartels led to pro-
found changes on the illicit drug market. A large number 
of smaller drug trafficking groups emerged, which led to 
intensified competition. Drug prices — cocaine prices in 
particular — fell markedly. Prevention and treatment 
efforts in the United States seem to have prevented cocaine 
use from increasing, despite the lower prices.
Profits from illicit drugs declined. Expressed in constant 
2009 United States dollars, the value of the world’s cocaine 
sales fell by nearly one half from 1995 to 2009, from $165 
billion to $85 billion (range: $75-100 billion).42 For all 
illicit drugs, total retail sales were estimated at $320 billion 
in 2003. UNODC estimates that in 2009 drugs represented 
about one fifth of global criminal proceeds.
In relative terms, however, the illicit drug markets are much 
more prominent in some countries. UNODC estimates 
suggest that the value of Afghan traders’ opiate-related sales 
was equivalent to slightly more than 60 per cent of the 
country’s GDP in 2004.43 While this proportion decreased 
to 16 per cent in 2011,44 this figure is still very significant. 
While drug-related sales generate the highest proceeds in 
developed countries, when assessed against their larger 
economies, those proceeds typically range from only 0.3 
to 0.7 per cent of GDP.45
The “nuts and bolts” of the illicit  
drug economy 
Like other sectors of activity in which goods or services are 
traded for a profit, the illicit drug economy is governed 
essentially by the law of supply and demand, although 
42 World Drug Report 2011, p. 31.
43 United Nations Office on Drugs and Crime and Afghanistan, Counter 
Narcotics Directorate, Afghanistan: Opium Survey 2004 (November 
2004).
44 United Nations Office on Drugs and Crime and Afghanistan, Ministry 
of Counter-Narcotics, Afghanistan: Opium Survey 2011 (December 
2011).
45  United Nations Office on Drugs and Crime, Estimating Illicit Finan-
cial Flows Resulting from Drug Trafficking and Other Transnational 
Organized Crimes: Research Report (Vienna, October 2011).
Fig. 8. Perceived trends in illicit drug use  
as reported by Member States,  
1992-2010
Source: UNODC annual report questionnaire data.  
Note: Average of all reported drug trends in illicit drug use (cannabis,  
opioids, cocaine, amphetamine-type stimulants, tranquillizers and sedatives, 
hallucinogens, solvents and inhalants) weighted by the population aged 
15-64. 
Note: Transformation ratios applied for trends over the reported year in 
prevalence: large decline = -2; some decline = 1; stable = 0; some increase 
= 1; strong increase = 2. If all countries had reported “some increase”, the 
trend in a specific year would have shown an increase of 1; if all countries 
had reported “no great change”, the trend curve would have remained at 
the same level.
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addiction and interdiction greatly influence the interaction 
of supply of, and demand for, illicit drugs. 
Currently, one out of eight people who use illicit drugs 
will develop drug dependency.46 The behaviour of depend-
ent users influences the demand curve by making it less 
price-elastic. Contrary to normal consumer behaviour, 
where price heavily influences demand (higher prices lead 
to lower consumption), in the short term, persons who are 
dependent on illicit drugs are usually not deterred by price 
increases. In the longer term, however, overall consump-
tion will eventually decline if prices rise markedly as 
dependent users face increasing difficulties to finance their 
habit. Conversely, dependent users may increase their con-
sumption once prices fall. Recreational users tend to react 
to price signals faster, in a way that is more similar to the 
consumption of legal products. While the group of recrea-
tional (non-dependent) users is far larger in number, it 
accounts for a small proportion of total sales.47
The drug control system has an impact on both supply 
and demand (see figure 9). Making production and traf-
ficking illegal tends to shift the supply curve to the left, 
which means that fewer producers and traffickers will be 
prepared to run the risks associated with supplying the 
drugs, at any given market price. The severity of the shift 
depends not only on the promulgation of a law, but also 
on its implementation. In parallel, drug control also tends 
to shift the demand curve to the left, which means a reduc-
tion in overall drug consumption. Fewer people will be 
inclined to use drugs if that means breaking the law and 
facing possible sanctions, at any given drug price. Leftward 
46 There are some 27 million “problem” drug users out of some 210 mil-
lion annual drug users (see World Drug Report 2011). 
47 W. Rhodes and others, What America’s Users Spend on Illegal Drugs 
1988-2000 (United States, Executive Office of the President, Office 
of National Drug Control Policy, December 2001).
shifts on the demand side can also be achieved, or aug-
mented, through demand reduction policies based on pre-
vention and treatment of drug use. In parallel, law 
enforcement can also encourage illicit drug users to enter 
and remain in treatment. Similarly, on the supply side, 
socioeconomic measures can amplify the effect of drug 
control.
One key effect of the drug control system, notably of 
supply control interventions, is the increase and mainte-
nance of high prices above the equilibrium that would have 
been reached in a legal market. Thus cocaine and heroin 
retail for many times their weight in gold, while their 
potential legal price may be similar to that of coffee.48 This 
reduces, first of all, the initiation of drug use. Secondly, 
many empirical studies show that problem drug users 
respond to increases in purity-adjusted prices by reducing 
consumption levels. In addition, supply shocks generated 
by means of supply control interventions have been shown 
to produce substantial and sometimes long-term reduc-
tions in drug availability, purity, use and harm in consumer 
countries.49
The globalization of the illicit drug 
economy?
Black markets do not respect borders, so in an era charac-
terized by globalization the development of a global drug 
economy might be expected. Indeed, similar trends are 
found in many countries. Illicit drug use tends to be higher 
in urban centres than in rural areas. More men than 
women tend to take drugs, and in many countries there is 
48 R. J. MacCoun and P. Reuter, Drug War Heresies: Learning from 
Other Vices, Times, and Places (Cambridge, Cambridge University 
Press, 2001).
49 J. Strang and others, “Drug policy and the public good: evidence for 
effective interventions”, The Lancet, vol. 379, No. 9810 (7 January 
2012), pp. 71-83.
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Fig. 9. Schematic presentation of the impact of drug control on drug production and consumption
Source: UNODC.
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a similar relationship between social stratification and drug 
use, with high prevalence of drug use among poorer sec-
tions of society, lower prevalence among the middle classes 
and higher prevalence among the upper classes. Drug use 
also tends to be affected by similar fashions and trends, 
often stemming from a relatively uniform youth culture. 
Finally, drug traffickers operate in almost all countries 
worldwide. 
In spite of these shared characteristics, there are still major 
differences. Drug type preferences still differ significantly 
across the world. For some drugs, production, trafficking 
and consumption are largely localized phenomena, while 
for others regional patterns can be identified. A single, 
unified global drug economy cannot yet be said to exist.
The markets for cannabis, the world’s most commonly 
produced and consumed illicit drug, are largely decentral-
ized. Production, trafficking, consumption and price 
trends differ significantly from country to country. With 
the advent of hydroponic cannabis cultivation in green-
houses in many developed countries, the trend towards 
decentralization has become more marked in recent years. 
An exception in this regard is the production of cannabis 
resin, or hashish, of which significant amounts are pro-
duced in two countries (Morocco and Afghanistan), while 
demand is concentrated mainly in Western Europe and 
the Near and Middle East/South-West Asia. Hashish is, 
however, less prominent than cannabis herb, or marijuana, 
which is cultivated and consumed much more widely.
The production of ATS is also largely decentralized. While 
exports do take place, they are mostly intraregional. Inter-
regional trafficking in amphetamine and methampheta-
mine is less common. The situation is slightly different 
when it comes to “ecstasy”, however. Production of 
“ecstasy” used to be centralized in Western Europe, notably 
in the Netherlands (the biggest producer) and Belgium. 
In recent years, its production has started to spread, includ-
ing to North America and several European and South-East 
Asian countries. The illegal trade in precursors of ATS, in 
contrast, is far more unified. Most of the precursor chemi-
cals used in illicit drug manufacture nowadays come from 
suppliers in South Asia and South-East Asia.
For opiates, there are currently three main interregional 
markets. The first, and largest, representing almost 90 per 
cent of global illicit opiate supply over the past five years, 
is that of opiates produced in South-West Asia, mainly 
Afghanistan. Those opiates are smuggled mostly within 
the region and into Europe (including the Russian Federa-
tion), which consumes the bulk of the world’s heroin, with 
additional small flows to Africa, China and Australia. The 
second comprises South-East Asian opiates — originating 
mainly in Myanmar — which are smuggled within the 
region, as well as into China and Oceania. Finally, some 
opiates are produced in Latin America. Most of those drugs 
are smuggled northward, in particular into the United 
States. Trends in production, trafficking, prices and con-
sumption frequently differ in those three illicit markets, 
which suggests that they are not highly interconnected, 
but rather operate in parallel.
The cocaine market is currently the most globalized of the 
illicit drug markets. Cocaine production is concentrated 
in the Andean subregion, and the main illicit markets for 
cocaine are North America, Western Europe, South Amer-
ica and, to a lesser extent, Oceania. The distribution of 
cocaine consumption between those regions has changed 
over the past decade, as declines in its use in North America 
have been offset by increases elsewhere.
Impact on society and state 
Impact on health 
The key impact of illicit drug use on society is the negative 
health consequences experienced by members of society. 
Drug use can have a serious health impact, even for casual 
users. Cocaine can induce a stroke; amphetamines can 
induce lethal arrhythmias or hyperthermia upon first expo-
sure. The use of cannabis may seriously impair the user’s 
driving capacity. Chronic cannabis use can lead to drug 
dependency as well as a number of behavioural and psy-
chiatric conditions, including internalizing disorders such 
as anxiety or depression. Indirect impacts include increased 
prevalence of infectious diseases among drug users as well 
as cardiovascular dysfunctions, lung diseases, kidney func-
tion impairments and endocrine dysfunctions.
Drug control tends to reduce the number of users, and 
thus the overall negative health impact on society. For the 
remaining user population, potential negative side effects 
of the existence of a black market may include a higher 
risk of obtaining low-quality drugs as traffickers attempt 
to increase their profits by “cutting” the substances with 
diluents to make more doses. In some countries, the fear 
of evoking a criminal justice system response and of harsh 
enforcement measures may deter drug users from seeking 
treatment or other medical attention.
Drug-related deaths — whether by overdose, drug-induced 
accident, suicide or medical conditions associated with or 
exacerbated by illicit drugs — represent the most severe 
health consequence of drug use. Some 0.2 million people 
die from drug use every year.50 Approximately half of those 
cases involve fatal overdoses. Moreover, drug-related deaths 
often affect young people. In Europe, for example, the 
mean age for deaths stemming from overdose is the 
mid-30s.51
50 The latest UNODC estimate of drug-related deaths is 172,000. The 
latest WHO estimate is 245,000. World Health Organization, Global 
Health Risks: Mortality and Burden of Disease Attributable to Selected 
Major Risks (Geneva, 2009).
51 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2010: The State of the Drugs Problem in Europe (Luxembourg, 
Publications Office of the European Union, 2010).
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Drug use, notably injecting drug use, is also a significant 
vector for spreading HIV and hepatitis B and C. Of the 
estimated 16 million injecting drug users worldwide,52 
UNODC estimates that almost one in five is HIV-positive. 
Approximately the same proportion are infected with hepa-
titis B, whereas some 8 million — about half of all inject-
ing drug users — are infected with hepatitis C. These 
viruses can cause or exacerbate a range of symptoms and 
ailments, with a potentially fatal outcome.
UNODC estimates suggest that about 12 per cent of illicit 
drug users — the cohort of people who report having used 
an illicit drug at least once in the past year — develop drug 
dependency and become “problem” drug users.53 This pro-
portion varies greatly between different drugs. Data from 
the 2010 United States household survey on drug use and 
health, for instance, suggest that 15 per cent of cocaine 
users can be considered to be substance-dependent.54 This 
proportion rises to 26 per cent for methamphetamine and 
to more than 50 per cent for heroin. For cannabis, the 
proportion is 10 per cent.55
Drug-dependent persons require treatment, which may 
place a financial burden on the individuals and their fami-
lies, or on society at large. In 2009, some 4.5 million 
people worldwide were receiving treatment for problems 
related to illicit drug use; among these, about 1 million 
were Europeans (excluding Belarusians, Moldovans, Rus-
sians and Ukrainians).56 In the United States, 2 million 
people received such treatment in 2002. In the same year, 
the health-related costs of illicit drug use in that country 
were estimated at $15.8 billion, equivalent to 0.15 per cent 
of GDP.57 Assuming that the health costs develop propor-
tionally to the number of persons in treatment and that 
health cost increases are in line with nominal GDP growth, 
annual drug-related health costs in the United States may 
have increased to some $24 billion by 2010. Somewhat 
lower expenditure levels have been reported from other 
Western countries.58
52 Range: 11.0-21.2 million (see B. Mathers and others, “Global epi-
demiology of injecting drug use and HIV among people who inject 
drugs: a systematic review”, The Lancet, vol. 372, No. 9651 (15 
November 2008), pp. 1733-1745.
53 World Drug Report 2011.
54 American Psychiatric Association, Diagnostic and Statistical Manual of 
Mental Disorders: DSM-IV, 4th ed. (Washington, D.C., 1994).
55 United States of America, Department of Health and Human Services, 
Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables 
(Rockville, Maryland, September 2011). 
56 European Monitoring Centre for Drugs and Drug Addiction, “Cost 
and financing of drug treatment services in Europe: an exploratory 
study” (Luxembourg, Publications Office of the European Union, 
2011).
57 United States, Executive Office of the President, Office of National 
Drug Control Policy, The Economic Costs of Drug Abuse in the United 
States: 1992-2002 (Washington, D.C., December 2004).
58 J. Rehm and others, The Costs of Substance Abuse in Canada 2002 
(Ottawa, Canadian Centre on Substance Abuse, 2006); L. Gordon and 
others, “The economic and social costs of Class A drug use in England 
and Wales, 2003/04”, in Measuring Different Aspects of Problem Drug 
While in 2010 some 7.9 million people in the United 
States alone needed treatment for problems related to illicit 
drug use, only 2.2 million received it.59 At the global level, 
the ratio is less than one in five, according to UNODC 
estimates.60 Expressed in monetary terms, at current preva-
lence rates (number of users), some $200 billion-250 bil-
lion (0.3-0.4 per cent of global GDP) would have been 
needed to cover global costs related to treatment for illicit 
drug use in 2010.
Impact on productivity 
Although many studies suggest that the impact of illicit 
drug use on a society’s productivity — in purely monetary 
terms — may be far more significant than the health 
impact, it is less commonly discussed. Productivity may 
decline owing to a large number of factors, including 
absenteeism, workplace accidents and conflicts at the work-
place, to name just a few.
A 2011 study estimated productivity losses in the United 
States at $120 billion (0.9 per cent of GDP) for the year 
2007. This is significantly higher than the health-related 
costs of illicit drug use discussed above and would be equiv-
alent to 62 per cent of all drug-related costs (calculated 
using a cost-of-illness approach). Reduced labour partici-
pation and incarcerations were the main causes.61 A similar 
study undertaken in Canada in 2002 suggested that pro-
ductivity losses due to illicit drug use amounted to 4.7 
billion Canadian dollars (0.4 per cent of GDP).62 Moreo-
ver, in Australia, a study found that the cost of such pro-
ductivity losses amounted to 2.1 billion Australian dollars 
for the financial year 2004/05 (0.3 per cent of GDP).63 
These costs are four and eight times higher than the health-
related costs, respectively.
In contrast to health costs, productivity loss calculations 
try to value the loss of potential resources. Productivity 
losses represent work that was never performed, but could 
reasonably be expected to have been performed without 
the impact of illicit drug use. Productivity losses can be 
thought of as a loss of potential income and thus of GDP 
brought about by a reduction in the supply and/or effec-
tiveness of the labour force. 
Use: Methodological Developments, N. Singleton, R. Murray and L. 
Tinsley, eds., Home Office Online Report 16/06 (London, Home 
Office, 2006); European Monitoring Centre for Drugs and Drug 
Addiction, “Cost and financing of drug treatment services in Europe”; 
D. J. Collins and H. M. Lapsley, The Costs of Tobacco, Alcohol and Illicit 
Drug Abuse to Australian Society in 2004/05, Monograph Series No. 64 
(Canberra, 2008).
59 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables. 
60 The precise figure for 2009 was 18 per cent. See World Drug Report 
2011. 
61 United States, Department of Justice, National Drug Intelligence 
Center, The Economic Impact of Illicit Drug Use on American Society 
(Johnstown, Pennsylvania, April 2011). 
62 Rehm and others, The Costs of Substance Abuse in Canada 2002.
63 Collins and Lapsley, The Costs of Tobacco, Alcohol and Illicit Drug Abuse 
to Australian Society. 
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Valuations of the loss of a drug user from productive activi-
ties is typically based on the expected value of the produc-
tivity of the person who illicitly uses drugs. In the labour 
market, this may equal their expected earnings. Non-mar-
ket or household productivity is also valued; it is equal to 
the cost of hiring someone to perform the services that the 
drug user is unable to perform because of sickness, disabil-
ity or death.
One key challenge for research in this area is to calculate 
the “value of life” of a drug user. Two of the main 
approaches used in the literature are the human capital 
approach and the demographic approach.
The United States and Canadian studies cited above use 
the human capital approach, in which premature deaths 
— a significant component of productivity losses — are 
valuated as the expected lifetime productivity of the 
deceased persons. This means that the expected salaries, 
including fringe benefits, of drug users until the normal 
retirement age are summed up, then discounted at a pre-
determined rate (real interest rate of 3 per cent in the 
United States example). Individuals who die earlier in their 
(potentially) productive life are given a higher value in 
these calculations than those closer to the age of retirement. 
On average, the United States estimates resulted in a poten-
tial productivity loss of slightly more than $1 million for 
each drug-related death.
The Australian study uses the demographic approach, 
which compares the actual population size and structure 
to the size and structure of a hypothetical alternative popu-
lation free of drug use. The actual and hypothetical outputs 
are then compared in order to estimate the productivity 
losses. 
The key difference between these approaches is that the 
human capital approach calculates present and future 
income flows that will no longer accrue owing to drug-
related deaths in the current year. The demographic 
approach calculates the income flows that would have 
accrued in the absence of drug-related deaths in the cur-
rent and previous years.
Impact on crime 
Illicit drug use is also closely linked to crime, in various 
ways. Drug users often resort to acquisitive crime to finance 
their habit. Additionally, many criminals are under the 
influence of illicit drugs, which reduce inhibitions, when 
committing crime. Illicit drug use is frequently associated 
with behavioural problems, which, depending on the sub-
stance and the amounts used, may include or result in 
aggression or violence. That said, drug users may have been 
affected by conduct disorders and anti-social personality 
disorders prior to their drug use, which makes them sus-
ceptible to involvement in crime and drug abuse. 
As a result, criminals in general tend to show far higher 
levels of drug use than the rest of the population. Urine 
tests made in 10 major cities in the United States in 2010 
revealed that, on average, about 70 per cent of the arrested 
males had used an illicit drug64 in comparison to a rate of 
current drug use among the general male population of 
11.2 per cent.65 Similar results were found in Australia, 
where one study, based on information collected from 10 
sites throughout the country, found that 65 per cent of all 
detainees, including drug offenders, tested positive for 
illicit drugs in 2008.66 In the United Kingdom, results in 
the same range were found for England and Wales as well.67
The costs of drug-related crime can be substantial. In the 
United Kingdom, a study of the economic and social costs 
of illicit drug use suggested that the cost of drug-related 
crime (mainly fraud, burglary, robbery and shoplifting) in 
England and Wales totalled some £13.9 billion in 2003/04, 
equivalent to 90 per cent of all social and economic costs 
related to drug abuse.68
Similarly, a study undertaken in Austria estimated the costs 
of crime related to illicit drug use (mainly fraud, robbery, 
burglary, car theft, other theft and extortion) at €2.6 bil-
lion for the year 2002, which is equivalent to 80 per cent 
of the total social costs caused by drug use. The costs to 
the general public of these drug-related crimes were found 
to be more than eight times larger than the benefits drug 
users obtained by selling the stolen goods.69 
Crime and drugs are also linked through drug trafficking. 
While traffickers generally avoid attracting attention from 
law enforcement authorities, at times competition between 
different trafficking groups can generate violence, often 
including homicide, as the different groups fight to defend 
or increase their illicit market shares. Moreover, criminal 
groups with access to large drug profits also often use them 
for corruption, which may with time lead to significant 
erosion of the State’s authority as drug criminals buy them-
selves impunity.
64 United States, Executive Office of the President, Office of National 
Drug Control Policy, ADAM II: 2010 Annual Report—Arrestee Drug 
Abuse Monitoring Program II (Washington, D.C., May 2011).
65 “Past-month prevalence among males aged 12 and above in 2010”, in 
United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, Results from the 
2010 National Survey on Drug Use and Health: Detailed Tables (Rock-
ville, Maryland, September 2011). 
66 A. Gaffney and others, Drug Use Monitoring in Australia: 2008 Annual 
Report on Drug Use among Police Detainees, Monitoring Report No. 9 
(Canberra, Australian Institute for Criminology, February 2010). 
67 T. Bennet and K. Holloway, “Drug use and offending: summary 
results of the first two years of the NEW-ADAM programme”, Home 
Office Findings No. 179 (London, Research, Development and Sta-
tistics Directorate, 2004); J. Hoare and D. Moon, eds., Drug Misuse 
Declared: Findings from the 2009/10 British Crime Survey—England 
and Wales, Home Office Statistical Bulletin No. 13/10 (London, 
Home Office, July 2010).
68 Gordon and others, “The economic and social costs of Class A drug 
use in England and Wales, 2003/04”, in Measuring Different Aspects 
of Problem Drug Use: Methodological Developments, N. Singleton, 
R. Murray and L. Tinsley, eds., Home Office Online Report 16/06 
(London, Home Office, 2006).
69 W. Hauptmann and E. Hübner, Soziale Kosten des Drogenmissbrauchs: 
Für 2002 dargestellt am Beispiel Österreichs, Neue Juristische Monogra-
phien No. 51 (Vienna, Neuer Wissenschaftlicher Verlag, 2008).
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B. HOW HAVE THE PATTERNS  
OF THE DRUG PROBLEM  
SHIFTED OVER TIME
Evolution of the largest illicit drug 
market: cannabis 
Cannabis has been the world’s most widely produced, traf-
ficked and consumed illicit drug for decades. Cannabis is 
consumed by some 75 per cent of illicit drug users — some 
170 million people (range: 119-225 million in 2010). Can-
nabis — in particular cannabis herb — is consumed and 
grown in practically every country and the overall amounts 
produced are far larger than the total production of other 
illicit drugs. 
Cultivation is widely dispersed and relatively little is known 
about the extent of cannabis production. UNODC esti-
mates range from 13,300 to 66,100 tons for the year 
200870 and subsequent years. For the mid-1990s, the best 
estimate of cannabis production was some 30,000 tons 
(range: 10,000-300,000 tons).71
The regionalization of cannabis markets 
Over the past few decades, the cannabis markets have 
become more regionalized. This can be seen, for instance, 
in the production of and trafficking in cannabis herb. 
While in the 1970s significant quantities were imported 
into the United States from South America, notably from 
Colombia, most of the cannabis consumed nowadays in 
North America is produced there. Similar trends have been 
observed in Europe. Rising domestic production of can-
nabis herb in a number of major consumer countries has 
70 World Drug Report 2009 (United Nations publication, Sales No. E.09.
XI.12).
71 “Cannabis as an illicit narcotic crop: a review of the global situation 
of cannabis consumption, trafficking and production”, Bulletin on 
Narcotics, vol. XLIX, Nos. 1 and 2 (1997), and vol. L, Nos. 1 and 2 
(1998) (United Nations publication), pp. 45-84.
reduced the need to import it, and interregional trafficking 
in this drug is now limited. Cannabis resin — the less 
prominent of the two main cannabis products — is excep-
tional as it continues to be imported mainly into Europe. 
The regionalization can also be seen in the distinct regional 
consumption preferences. In the Americas, Oceania, 
South-East Asia, Southern Africa and West Africa, canna-
bis is consumed mainly in the form of cannabis herb (mari-
juana). In contrast, in the Near and Middle East, North 
Africa and Western and Central Europe, cannabis is also 
used — primarily or in addition to the herbal product — 
in the form of cannabis resin (hashish). 
While the overall trends in cannabis production, traffick-
ing and consumption show strong increases since the 
1960s, regional trends may differ significantly. One indi-
cator that illustrates those differences is cannabis seizures 
(see figure 10). Until the late 1980s, most of the world’s 
cannabis herb seizures used to be made in South America, 
including Central America and the Caribbean, reflecting 
the large-scale cannabis production in that area. As pro-
duction moved closer to the consumer markets of North 
America, this changed. From the early 1990s, seizures 
became more frequent in North America, notably in 
Mexico and the United States. By 2010, cannabis herb 
seizures in North America accounted for some 70 per cent 
of the world total, whereas South America only accounted 
for some 10 per cent (as did Africa). The regional shares 
for Asia, Europe and Oceania were small.
Given the dominant role of North America in the global 
cannabis market, it is not surprising that cannabis herb 
seizures made globally and in North America show similar 
Fig. 10. Global cannabis herb seizures, 1947-2010
Source: UNODC.
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Fig. 11. Incidence and past-month prevalence of cannabis use in the United States,1962-2011
Source: United States, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables (Rockville, Maryland, September 2011); United States, National 
Institute on Drug Abuse, Monitoring the Future Survey, 2010. 
aHousehold survey. 
bHigh school survey.
patterns. The same is true for consumption, as the global 
trend closely follows that of the United States, the country 
with the world’s largest cannabis market. 
Cannabis use in the United States has fluctuated over the 
past 50 years (see figure 11). The 1960s and 1970s saw 
sizeable increases, followed by steep declines in the 1980s. 
Cannabis use increased again in the 1990s along with 
domestic production in the United States. During the first 
decade of the new millennium, the overall trend was stable, 
although initial declines were followed by increases between 
2006 and 2011, a period during which the medical use 
and legal status of cannabis were debated extensively. 
Despite these recent increases, past-month prevalence of 
cannabis use among persons aged 12-34, as well as annual 
prevalence among persons aged 12 and over in the United 
States, is still some 50 per cent lower than the 1979 peak.
Different trends have been reported for Oceania, which 
for years has been the region with the world’s highest can-
nabis prevalence — 9.1-14.6 per cent in 2010. This is far 
higher than the global average of 2.6-5.0 per cent.72 Aus-
tralia is the country with the region’s largest market for 
cannabis. Cannabis use in Australia increased from the 
1960s to the late 1990s before falling strongly between 
1998 and 2007. It appears that prevention campaigns and 
press attention to problems related to the use of cannabis 
with a high THC content, as well as police efforts,73 con-
tributed to that decline. Despite some recent increases, in 
2010, cannabis prevalence remained 42 per cent below the 
1998 level.
72 UNODC estimates.
73 Police sanctions shifted away from cumbersome arrest procedures 
towards fines and warnings, which freed up time for more systematic 
enforcement.
Cannabis consumption in Europe showed an upward trend 
between the 1960s and the first decade of the new millen-
nium before stabilizing in recent years (2003-2010) in the 
European Union or even falling in some major markets 
(see figure 12). In the United Kingdom, for instance, data 
for England and Wales showed increases until 2002/03, 
followed by significant decreases until 2010/11. Declines 
were also noted in France, Germany, Italy and, to a lesser 
extent, Spain.
In contrast, in several European Union countries with 
smaller cannabis markets, cannabis use has continued to 
increase, offsetting declines seen elsewhere. Prevalence rates 
of cannabis use in the European Union as a whole has thus 
been stable in recent years (about 6.7 per cent among per-
sons aged 15-64 in 2010).74
European consumers use both cannabis herb and cannabis 
resin. The total amount of cannabis resin seized in Europe 
continues to be substantially higher than the total amount 
of cannabis herb seized in Europe, though at the global 
level cannabis resin seizures amounted to just about one 
quarter of cannabis herb seizures over the period 
1990-2009.
The evolution of cannabis products
Cannabis herb and resin have remained the two main 
forms of illicitly used cannabis. Traditionally, cannabis 
resin had far higher levels of THC than cannabis herb. 
Hashish (with a traditional THC content of 2-10 per cent) 
74 The far lower figures reported for Italy for 2010 were not included in 
the calculations of the European Union average as the Italian 2010 
survey results were not directly comparable to those of previous years. 
Including the latest Italian figures would have yielded an overall can-
nabis prevalence rate for the European Union of 5.7 per cent. 
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was therefore often considered more problematic than 
marijuana (with a traditional THC content of 0.5-5 per 
cent).75 
High potency products, such as cannabis oil (with a THC 
content of some 10-30 per cent)76 and hash oil (with a 
THC content that could reach 40 per cent or more)77 
emerged in the 1970s, but their use remained limited. In 
2009, only some 0.05 per cent of the cannabis products 
seized worldwide was in the form of liquid cannabis.
Over the past two decades, there have been striking 
increases in the cultivation of cannabis varieties with a high 
THC content in most countries in North America, West-
ern Europe and Oceania. This has been achieved through 
plant breeding and/or hydroponic cultivation. The can-
nabis produced in the main OECD countries now tends 
to have higher THC levels than imported cannabis. For 
example, both sinsemilla-type cannabis herb,78 with a typi-
cal THC content of about 13 per cent in the United States, 
and “Dutch weed” (“nederwiet”, also known as “skunk”,79 
with average THC levels of 15-19 per cent,)80 tend to have 
75 United Nations, Recommended Methods for the Detection and Assay 
of Heroin, Cannabinoids, Cocaine, Amphetamine, Methamphetamine 
and Ring-Substituted Amphetamine Derivatives in Biological Specimens: 
Manual for Use by National Laboratories (ST/NAR/27).
76 Ibid.
77 Bulletin on Narcotics, vol. XXXII, No. 4 (1980) (United Nations pub-
lication).
78 Sinsemilla-type cannabis is created by removing the male plants from 
the fields, leaving the unfertilized female plants to mature. Much of the 
sinsemilla-type cannabis is still grown outdoors, but indoor cultivation 
seems to be on the increase.
79 A hybrid cannabis plant cultivated in the Netherlands that is a cross 
between Cannabis sativa and Cannabis indica and that may have a 
THC-content of more than 20 per cent, depending on the varieties 
used.
80 THC-monitor, mentioned in The Netherlands Drug Situation 2010: 
Report to the EMCDDA by the Reitox National Focal Point (Netherlands 
significantly higher levels of THC than cannabis resin (typ-
ically about 8 per cent in Europe in 2009).81 
Analyses of the THC content of samples of cannabis seized 
by federal authorities in the United States show that the 
average THC content has more than doubled since the 
1980s (see figure 13). This mainly reflects a growing pro-
portion of sinsemilla-type cannabis with a high THC con-
tent. The average cannabis potency of sinsemilla seized by 
federal authorities was 8 per cent in 1985, compared with 
12.9 per cent in 2009.82
This means that, in the Western countries, cannabis herb 
may no longer be less problematic than cannabis resin. 
Moreover, for the large cannabis markets, cannabis imports 
have become far less significant, while hydroponic cultiva-
tion of cannabis for local or regional markets has increased. 
The traditional divide between cannabis-producing and 
cannabis-consuming countries and regions has thus 
become less relevant.
In recent years, a number of synthetic cannabinoids that 
are not yet under international control have emerged in 
several large cannabis markets.83 Those substances mimic 
the effects of cannabis and have been included in various 
herbal mixtures sold under the brand name Spice, some-
times marketed as “legal alternatives” to cannabis. A large 
and complex variety of synthetic cannabinoids have been 
used in these attempts at circumventing existing regula-
Institute of Mental Health and Addiction (Trimbos Instituut), Decem-
ber 2010).
81 “Potency of cannabis products at retail level, 2009”, in Statistical Bul-
letin 2011 (Lisbon, European Monitoring Centre for Drugs and Drug 
Addiction, September 2011).
82 United States, Executive Office of the President, Office of National 
Drug Control Policy, National Drug Control Strategy: Data Supplement 
2011 (Washington, D.C., 2011).
83 See World Drug Report 2011.
Fig. 12. Annual prevalence of cannabis use among youth and adults in the European Union and  
selected European Union Member States, 1981-2010
Source: UNODC estimates based on United Kingdom, Home Office, British Crime Survey 2010/11 and previous years; UNODC, annual 
report questionnaire data; European Monitoring Centre for Drugs and Drug Addiction, Statistical Bulletin 2011. 
aPreliminary data.
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tions. While some of the substances have been placed 
under control in some jurisdictions, new synthetic can-
nabinoids are rapidly emerging, which creates special chal-
lenges for drug control efforts.
Shifts in the transnational opiate  
and cocaine markets
Though other drugs, in particular ATS, have started to 
have significant negative effects over the past few decades, 
opiates and cocaine continue to be responsible for the bulk 
of drug-related problems worldwide. This is reflected in, 
for example, the fact that they have figured prominently 
with regard to treatment demand, drug-related deaths and 
violence, and the financing of illegal armed activities. 
Major changes have taken place, however, in the illicit 
markets for opiates and cocaine over the past few 
decades.
Production: concentration  
and displacement
In contrast to the production of cannabis, which takes 
place in countries throughout the world, the production 
of opium (the raw material for morphine and heroin) and 
coca leaf (the raw material for cocaine) has shifted over 
time and is nowadays concentrated in a few countries. 
Opium
A century ago, large-scale opium production took place, 
inter alia, in China, India, Persia, Indochina and the Otto-
man Empire. Today, illicit opium production is concen-
trated in Afghanistan and Myanmar, which together 
account for more than 90 per cent of the world total. Illicit 
opium production is substantially lower today than it was 
at the beginning of the twentieth century and in the 1930s. 
This holds true even when the licit production of opium 
Fig. 13. Cannabis potency in the United States,  
1975-2009
Source: United States, Executive Office of the President, Office of 
National Drug Control Policy, National Drug Control Strategy: Data 
Supplement 2011 (Washington, D.C., 2011); Mehmedic, Z et al, 
‘Potency trends of 9-THC and Other Cannabinoids in Confiscated 
Cannabis Preparations from 1993 to 2008’, Journal of Forensic 
Sciences, September 2010, Vol. 55, No 5, pp 1209-1217; UNODC 
World Drug Report, 2011 (United Nations publication, Sales No. 
E.11.XI.10).
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Fig. 14. Global opium production, 1906-2010
Source: Report of the International Opium Commission, Shanghai, China, February 1 to February 26, 1909, vol. II, Reports of the  
Delegations (Shanghai, North-China Daily News and Herald Limited, 1909); Narcotic Drugs: Estimated World Requirements for 2012—
Statistics for 2010 (and previous years) (United Nations publication, Sales No. T.11.XI.2) (An International Narcotics Control Board techni-
cal report); United Nations Office on Drugs and Crime, A Century of International Drug Control (2009); World Drug Report 2011 (United 
Nations publication, Sales No. E.11.XI.10); World Drug Report 2008 (United Nations publication, Sales No. E.08.XI.11 and corrigendum). 
Note: The transformation of poppy straw into opium equivalents is only tentative. A transformation ratio of 6.9 kg of opium for 100 kg of poppy straw was 
applied, derived from average morphine output from poppy straw of 0.73 per cent at the global level (2006-2010) and an average morphine output from 
opium of 10.56 per cent at the global level (2006-2010). Annual specific results were applied for data over the 2006-2010 period.
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and the licit production of poppy straw (both used for the 
manufacture of medicinal morphine) are added.
During the first half of the twentieth century, global illicit 
opium production declined sharply. That was largely due 
to decreasing production in India and, later, in China. Fol-
lowing the cessation of opium production in mainland 
China in the early 1950s, production shifted to South-East 
Asian countries, including Thailand, Burma (now Myan-
mar) and Laos (today’s Lao People’s Democratic Republic). 
There was also some opium production in Iran, but that 
was halted after the Iranian revolution in 1979. 
Myanmar remained the world’s largest illicit opium pro-
ducer until the early 1990s, when it was overtaken by 
Afghanistan. Opium production there had continued to 
expand following the withdrawal of Soviet troops in 1989. 
Afghanistan has remained the world’s top illicit opium 
producer since then, as Myanmar’s opium production 
declined steeply over the period 1996-2006, before start-
ing to rise again thereafter. Opium production in the Lao 
People’s Democratic Republic followed a similar pattern, 
though at a far lower level. Over the period 2005-2010 
Afghanistan accounted, on average, for 88 per cent of 
global opium production and Myanmar for 6 per cent.
Other significant opium production areas have emerged 
in Latin America, notably in Mexico (starting in the mid-
1970s) and Colombia (in the 1990s). Recent years have 
seen declining opium production in Colombia, while in 
Mexico such production appears to have increased in spite 
of extensive illicit crop eradication efforts by the Mexican 
authorities.
Coca leaf/cocaine 
While coca leaf today is produced almost exclusively in the 
Andean countries, this was not always so. In the period 
between the First World War and the Second World War, 
significant coca leaf production took place on Java84 (part 
of today’s Indonesia) and today’s Taiwan Province of China, 
in addition to the Andean countries.85 After the Second 
World War, coca leaf production outside the Andean coun-
tries was eliminated and global coca leaf production 
remained relatively modest over the next few decades, until 
the 1970s (see figure 15).
Coca leaf production increased considerably in the 1980s, 
when it was concentrated mainly in Peru, followed by 
Bolivia. That changed during the mid-1990s, and the two 
key producing countries were Colombia and Peru. Coca 
bush cultivation — and thus coca leaf production — 
declined, in particular in Peru, in the late 1990s, whereas 
coca leaf production in Colombia increased markedly. The 
84 P. Gootenberg, “The Dutch colonial coca boom, 1905-1930”, in The 
Rise and Demise of Coca and Cocaine: As Licit Global “Commodity 
Chains”, 1860-1960, P. Gootenberg (Stony Brook, New York, Stony 
Brook University, October 2001).
85 P. Gootenberg, ed., Cocaine: Global Histories (London, Routledge, 
1999).
total area under coca bush cultivation thus stabilized, at a 
high level, in the 1990s.
In the 2000s, the area under coca bush cultivation declined 
by almost a third. Massive eradication programmes under-
taken by the authorities in Colombia over the past few 
decades have offset the increases reported in the Plurina-
tional State of Bolivia and Peru. In 2010, Colombia and 
Peru each accounted for some 40 per cent of the total area 
under coca bush cultivation worldwide, and the Plurina-
tional State of Bolivia accounted for the remaining 20 per 
cent.
Like the area under coca bush cultivation, cocaine produc-
tion increased substantially in the 1980s. In contrast to 
the area under coca bush cultivation, however, cocaine 
production continued to grow over the next 20 years, 
though at a slower pace. Improved yields and laboratory 
efficiency meant that decreases in coca bush cultivation 
did not translate into lower cocaine production. Significant 
increases in seizures largely offset the growth in cocaine 
production, however, and an actual decline in cocaine 
output was noted between 2007 and 2010.
Consumption: from old to  
new markets 
There have been significant shifts in both heroin and 
cocaine consumption patterns over the past few decades. 
While consumption has either stabilized (heroin) or 
declined (cocaine) in the regions with the largest illicit 
markets (Europe for heroin, North America for cocaine), 
consumption has increased in several other parts of the 
world. That is particularly true for some of the countries 
used as transit areas by drug traffickers. For cocaine, 
demand has partially shifted from North America (in par-
ticular the United States) to Western Europe.
Fig. 15. Total area under coca bush cultivation, 
1980-2010
Source: Data from the UNODC international crop monitoring  
programme; UNODC World Drug Report 2011 (United Nations 
publication, Sales No. E.11.XI.10).
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Heroin 
Following increases in the 1980s and 1990s, heroin con-
sumption has remained generally stable in the main con-
sumer markets over the past decade. It has, however, 
increased significantly in Afghanistan and a number of 
countries of transit for heroin. 
One indicator of the stabilization of heroin consumption 
in Europe is the number of drug-induced deaths (“overdose 
deaths”), as those deaths are predominantly linked to 
heroin use (see figure 16).86 Drug-induced deaths rose 
strongly in the 1980s and the 1990s, and then declined 
slightly in the 2000s. Improved treatment and measures 
aimed at reducing the negative consequences of drug abuse 
86 According to data from EMCDDA, heroin was involved in 80 per 
cent or more of the reported overdose cases in 17 European Union 
countries.
may explain some of the recent decline,87 although it 
would not have been possible without an overall stabiliza-
tion of heroin use.
Different trends have been observed in Oceania. Heroin 
use in Australia increased strongly in the 1990s but 
declined by some 75 per cent in 2001, following a “heroin 
drought” brought on by coordinated Australian and South-
East Asian law enforcement operations targeting major 
heroin trafficking groups. Even when the supply of heroin 
normalized, prevalence of heroin use among the adult pop-
ulation remained at the low level of 2001 — 0.2 per cent 
— for the rest of the decade.
The emergence of large-scale heroin trafficking via the 
Islamic Republic of Iran and Pakistan has also entailed 
significant increases in heroin consumption in those coun-
tries. Prevalence of opiate use, including the smoking of 
opium, in Pakistan is similar to that in Western Europe, 
while in the Islamic Republic of Iran it exceeds that of 
Western Europe by a factor of four or five.
Cocaine 
Data for the United States, the country with the world’s 
largest cocaine market, show marked increases in cocaine 
use in the 1960s and the 1970s, decreases in the 1980s, 
new increases in the 1990s and declines in the new mil-
lennium, notably after 2006. Those trends have been 
reflected in the incidence and prevalence of cocaine use 
found in household surveys and school surveys (see figure 
17). Irrespective of the shorter-term fluctuations, there 
have been significant overall declines over the past three 
decades. Annual prevalence of cocaine use among the gen-
87 Strang and others, “Drug policy and the public good: evidence for 
effective interventions”.
Fig. 16. Drug-induced deaths in the European 
Union, 1985-2009
Source: European Monitoring Centre for Drugs and Drug  
Addiction, Statistical Bulletin 2011.
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Fig. 17. Incidence and prevalence of cocaine use in the United States, 1965-2011 
Source: United States, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration,  
National Survey on Drug Use and Health, 2010 (and previous years); United States, National Institute on Drug Abuse, Monitoring the 
Future survey, 2011.
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eral population fell by more than two thirds between the 
peak in 1982 and 2010. Among students in their final year 
of high school (17-18 years old), where prevalence of 
cocaine use is significantly higher than among the general 
population, it declined by 78 per cent between the peak 
in 1985 and 2011.
Following the significant decline in cocaine use in the 
United States and the expansion of cocaine production 
since the 1980s, new illicit markets for cocaine were found, 
mainly in Western Europe, but also in South America.
Illicit cocaine use in Western and Central Europe has tri-
pled since 1990, although there have been signs of stabili-
zation at a higher level in recent years (see figure 18). This 
more stable trend reflects declines in the main cocaine mar-
kets in Europe — the United Kingdom, Spain and Italy (in 
decreasing order),88 which have offset increases in several 
smaller markets. The overall annual cocaine prevalence 
among persons in the age group 15-64 in the European 
Union (1.2 per cent) is still only about half of the figure in 
the United States (2.2 per cent in 2010).
Cocaine use also increased in South America, notably in 
Brazil and other countries that are part of the Southern 
Cone, from the mid-1990s to about 2005. Since 2006, 
the overall trend has been less clear.
88 Data for Italy showed a decline in the cocaine prevalence rate from 
2.1 per cent in 2008 to 0.9 per cent in 2010; data for Spain showed 
a decline from 3.1 per cent in 2007 to 2.7 per cent in 2009; and data 
for the United Kingdom (England and Wales) showed a decline from 3 
per cent in 2008/09 to 2.1 per cent in 2010/11. (For Italy, given meth-
odological changes, a very low response rate (12 per cent) and marked 
declines in the lifetime prevalence rates (which is impossible unless a 
large number of cocaine users had died or left Italy between 2008 and 
2010), the most recent data were not included in the calculation of the 
European averages.)
The evolution of trafficking routes 
The trafficking routes for heroin and cocaine have evolved 
over time, largely in response to interdiction efforts, com-
petition among actors and shifts in demand.
Heroin 
While some shipments of heroin from the Golden Triangle 
of South-East Asia to Europe were made during the 1970s 
and early 1980s, the prominent Balkan route was estab-
lished in the 1980s and is still used today. The Balkan route 
starts with the shipment of Afghan opiates through Pakistan 
and the Islamic Republic of Iran into Turkey. The drugs 
are then shipped onwards through the Balkans and into 
Western Europe, where they are distributed and consumed. 
While much of the heroin processing used to be carried 
out in Turkey, over the past decade this appears to have 
stopped as heroin is now produced mainly in Afghanistan 
and some of its neighbouring countries.
As a result of instability in the Balkans in the 1990s, the 
main Balkan route temporarily shifted from the western 
Balkan countries towards the eastern ones. During the late 
1990s, trafficking via Albania to Italy also became more 
prominent. Once stability had been restored, the western 
Balkan trafficking routes were reactivated. In Western 
Europe, the Netherlands evolved as an important redistri-
bution centre for heroin.
After the collapse of the Soviet Union and the subsequent 
establishment of a number of new States, large-scale smug-
gling of heroin from Afghanistan into Central Asia and 
the Russian Federation developed. With time, that area 
became a major illicit market for opiates, with a larger 
number of opiate users than Western Europe.
Heroin produced in South-East Asia used to be intended 
for illicit markets in North America, Oceania and Europe. 
Nowadays, the heroin produced in South-East Asia is con-
sumed mostly in China, though the total production has 
declined significantly and, in recent years, has been insuf-
ficient to satisfy the illicit demand in that country. There-
fore, heroin from Afghanistan is now also smuggled into 
China; it usually is transported through Pakistan to China, 
either directly or via South-East Asia. 
The heroin available on the North American market used 
to be largely from South-East Asia as well, though South-
East Asia’s share of that market has been gradually declin-
ing since the mid-1990s. Latin American countries — notably 
Colombia and Mexico — have emerged as the primary 
sources of heroin, in particular on the illicit market in the 
United States. 
Cocaine
In the 1970s and early 1980s, the cocaine from the Andean 
subregion was smuggled into North America primarily 
using air shipments from Colombia to Florida and other 
destinations along the eastern coast of the United States. 
As a result of increased law enforcement efforts, traffickers 
Fig. 18. Annual prevalence of cocaine use in 
the European Union, 1990-2010
Source: Estimates based on UNODC annual report questionnaire 
data; European Monitoring Centre for Drugs and Drug Addiction, 
Statistical Bulletin 2011 (and previous years).
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changed their preferred smuggling method in the 1980s 
and 1990s to shipping the cocaine by boat via the Carib-
bean. In the twenty-first century, this changed again, as 
boats and, more recently, semi-submarines carrying cocaine 
started leaving the Pacific coast of Colombia for Mexico; 
from Mexico, the drugs were then transported by road into 
the United States to final destinations across the country. 
More recently, shipments to countries in Central America, 
for subsequent onward delivery to Mexico and the United 
States, increased.
In the past, cocaine for the European market used to be 
shipped directly from Colombia to Spain or, to a lesser 
extent, the Netherlands. During the first decade of the new 
millennium, however, such direct shipments declined. 
Cocaine was often transported to the Bolivarian Republic 
of Venezuela and onwards to various countries in the Car-
ibbean, from where it was then transported to Europe, 
often by air. Some cocaine was also trafficked from Ecuador 
and Peru, as well as from Brazil.
Bolivia (Plurinational State of ) and Peru have become 
important sources of cocaine for the illicit markets in Brazil 
and the Southern Cone countries of South America. Some 
of the cocaine shipped to Brazil is subsequently smuggled 
into Africa (mostly Western and Southern Africa), with 
Europe as its final destination. Because of linguistic affini-
ties with Brazil and some African countries, Portugal 
emerged as a significant trans-shipment area for cocaine, 
notably during the period 2004-2007. The West African 
route appears to have become less active in recent years, 
however. 
Finally, there has been a clear increase in cocaine traffick-
ing via some of the Balkan countries in recent years. It 
seems that drug traffickers from the Balkans, some based 
in South America, are trying to obtain shipments of 
cocaine for distribution to illicit markets in Western 
Europe, after purchasing the drug from Nigerian groups 
operating in Brasil.
The emergence and growth of the 
illicit markets for ATS 
The strongest growth in the illicit drug markets in recent 
years has been in the illicit markets for ATS (methampheta-
mine, amphetamine and “ecstasy”), as reflected in seizure 
data (see figure 19). While seizures of heroin and morphine 
rose by less than half, cocaine by some 65 per cent and 
cannabis by 100 per cent between 1998 and 2010, seizures 
of ATS nearly tripled over that period, though that may 
be partly attributable to increased awareness among law 
enforcement agencies.
The increase in the use of ATS
The increases in seizures of ATS were primarily a reflection 
of increased demand and thus of growing trafficking. For 
the past few decades, far more countries have been report-
ing perceived increases in use than declines. Over the 
period 2002-2010, for example, 44 per cent of the report-
ing countries signalled an increase in ATS use, whereas 42 
per cent reported a stable situation and 14 per cent saw a 
decline.89
While in the 1990s significant increases in ATS use were 
reported in Europe and North America, in recent years the 
strongest increases have been reported in countries in East 
and South-East Asia and the Near and Middle East. In the 
Near and Middle East, notably on the Arabian Peninsula, 
illicit demand for drugs has been mainly for tablets con-
taining amphetamine (and caffeine) referred to as Capta-
gon, a brand name once used for a pharmaceutical 
preparation containing fenetylline.90 
ATS use in several of the developed countries, in contrast, 
is now showing signs of stabilizing or even declining. In 
the United Kingdom, for example, illicit use of ampheta-
mines (that is, ATS excluding “ecstasy”) fell from a peak 
of 3.2 per cent of the population aged 16-59 in 1996 to 
1.0 per cent in 2010/11 in England and Wales.91 In Aus-
tralia, use of amphetamines (mostly methamphetamine) 
fell from a peak of 3.7 per cent of the population aged 14 
and older in 1998 to 2.1 per cent in 2010.92 
89 UNODC, data from the annual report questionnaire.
90 Fenetylline is transformed by the body into the active stimulants 
amphetamine and theophylline.
91 J. Hoare and D. Moon, eds., Drug Misuse Declared: Findings from 
the 2009/10 British Crime Survey—England and Wales, Home Office 
Statistical Bulletin No. 13/10 (London, Home Office, July 2010). 
92 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report, Drug Statistics Series No. 25 (Canberra, 
July 2011). 
Fig. 19. Seizures of amphetamine-type stimu-
lants compared with seizures of major 
plant-based drugs, 1990-2010a (Index: 
1998 = 100)
Source: UNODC, annual report questionnaire data.  
aSeizures reported as of 8 February 2011.
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Dispersion of manufacture of ATS  
and regionalization of the illicit markets 
for ATS 
The illicit manufacture of ATS used to be heavily concen-
trated, but has gradually become more dispersed. At the 
same time, much of the ATS currently being produced is 
for use within a region, rather than for local or worldwide 
use, though limited interregional trafficking in ATS also 
takes place. 
In North America, the illicit manufacture of methampheta-
mine, which used to be concentrated in the western states 
of the United States, gradually moved eastwards, as well as 
northwards into Canada. Recently, illicit methampheta-
mine manufacture has been increasing in Mexico. 
In Europe, illicit manufacture of ATS (mostly ampheta-
mine and “ecstasy”) used to be largely concentrated in the 
Netherlands, and to a lesser extent Belgium and Poland, 
but is nowadays found in many European countries, 
including Bulgaria, countries of the western Balkans, the 
Baltic countries and Germany. Nonetheless the Nether-
lands, Belgium and Poland continue to play prominent 
roles. 
In East Asia, illicit manufacture of ATS was concentrated 
in Japan in the 1940s and 1950s, but subsequently moved 
to the Republic of Korea, Taiwan Province of China and 
Thailand. Nowadays, ATS manufacture is concentrated 
mainly in China, Myanmar and the Philippines. One trend 
that has emerged during the past few years is the expan-
sion of illicit ATS manufacture in countries such as Cam-
bodia, Indonesia and Malaysia, which had hitherto been 
primarily used as transit countries for ATS. The South-East 
Asian methamphetamine market has recently also been 
supplied by illicit manufacture taking place on the terri-
tory of the Islamic Republic of Iran.93 
In Oceania, most of the ATS (primarily amphetamine and 
“ecstasy”) have been of European origin; over the past two 
decades, however, significant illicit manufacture of ATS, 
mostly methamphetamine, has been taking place in Aus-
tralia and New Zealand. Improvements in domestic supply 
control there, however, seem to have brought back the need 
for ATS imports and the preferred source region is now 
South-East Asia. 
While ATS used to be imported into the countries of 
Southern Africa, nowadays ATS (mainly methampheta-
mine and methcathinone) are produced locally, in South 
Africa. For many years, ATS (mainly in the form of meth-
amphetamine) have been illicitly manufactured and con-
sumed in Egypt as Maxiton Forte — the brand name for 
a discontinued pharmaceutical preparation containing 
dexamfetamine. Recently, illicit methamphetamine manu-
93 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs: Asia and the Pacific, 
2011—A Report from the Global SMART Programme (November 
2011); UNODC, Global SMART Update 2012, vol. 7, March 2012.
facture has also been emerging in West African countries, 
notably Nigeria; the methamphetamine produced in those 
countries is mainly for illicit markets in South-East Asia. 
The evolution of products 
ATS markets are very dynamic, not only in terms of their 
geographical spread and changing production and traffick-
ing patterns, but also in terms of the evolution of products. 
Methamphetamine was first synthesized and consumed in 
Japan in the late nineteenth century, with manufacture 
and consumption later spreading to North America, East 
and South-East Asia and Europe. Amphetamine, on the 
other hand, has long been illicitly manufactured and con-
sumed in Europe. Some illicit manufacture of methcathi-
none also existed in the Russian Federation and the United 
States. 
“Ecstasy” appeared on the illicit markets later, in North 
America in the early 1980s and in Western Europe in the 
late 1980s. For several years, various other “ecstasy”-type 
substances (such as methylenedioxyamphetamine (MDA) 
and N-ethyl-tenamfetamine (MDE)) were more wide-
spread as they were not controlled. Once the main “ecstasy-
type” substances were all brought under national and 
international control, MDMA — the original “ecstasy” 
— largely replaced them. 
During the second half of the 2000s, the decline in the 
availability of the main precursor of “ecstasy” 3,4-MDP-
2-P (also known as piperonyl methyl ketone (PMK)) led 
to a shortage of MDMA. Producers identified a number 
of strategies to cope with this, of which the first was to 
reduce the MDMA content in “ecstasy” tablets and use 
various other substances to compensate. Those substances 
included methamphetamine, as well as ketamine, a sub-
stance not under international control that is used in vet-
erinary medicine. In some instances, methamphetamine 
and ketamine tablets have also been sold as “ecstasy”, as 
have tablets containing piperazines, another group of sub-
stances that are not internationally controlled. As many 
countries have placed piperazines under national control, 
however, the attractiveness of those substances appears to 
have declined in those countries, and producers are revert-
ing to MDMA. Recent trends indicate that the market for 
“ecstasy” is recovering, but without the re-emergence of 
3,4-MDP-2-P as main precursor. Instead, laboratory oper-
ators have started using substitute chemicals to manufac-
ture MDMA.
In recent years, new psychoactive substances often mar-
keted as “bath salts” and “plant food” have emerged in 
several ATS markets around the world. These are psycho-
active substances not under international control and 
include 4-MMC, known as “mephedrone”, which is used 
widely in Europe, as well as MDPV, which is more 
common in the United States. Both substances are struc-
turally related to cathinone, which is internationally con-
trolled. The fact that these substances were not illegal in 
most countries until recently made their use more wide-
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spread. In the United Kingdom, for example, the latest 
drug use survey conducted in England and Wales found 
mephedrone to be the third most widely consumed illicit 
drug among adults (after cannabis and cocaine), second 
only to cannabis among persons aged 16-24.94 
Emerging patterns of illicit drug use 
Illicit drug use is not a static phenomenon. As seen above, 
drug users may change to new substances. But they may 
also use different drug combinations or various 
consumption modes and/or use licit substances, including 
prescription drugs, for non-medical purposes. Such drug 
consumption patterns are widespread in many countries. 
Polydrug use 
One salient and geographically widespread feature of drug 
use behaviour in recent years has been the increase in poly-
drug use. While polydrug use was considered exceptional 
a few decades ago, it is now almost the norm in many 
countries. Users may still have a preferred drug, but at the 
same time they are often capable of switching to other 
drugs if need be. “Ecstasy” users, for example, have adapted 
by consuming fake “ecstasy” tablets which may contain 
methamphetamine, ketamine or piperazines instead of 
MDMA, and opiate users often consume synthetic opioids 
or benzodiazepines when faced with heroin shortages. 
Moreover, many recreational drug users have started to use 
drugs in a more targeted manner than in the past. To 
reduce the need for sleep and increase endurance, users 
consume various stimulants and “ecstasy”, and use canna-
bis or even heroin to “come down” and sleep. In order to 
experience the familiar “kick” of illicit drugs, heroin users 
taking part in methadone maintenance treatment may use 
“crack” cocaine. While sequential use of various drugs is 
most common, some drugs are also taken in combination 
with others. The most frequent combination is that of 
alcohol and various illicit drugs, although “speedball”, a 
mix of heroin and cocaine, is also common in some parts 
of the world.
One major concern with regard to polydrug use is that it 
tends to enhance both the intended effects and the side 
effects of drugs and compound the impact of those drugs 
on the body. This can have serious health consequences: 
mixtures of heroin and the synthetic opioid fentanyl, for 
example, may lead to respiratory arrest and death. Some 
polydrug use may also facilitate the consumption of even 
more drugs. For example, persons who consume cocaine 
or ATS to combat the drowsiness that often accompanies 
heroin use may consume larger doses and thus increase the 
risk of an overdose. 
National surveys on the extent of polydrug use are still 
rare. One method of generating a rough estimate of the 
problem is to add up the number of users of individual 
94 Hoare and Moon, Drug Misuse Declared: Findings from the 2009/10 
British Crime Survey. 
drugs (those responding “yes” to the question “Have you 
used a specified illicit drug (cannabis, cocaine, “ecstasy” 
etc.) over the past 12 months?”) and compare the total 
with the overall number of drug users (“have you used any 
illicit drug over the past 12 months?”). For a diverse group 
of 15 countries,95 the total number of users of five drugs 
(cannabis, amphetamines, “ecstasy”, cocaine and opiates) 
exceeded the overall number of illicit drug users by, on 
average, about 20 per cent, based on UNODC calcula-
tions. For countries with highly diversified illicit drug mar-
kets, such as the United Kingdom and the United States, 
the figure was greater than 40 per cent. Adding other drug 
categories, such as hallucinogens, tranquillizers and seda-
tives, yields a figure of some 60 per cent for the United 
States,96 which shows that polydrug use is very common 
there.
Undertaking the same exercise for Australia reveals even 
more common polydrug use in that country, as the aggre-
gate number of users of individual drugs exceeds the total 
number of drug users by some 100 per cent. One study 
showed that clear majorities of users of all other drugs also 
consumed cannabis, but — exceptionally — the majority 
of cannabis users (61 per cent) did not use any other illicit 
drug. About half of Australian cocaine and “ecstasy” users 
reported also using the other drug.97
Non-medical use of prescription drugs 
Several countries have reported increases in the non-med-
ical use of prescription drugs in recent years. “Non-medical 
use” includes use by the person the drug was prescribed 
for but not in the prescribed manner or dosage, as well as 
use by another person. Diversion takes place using various 
means, such as prescriptions acquired through corruption, 
fake prescriptions, illegal sales by pharmacies, misuse 
within families, illegal patient-to-patient sales and coun-
terfeit medication, sometimes bought via the Internet.
In some countries, including Australia and the United 
States, the non-medical use of pharmaceutical drugs is 
more prevalent than that of any illegal drug except can-
nabis.98 While many prescription drugs may be misused, 
the most commonly misused drugs belong to one of the 
following three categories (listed in order of magnitude): 
opioids, central nervous system depressants and 
stimulants.
95 Argentina, Australia, Bolivia (Plurinational State of ), Brazil, Canada, 
Chile, Germany, Indonesia, Italy, Mexico, Peru, the Philippines, Spain, 
the United Kingdom and the United States (UNODC, data from the 
annual report questionnaire and national drug survey reports).
96 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables. 
97 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report.
98 According to national drug use surveys, in the United States 6.3 per 
cent of the population aged 12 and above engaged in non-medical use 
of prescription drugs in 2010, whereas in Australia the figure was 4.2 
per cent of the population aged 14 and above.
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Opioids
The main medical use for opioids is pain relief, and it is 
for this purpose that most opioids (such as morphine) are 
prescribed. Opioids may also be prescribed to persons 
undergoing treatment for heroin dependence. They are the 
most commonly misused prescription drugs and non-med-
ical use is a concern for most countries, though the sub-
stances involved may differ significantly between regions 
and countries.
The non-medical use of any psychotherapeutic drug may 
have major negative health implications. In addition to the 
risk of dependency, the misuse of opioid pain killers, in 
particular, has led to large numbers of deaths. Overdose 
deaths involving prescription opioids in the United States 
— a country for which there are reliable data — have quad-
rupled since 1999 and now clearly outnumber deaths 
involving heroin and cocaine combined (see figure 20).99
Global licit production of many opioids, including mor-
phine, codeine, thebaine, hydrocodone, oxycodone and 
methadone, has increased dramatically over the past two 
decades. For example, global manufacture of oxycodone, 
a commonly misused opioid marketed as OxyContin in 
the United States, increased from 2 tons in 1990 to more 
than 135 tons in 2009 (see figure 21), more than two thirds 
of which was manufactured in the United States.100 While 
there may have been good medical reasons for the expan-
sion of production of those substances, it also increases the 
risk of their subsequent overprescription and/or their diver-
sion into illicit channels.
As for most other drug behaviour, countries and regions 
differ significantly with regard to specific opioid prefer-
ences. The misuse of buprenorphine, for example, which 
in Europe and some other countries is used as a substitu-
tion drug for heroin, is widespread in some countries in 
South Asia and in the Caucasus. In Nigeria, pentazocine 
seems to be far more prevalent than heroin. In some coun-
tries, especially in Asia, cough syrups containing codeine 
are frequently misused. 
Central nervous system depressants
Central nervous system depressants are usually prescribed 
as sedatives or anxiolytics (for the treatment of anxiety 
disorders). Benzodiazepines are currently the main sub-
stances of concern in this class of drugs, having largely 
replaced barbiturates (both are used as anxiolytics and sed-
ative-hypnotics) because barbiturates carry a higher risk of 
lethal overdose. These drugs have a high rate of represen-
tation in drug-related deaths (second only to opioids) and 
they are misused in many countries. The countries that 
report the highest per capita consumption of benzodiaz-
99 United States, National Institute on Drug Abuse, “Prescription drug 
abuse”, Topics in Brief (December 2011). Available from www.nida.
nih.gov/tib/prescription.html. 
100 Narcotic Drugs: Estimated World Requirements for 2011—Statistics for 
2009 (United Nations publication, Sales No. T.11.XI.2). (An Interna-
tional Narcotics Control Board technical report.)
epines — regardless of whether for sedative, anxiolytic or 
anti-epileptic purposes — are (in order of magnitude) Bel-
gium, Uruguay, Portugal and Serbia.101 Some of the com-
monly misused benzodiazepines are flunitrazepam 
(marketed as Rohypnol,102 used as a sedative) and diaze-
pam (marketed as Valium, used as an anxiolytic). 
101 Psychotropic Substances: Statistics for 2009—Assessments of Annual Medi-
cal and Scientific Requirements for Substances in Schedules II, III and IV 
of the Convention on Psychotropic Substances of 1971 (United Nations 
publication, Sales No. T.11.XI.3). (An International Narcotics Control 
Board technical report.)
102  Also referred to as a “date rape” drug.
Fig. 20. Overdose deaths by major type of  
drug in the United States, 1999-2008
source: national institute on drug abuse, “prescription drug 
abuse”, Topics in brief (december 2011).
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Fig. 21. Global manufacture, consumption and 
stocks of oxycodone, 1991-2009
source: Narcotic Drugs: Estimated World Requirements for 
2011—Statistics for 2009 (united nations publication, sales no. 
T.11.Xi.2).
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Stimulants
The third class of frequently misused prescription drugs is 
stimulants. The medical use of stimulants has decreased in 
recent years, though they are still prescribed for the 
treatment of attention deficit disorder and narcolepsy. In 
addition to the risk of dependency, non-medical use of 
stimulants may lead to heartbeat irregularities, elevated 
body temperature or even cardiovascular failure and 
seizures. A number of drug use surveys have indicated that 
prescription stimulants are frequently misused in the 
Americas. The use of prescription drugs well above the 
global average over the period 2007-2009 was reported by 
the following countries (listed in order of magnitude): the 
United States, Argentina, Brazil, Mexico and Chile.103 In 
South America, in particular, stimulant use is often linked 
to weight loss efforts. The problem is not confined to that 
region, however, as countries in all major regions have 
reported relatively high levels of consumption of stimulants. 
Some countries have seen dramatic increases in the avail-
ability of prescription stimulants. In the United States, for 
example, the number of prescriptions for these drugs 
increased from 5 million in 1991 to nearly 45 million in 
2010.104 This is linked, inter alia, to increased prescription 
of methylphenidate (marketed as Ritalin), a drug used to 
treat attention deficit disorder. Consumption of methyl-
phenidate is much higher in the United States than at the 
global level, though global consumption of that substance 
has increased significantly over the past decade.105 
Injecting drug use in new areas 
From a public health point of view, injection is the most 
problematic form of illicit drug administration. This 
method places users at a higher risk of fatal overdoses 
because the rapid onset of effects makes it difficult to gauge 
how much to use. Overdoses also require immediate medi-
cal attention, which may not always be available. Addition-
ally, injecting drug use carries a high risk of contracting 
infectious diseases, in particular if injecting equipment is 
shared. 
The prevalence of drug injection depends on the region 
and country, as well as on which illicit drug is being used. 
Heroin and methamphetamine are the most commonly 
injected illicit drugs. There is no injection of cannabis, and 
“ecstasy” injection is uncommon. With a few exceptions, 
cocaine is also rarely injected. Cocaine hydrochloride 
(cocaine in powder form) is usually snorted, whereas 
“crack” cocaine is usually smoked. 
103 Psychotropic Substances: Statistics for 2009—Assessments of Annual Medi-
cal and Scientific Requirements for Substances in Schedules II, III and IV 
of the Convention on Psychotropic Substances of 1971 (United Nations 
publication, Sales No. T.11.XI.3). (An International Narcotics Control 
Board technical report.)
104 National Institute on Drug Abuse, “Prescription drug abuse”.
105 Psychotropic Substances: Statistics for 2009—Assessments of Annual Medi-
cal and Scientific Requirements for Substances in Schedules II, III and IV 
of the Convention on Psychotropic Substances of 1971 (United Nations 
publication, Sales No. T.11.XI.3). (An International Narcotics Control 
Board technical report.)
Over the past decade, injecting drug use appears to have 
remained relatively stable. Most countries report that a 
high proportion of heroin users inject the drug, although 
the prevalence of injection of any illicit drug differs sub-
stantially between countries. In the country with the 
world’s largest illicit drug market, the United States, almost 
half of heroin users, 13.5 per cent of methamphetamine 
users and 2.5 per cent of cocaine users report injecting 
their drug of choice.106 Similar proportions are found in 
the United Kingdom, another country with a mature and 
diversified illicit drug market, as well as in many other 
European countries. Some countries, such as Argentina, 
Malaysia, the Netherlands and Spain, report low levels of 
injecting drug use, though it is most common among 
heroin users in those countries. On the other end of the 
scale, Belarus, France and New Zealand report high levels 
of injecting drug use, in particular among heroin users. 
Some countries report injecting drug use as being limited 
largely to heroin users; examples include China, Kyr-
gyzstan, Lebanon, Myanmar and the Russian 
Federation.
In some countries, the injection of ATS, especially meth-
amphetamine, is more common. Countries that report the 
injection of ATS to be more common than the injection 
of heroin include Indonesia, Sweden and Togo, with low 
overall levels of injecting drug use, and the Czech Repub-
lic, Japan and Slovakia, with higher levels. 
Only four countries report that more than 20 per cent of 
their cocaine users inject the drug: France, Guatemala, 
Mexico and New Zealand. All these countries also report 
injecting drug use to be widespread among heroin users.
New actors, changing methods  
and threats 
Bringing the drugs from producers to consumers requires 
a certain level of organization. The modus operandi of 
those involved in drug trafficking has evolved over time, 
in line with market and technological developments. In 
the past, drug trafficking may have personally enriched the 
key actors involved; in recent years, however, significant 
profits from the illicit drug trade have in some cases been 
used to fund illegal armed activities. 
The rise and fall of drug trafficking  
organizations
Patterns of illicit drug use are highly dynamic and, as they 
evolve, the operations of drug trafficking organizations 
tend to change in response. There have been major changes 
related to drug trafficking over the past few decades. The 
nature of those changes depends on the drugs and illicit 
markets involved, though one enduring characteristic of 
many drug trafficking organizations is a shared language 
and/or nationality among its participants. 
106 UNODC, data from the annual report questionnaire. 
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The smuggling of heroin into and within the United States 
was dominated by Italian organized criminal groups after 
the Second World War. Those groups purchased heroin 
and had it transported into the United States via Turkey 
and France. Later, major Chinese groups, known as 
“triads”, brought heroin via the territory of present-day 
Hong Kong, China, until Latin American heroin started 
to be trafficked into the United States in the mid-1990s, 
mainly by Colombian and Mexican groups. As heroin pro-
duction in Colombia has declined in recent years, more of 
the heroin appears to be coming from Mexico.
The smuggling of cocaine into the United States was domi-
nated by two Colombian drug cartels, the Medellin and 
Cali cartels, until the early 1990s. Those organizations 
controlled the entire supply chain. They proved to be the 
last of their kind, though, as they were dismantled by the 
mid-1990s. A large number of smaller Colombian cartelitos 
(small cartels) then emerged and changed the operation of 
the supply chain by selling cocaine to Mexican groups, as 
well as to customers in the emerging cocaine markets in 
Europe. The Mexican groups controlled the trafficking 
from Mexico into the United States. The shipment meth-
ods have changed, too: while originally most of the cocaine 
shipments went directly from Colombia to the United 
States by air, nowadays the shipments are mainly sent by 
boat or semi-submarine to the Central American/Mexican 
corridor and then overland into the United States. 
For the past two decades, heroin has been trafficked into 
Western Europe mainly along the Balkan route by Turkish 
groups and groups from various Balkan countries. The 
heroin used to be manufactured in Turkey using opium 
and morphine from Afghanistan. In recent years, however, 
most of the opiates are imported in the form of heroin. 
From the late 1990s to about 2004, ethnic Albanian organ-
ized criminal groups played a very significant role in that 
illicit trade, but their role has subsequently become less 
prominent, while criminal groups from the other countries 
in the Balkans continue to be involved in such trade. 
Recently, a number of criminal groups with roots in the 
former Yugoslav Republic of Macedonia have emerged in 
several Western European cities as organizers of heroin 
trafficking. 
Cocaine trafficking into Western Europe has for years been 
organized by Colombian criminal groups. In addition, a 
number of criminal groups from Caribbean countries, 
including the Dominican Republic and Jamaica, have been 
involved. Since 2005, various West African criminal 
groups, often led by Nigerians, have become deeply 
involved in the cocaine market in many Western European 
countries. Nigerian groups have also become active in 
exporting cocaine from Brazil, notably Sao Paulo, to des-
tinations in Africa and Europe. Most of those groups are 
not organized hierarchically but operate as independent 
units in loose networks. 
Heroin trafficking into the Russian Federation has for long 
been organized mainly by various criminal groups whose 
members are ethnic Tajiks. These groups traffic heroin 
from Tajikistan into other Central Asian countries and the 
Russian Federation. While Tajik criminal groups are heav-
ily involved in smuggling heroin out of Tajikistan and into 
the Russian Federation, they hardly ever appear in arrests 
made in other Central Asian countries. 
The smuggling of methamphetamine into the profitable 
Japanese market was, and continues to be, largely domi-
nated by the Yakuza, the traditional Japanese organized 
criminal syndicates. While the sources of the metham-
phetamine have changed over the years, the traffickers have 
not. Almost half of all persons arrested in Japan for traf-
ficking methamphetamine are Yakuza members. After the 
Second World War, methamphetamine was domestically 
produced; then, in 1951, it was banned. Methampheta-
mine production then moved to nearby areas, such as the 
Republic of Korea and Taiwan Province of China, before 
shifting again to mainland China and the Philippines. 
Recently, Iranian organized criminal groups became 
involved in the illicit methamphetamine trade, and 
branches of the Yakuza in Istanbul, Turkey, have begun 
smuggling into Japan methamphetamine illicitly manu-
factured on the territory of the Islamic Republic of Iran.107 
In addition, Nigerian groups have started to produce meth-
amphetamine in Nigeria and export it to East and South-
East Asia. 
The convergence of threats and their  
evolution
As noted above, drug trafficking has long had close links 
with transnational organized crime. For decades, a large 
proportion of the income of transnational organized crimi-
nal groups has been derived from drug trafficking. Esti-
mates suggest that drug trafficking generates between a 
fifth and a quarter of all income derived from organized 
crime, and almost half of the income from transnational 
organized crime.108 
In contrast, the links between drug trafficking and the 
activities of illegal armed groups and, in some cases, ter-
rorism appear to have developed later. Some well-known 
examples of this include the links between various rebel 
armies and production of and trafficking in opium and 
ATS in and out of the Shan State of Myanmar, the links 
between coca trafficking and the Shining Path in Peru in 
the 1990s, the use of income from the illicit drug trade to 
finance the Revolutionary Armed Forces of Colombia 
(FARC) in Colombia in the 2000s and the use by the 
Kurdistan Workers’ Party (PKK) of income from the heroin 
trade to finance illegal armed activities in Turkey. Moreo-
ver, many of the militias involved in the instabilities in 
Yugoslavia in the 1990s used drug trafficking — notably 
heroin trafficking along the Balkan route — to finance 
107 United Nations Office on Drugs and Crime, Patterns and Trends of 
Amphetamine-Type Stimulants and Other Drugs; Global SMART Update.
108 United Nations Office on Drugs and Crime, Estimating Illicit Finan-
cial Flows Resulting from Drug Trafficking.
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their involvement, and the Taliban in Afghanistan and 
Pakistan have been drawing some of their income from 
the opium and heroin trade. Profits from cannabis and 
cocaine trafficking have allegedly been used by Al-Qaida 
in the Islamic Maghreb, and the Irish Republican Army 
(IRA) was also allegedly involved in international drug 
trafficking. In Sri Lanka, the Tamil Tigers were said to have 
derived some of their income from heroin trafficking prior 
to being dismantled in 2009, while in Lebanon Hizbullah 
has also been accused of involvement in drug trafficking. 
The above list could be much longer. Not all the allega-
tions are necessarily well founded, however, and solid evi-
dence to establish the existence and to assess the importance 
of these links is not always readily available. It should also 
be noted that individual members’ proven involvement in 
illicit drug-related activities does not necessarily mean that 
the group as such has been involved. Nonetheless, there is 
no doubt that there are links between drug trafficking and 
the operations of criminal, insurgent and terrorist organi-
zations worldwide. 
The far-reaching threats emerging from drug trafficking 
and organized crime were recognized internationally more 
than 20 years ago, in the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988, in which it was noted that illicit traf-
ficking enabled transnational criminal organizations to 
penetrate, contaminate and corrupt the structure of gov-
ernment, legitimate commercial and financial business and 
society at all levels. Those concerns were echoed and 
expanded upon by Member States in 1998 and 2009 in 
the Political Declaration adopted by the General Assembly 
at its twentieth special session and the Political Declaration 
and Plan of Action adopted by the Commission on Nar-
cotic Drugs during the high-level segment of its fifty-sec-
ond session, in 2009. The links between drug trafficking, 
organized crime and, in some cases, terrorism have been 
also addressed by the Security Council in a number of its 
resolutions.
These links prompted several countries to step up their 
efforts against drug trafficking. In several cases where the 
authorities targeted illicit drug production and drug traf-
ficking, the insurgency problem was also diminished. Two 
examples are the Shining Path in Peru in the 1990s and 
the FARC in Colombia in the 2000s. Efforts to reduce 
illicit drug production and trafficking helped to reduce the 
income of the illegal armed groups and thus their capacity 
to fight.
The role of new technologies
Over the past few decades, increasingly sophisticated 
mobile telephones and Internet-connected computers have 
become available to a growing share of the world popula-
tion. The use of the Internet has increased rapidly, with 
the number of people with Internet access skyrocketing 
from 2.6 million in 1990 to 2 billion in 2010. Similarly, 
the proportion of the population with Internet access rose 
from 0.05 per cent in 1990 to 30.5 per cent in 2010 and 
to as much as 76.5 per cent among the high-income 
OECD countries that are heavily affected by drug use.109 
The Internet has had a major impact on the illicit drug 
business. For traffickers, it is now far easier to understand 
the price levels in various markets, obtain precursor chemi-
cals and hide drug-related profits. Illicit drug users have 
started to use the Internet as a means of exchanging infor-
mation about the use of various illicit drugs and on the 
best opportunities to acquire more potent drugs cheaply. 
Moreover, new drugs not yet under international control 
(such as those sold under the brand name Spice) have been 
successfully marketed via the Internet. 
The Internet has also opened new avenues for drug control 
interventions. It is a crucial vector for spreading informa-
tion about the risks associated with illicit drug use. More-
over, the Internet also provides authorities with an 
additional means to monitor the illicit drug market and 
the criminals’ planning and operations. It is also now easier 
for law enforcement authorities to cooperate closely across 
borders. That said, drug traffickers seem to have become 
more cautious — and sophisticated — in their Internet 
usage. Rich in cash, they have the means to employ top 
computer experts to ensure that their communications are 
encrypted, locations untraceable and stored files destroyed 
in case computers are seized. The speed of technological 
development as well as criminals’ rapid adaptation of the 
available technology to their needs presents major chal-
lenges to most countries’ regulatory bodies. Additionally, 
the absence of international Internet regulations makes it 
difficult to impede criminals who operate internationally.
Another key technological development over the past few 
years has been the rapid spread of mobile telephony. The 
share of the world population with a mobile phone sub-
scription rose from 0.2 per cent in 1990 to 78.6 per cent 
in 2010. The growth averaged 36 per cent per year over 
the period 1990-2010. While in the developed countries 
the number of mobile phone subscriptions often exceeds 
the total population figure, even the least developed coun-
tries have substantial rates of mobile telephone penetration 
(33.5 mobile phones per 100 inhabitants). For Afghani-
stan, for example, the rate is 37.8.110 
The mobile telephone, in particular its short message ser-
vice (SMS) function as well as anonymous prepaid sub-
scriber identity module (SIM) cards, has revolutionized 
the illicit drug business at all levels. SMS messages are dif-
ficult for law enforcement authorities to monitor and trace, 
and the widespread use of cheap anonymous SIM cards 
makes tracing even more cumbersome. Moreover, the 
109 World Bank, “Internet users”, World Development Indicators data-
base. Available from http://data.worldbank.org/indicator/IT.NET.
USER.P2 (accessed January 2012).
110 World Bank, “Mobile cellular subscriptions”, World Development 
Indicators database. Available from http://data.worldbank.org/indica-
tor/IT.CEL.SETS.P2 (accessed January 2012). 
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mobile phone may act as a drug trafficker’s customer reg-
istry, and for some traffickers their main assets are the 
numbers stored on the telephone.
The rapid growth in international trade has also facilitated 
drug trafficking, as the large volumes of licit goods that 
are transported worldwide make it difficult for authorities 
to detect illicit drug shipments. Global merchandise 
exports rose in nominal terms by 440 per cent over the 
period 1990-2010.111 Taking inflation into account, this 
is equivalent to a 5 per cent yearly increase in terms of 
volume. Much of the traded merchandise is shipped in 
containers. The total annual capacity of container ship-
ments is about 1,100 million tons; global illicit drug pro-
duction would amount to less than 0.005 per cent of this 
(though not all drugs are transported by container). The 
likelihood of detecting illicit drugs by random container 
checks is thus extremely low. 
Another major development over the past few decades has 
been the increase in air traffic. The number of aircraft 
departures rose by more than 80 per cent between 1990 
and 2009, or 3.2 per cent per year.112 Combined with 
declining airfares, these increases have acted as an incentive 
to drug trafficking groups to take advantage of the larger 
volume of air traffic, either by employing large numbers 
of persons to act as “mules” (transporting illicit drugs across 
borders inside their bodies) or by concealing drugs inside 
air freight or postal parcels. The overall number of passen-
gers transported by aircraft rose by 4 per cent per year over 
the period 1990-2010 and the amount of freight trans-
ported rose by 4.6 per cent per year. 
C. WHICH FACTORS SHAPE THE 
EVOLUTION OF THE PROBLEM
What are the key observable drivers 
of long-term trends? 
The illicit drug economy continues to evolve. Understand-
ing why and how is a complex undertaking, as there is a 
wide range of potential factors to consider and uncertain-
ties as regards the manner in which they interact and the 
effects of those interactions. Moreover, many of the factors 
involved and their effects are difficult to measure or quan-
tify with any confidence, which makes solid analysis dif-
ficult. Nonetheless, a brief review, on the one hand, of 
what can reasonably be considered to be risk factors and 
predictable drivers of the illegal drug economy and, on the 
other, of what remains largely unforeseeable, can help take 
111 World Trade Organization, “International trade and tariff data”, Sta-
tistics Database. Available from www.wto.org/english/res_e/statis_e/
statis_e.htm (accessed January 2012).
112 World Bank, “Air transport, registered carrier departures worldwide”, 
World Development Indicators database. Available from http://data.
worldbank.org/indicator/IS.AIR.DPRT/countries (accessed January 
2012).
stock of the challenge that designing proactive drug policy 
represents and draw some cautious conclusions.
Sociodemographic drivers
Under the current drug control system, illicit drug use is 
more common among certain groups and in certain envi-
ronments. Statistically, a young man in a city has the high-
est risk of using illicit drugs and an old woman in the 
countryside has the lowest risk. While it may not be uni-
versally valid, this pattern can be seen in many countries.
As explained earlier in this chapter, young people generally 
use more drugs than older people, even if the gap is nar-
rowing in some places. In the United Kingdom, for 
instance, annual prevalence of illicit drug use among those 
aged 20-24 is almost 12 times higher than among those 
aged 55-59.113 In the United States, annual prevalence is 
7 times higher among people in the age group 18-25 than 
among people 50 and above,114 but it was 16 times higher 
in 1995.115
Data also show that more males than females use drugs. 
Even in mature illicit drug markets in countries with a high 
degree of gender equality, such as the United States, past-
month prevalence of illicit drug use among females (6.8 
per cent in 2010) is some 40 per cent lower than among 
males (11.2 per cent).116 Nonetheless, the gender gap also 
declined over the past three decades. In 1979, past-month 
prevalence of illicit drug use among females in the United 
States (9.4 per cent of the population aged 12 and above) 
was 51 per cent lower than the corresponding rate among 
males (19.2 per cent).117 
Another major sociodemographic driving factor for illicit 
drug use is agglomeration density, or level of urbanization. 
Apart from the particular situation in some of the main 
drug-producing countries, generally, more illicit drug use 
takes place in urban settings than in rural settings. 
In the United States, for instance, illicit drug use affected 
7.9 per cent of the population aged 12 and above in rural 
communities in 2010. Drug use was twice as high (16.2 
per cent) in large metropolitan areas with a population of 
more than 1 million. In the United Kingdom, the British 
Crime Survey revealed that in 2010/11, prevalence of the 
113 K. Smith and J. Flatley, eds., Drug Misuse Declared: Findings from 
the 2010/11 British Crime Survey—England and Wales, Home Office 
Statistical Bulletin No. 12/11 (London, Home Office, July 2011). 
114 Substance Abuse and Mental Health Services Administration, Results 
from the 2010 National Survey on Drug Use and Health: Detailed Tables.
115 J. Gfroerer, Preliminary Estimates from the 1995 National Household 
Survey on Drug Abuse, Advance Report No. 18 (Rockville, Maryland, 
Substance Abuse and Mental Health Services Administration, Office 
of Applied Studies, 1996).
116 Substance Abuse and Mental Health Services Administration, Results-
from the 2010 National Survey on Drug Use and Health: Detailed Tables.
117 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, Office of Applied 
Studies, Preliminary Results from the 1996 National Household Survey 
on Drug Abuse, OAS Series No. H-13, DHHS Publication No. (SMA) 
97-3149 (Rockville, Maryland, 1997).
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use of so-called “class A” drugs — heroin, methadone, 
cocaine, methamphetamine, “ecstasy”, LSD and “magic 
mushrooms” (listed in order of their potential to cause 
harm) — was significantly higher in urban areas of Eng-
land and Wales than in rural areas (3.2 per cent versus 1.8 
per cent), with a particularly large difference for “ecstasy”. 
In Germany, communities with fewer than 20,000 inhab-
itants had 2.7 drug-related offences (identified by the 
police) per 1,000 households in 2010, while urban areas 
with more than half a million inhabitants had, on average, 
6.6.118
Sociocultural drivers
Several sociocultural factors have also greatly influenced 
the evolution of the illicit drug problem. These include 
the changing societal value systems and an increasingly 
prominent youth culture, though some of these phenom-
ena are difficult to measure and quantify. 
The most significant sociocultural driving factor for the 
evolution of the drug problem appears to have been the 
popularization of a youth culture. In many developing 
countries, this has taken place alongside an orientation 
towards a Western way of life, which may, for some, 
include the temptation to use illicit drugs. 
Moreover, in many societies, there is a trend towards 
decreasing social control, often in parallel with high urban-
ization and migration rates. This may lead to cultural 
changes, the weakening of traditionally strong family ties 
and a declining importance of traditional value systems. 
In some cases, subcultural values that are more vulnerable 
to transgression, crime, violence and illicit drug use may 
emerge as a replacement. 
Most of the currently predominant religions denounce 
illicit drug use and intoxication. Some surveys have shown 
that individuals for whom religion plays an important role 
in their daily life are less prone to taking drugs.119 In the 
United States, for example, high school students who 
attended religious services frequently were more likely to 
abstain from illicit drug use than their less religious coun-
terparts.120 There may be secular explanations for this phe-
118 Germany Bundeskriminalamt (Federal Criminal Police Office), 
“Rauschgiftkriminalität: Bundeslagebild 2010—Tabellenanhang” 
(Wiesbaden, 2011); Statistisches Bundesamt (Federal Statistical 
Office), “Bevölkerung und Erwerbstätigkeit” (Population and employ-
ment) (Wiesbaden, 2011). 
119 B. H. Bry, P. McKeon and R. J. Pandina, “Extent of drug use as a func-
tion of number of risk factors”, Journal of Abnormal Psychology, vol. 91, 
No. 4 (1982), pp. 273-279; M. D. Newcomb and others, “Substance 
abuse and psychosocial risk factors among teenagers: associations with 
sex, age, ethnicity, and type of school”, American Journal of Drug and 
Alcohol Abuse, vol. 13, No. 4 (1987), pp. 413-433; E. Maddahian, M. 
D. Newcomb and P. M. Bentler, “Risk factors for substance use: ethnic 
differences among adolescents”, Journal of Substance Abuse, vol. 1, No. 
1 (1988), pp. 11-23; J. D. Hawkins, R. F. Catalano and J. Y. Miller, 
“Risk and protective factors for alcohol and other drug problems in 
adolescence and early adulthood: implications for prevention”, Psycho-
logical Bulletin, vol. 112, No. 1 (1992), pp. 64-105.
120 J. M. Wallace Jr. and others, “Race/ethnicity, religiosity and adolescent 
alcohol, cigarette and marijuana use”, Social Work in Public Health, 
nomenon, however, one of which is linked to the role of 
peer group pressure. Individuals who share a religious faith 
often form groups of like-minded people. As illicit drug 
use, in general, is not a feature of such groups, individual 
group members may, to a certain degree, be “protected” 
from it. 
Other sociocultural factors that contribute to shaping the 
evolution of the drug problem are related to conditions 
among vulnerable groups, such as children and adolescents, 
inducing early onset of behavioural and psychological 
problems, as well as mental health disorders. Such factors 
are often connected to the exposure of children and ado-
lescents to neglect, abuse, household dysfunction, violence 
and instability. These conditions can have effects not only 
on the functioning but also on the morphology of the 
brain, resulting in significant changes in the reward system, 
the motivational system, the emotional memory and the 
decision-making drive. Most of these factors tend to under-
mine the mental health of children and adolescents and, 
at the same time, to increase the likelihood of substance 
abuse. 
Socioeconomic drivers
Over the past few decades, the availability of disposable 
income, notably among the younger generation in devel-
oped countries, has increased significantly, thus facilitating 
the growth of drug consumption. Levels of illicit drug use 
are generally higher in developed countries, where dispos-
able income is high. This effect can sometimes be seen 
within regions, subregions or even countries. In North 
America, drug use is higher in Canada and the United 
States, where disposable income is higher than in Mexico. 
In South America, drug use is higher in the Southern Cone 
countries, which have higher levels of disposable income 
than the rest of the continent. Within the largest South 
American country, Brazil, drug use is more widespread in 
the relatively more affluent south than in the rest of the 
country. Similarly, in Europe, overall drug use is higher in 
Western Europe, where disposable income is higher than 
in Eastern or South-Eastern Europe. 
Disposable income, in isolation, does not explain all dif-
ferences. In Afghanistan, disposable income levels are 
low, whereas illicit drug use is high. Moreover, drug use 
in most of the Nordic countries is relatively low com-
pared with the rest of Western Europe, despite their high 
levels of disposable income. Similarly, although the dis-
posable income is high in Japan and Singapore, the spread 
of illicit drug use is limited there. 
vol. 23, Nos. 2 and 3 (2007), pp. 193-213; J. M. Wallace Jr. and 
others, “Religion, race and abstinence from drug use among American 
adolescents”, Monitoring the Future Occasional Paper 58 (Ann Arbor, 
Michigan, University of Michigan, 2003).
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Another relevant socio-economic factor is the level of social 
inequality within a given society. While this is not neces-
sarily a driving factor, it appears to contribute to or enable 
the development of a drug problem. Societies characterized 
by high income inequality tend to be more prone to crime, 
including drug trafficking, and a high level of drug traf-
ficking is a risk factor for increased consumption. In 
extremely unequal societies, some members of marginal-
ized groups may view involvement in drug trafficking as 
the only feasible strategy for upward social mobility. Simi-
larly, without realistic hopes of a better future, members 
of those groups may become disillusioned and more vul-
nerable to illicit drug use. The social barriers against acquis-
itive crime also tend to be lower in societies with high 
income inequalities. 
Inequality can be measured as the extent to which the dis-
tribution of income among individuals within an economy 
deviates from a totally equal distribution. It is frequently 
measured by the Gini index, in which a coefficient of 0 
signals absolute equality (everyone earns the same), while 
100 indicates total inequality (one person earns every-
thing). The analysis of existing Gini coefficients, as pub-
lished by the World Bank, shows a global average of 42.121 
Countries with the lowest income inequality (Gini coef-
ficient of less than 30) tend to have relatively low levels of 
drug problems. Conversely, a number of countries with 
high levels of inequality (Gini coefficients exceeding 50) 
face relatively higher levels of drug problems as well, mostly 
as transit or production locations.
Unemployment appears to be another key socio-economic 
driver of drug trafficking and illicit drug use. Among 
young males, in particular, unemployment increases the 
likelihood of participation in the illicit drug trade and illicit 
drug use. Given the high unemployment rates in many 
countries, in particular among youth, entry into the work-
force is often a major challenge. Consumption of illicit 
drugs may limit an individual’s chances of entering (or 
remaining in) the workforce, while frustration caused by 
failure to find adequate employment sometimes favours 
drug consumption, thus creating a vicious circle.122
Surveys across the world have repeatedly shown illicit drug 
use to be far more widespread among unemployed people 
than among the general population. In a number of coun-
tries, including France, the United Kingdom and the 
United States, the rates among those unemployed were 
about twice as high as among the working population. In 
the Philippines, a national household survey conducted in 
2008 found that more than a third of the current123 drug 
121 World Bank, “Gini index”, World Development Indicators database. 
Available from http://data.worldbank.org/indicator/SI.POV.GINI 
(accessed 30 March 2012).
122 United Nations International Drug Control Programme, Economic 
and Social Consequences of Drug Abuse and Illicit Trafficking, UNDCP 
Technical Series No. 6 (Vienna, 1998).
123 “Current drug users” were defined in that survey as those who admit-
ted that they were still using “dangerous” drugs up to the time the 
survey was conducted. 
users were unemployed,124 while the overall unemploy-
ment rate was 7.3 per cent. This suggests that current drug 
users were far more likely to be unemployed than the gen-
eral population.
Unemployment is even more significant when it comes to 
people requiring treatment for illicit drug use. A study 
conducted throughout the European Union in the early 
2000s revealed that 47.4 per cent of those receiving treat-
ment were officially unemployed and a further 9.6 per cent 
were “economically inactive”. In comparison, the general 
unemployment rate at that time (in 2001) was 8.2 per 
cent.125 Similarly, a study conducted by UNODC in Cen-
tral Asia (Kazakhstan, Kyrgyzstan, Tajikistan and Uzbeki-
stan), covering the period 2003-2005,126 revealed that 
close to 60 per cent of persons entering treatment for illicit 
drug use were unemployed, whereas the average unemploy-
ment rate in those four countries over the same period was 
less than 9 per cent. 
Several countries also report that unemployed persons are 
more likely to be involved in drug trafficking than those 
in formal employment. In Poland, for instance, 30 per cent 
of the people arrested for drug trafficking were unemployed 
in 2009, compared with a general unemployment rate of 
8.2 per cent that year. In Italy, 38 per cent of arrested drug 
traffickers were unemployed in 2009, whereas the unem-
ployment rate was 7.8 per cent. Similarly, in Argentina, 
54 per cent of all arrested drug traffickers with known 
employment status were unemployed in 2009. The unem-
ployment rate was 8.6 per cent in that country.127 
While the unemployment rates among illicit drug users 
and drug traffickers are significantly higher than among 
the general population, it is less clear whether changes in 
a country’s unemployment rates result in parallel changes 
in the number of drug users. There seems to be no strong 
correlation between changes in unemployment rates and 
the prevalence of illicit drug use over time. The longest 
time-series data available are for the United States. For the 
period 1979-2010, those data show a slightly positive, 
though statistically significant, correlation between unem-
ployment and annual prevalence of illicit drug use among 
the general population (R=0.5). 
Another key finding, seen in most studies, is that people 
from disadvantaged backgrounds are more likely to use 
illicit drugs.128 Data for the United States, for instance, 
show that prevalence of illicit drug use among people with 
124 Dangerous Drugs Board, Study on the Current Nature and Extent of 
Drug Abuse in the Philippines.
125 European Monitoring Centre for Drugs and Drug Addiction, Annual 
Report 2003: The State of the Drugs Problem in the European Union and 
Norway (Luxembourg, Office for Official Publications of the European 
Communities, 2003), p. 67.
126 United Nations Office on Drugs and Crime, “Drug abuse in Central 
Asia: trends in treatment demand 2003-2005” (Tashkent, October 
2006). 
127 UNODC, data from the annual report questionnaire.
128 Degenhardt and Hall, “Extent of illicit drug use and dependence”. 
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low incomes is far higher than among people in higher 
income groups (21 per cent annual prevalence of illicit 
drug use among people from households with an income 
of less than $20,000 in 2010, compared with 12.4 per cent 
for those in households with an income of more than 
$75,000).129 In addition, a number of countries experi-
ence an inverted J-curve phenomenon, that is, illicit drug 
use is highest among the poorest sections of society, low 
among the middle class, before increasing again among the 
richest. In the United Kingdom, for example, annual prev-
alence in 2010/11 was 12.9 per cent among persons in 
England and Wales earning less than £10,000 per year; 6.7 
per cent among those earning between £30,000 and 
£40,000; and 7.7 per cent among those earning more than 
£50,000.130 
The drug control system
While the various sociocultural, sociodemographic and 
socio-economic factors discussed above clearly have a sig-
nificant impact on the development of the various facets 
of the drug problem, there is another key factor: drug con-
trol policy. The fundamental features of the current drug 
control system have remained stable over time. These 
include the principles of restricting the use of drugs to 
medical and scientific purposes, supply reduction, demand 
reduction and the need for a balanced approach — apply-
ing measures at both the supply and the demand sides — 
to tackle the problem.
Drug control is applied to increase the risks for producers, 
traffickers and users of illicit drugs. Far higher drug prices 
and/or the risk of a law enforcement response tend to lower 
illicit drug use (compared with a hypothetical situation in 
which such measures were not in place). Similarly, higher 
risks for illicit drug producers and traffickers limit their 
readiness to participate in the market. Without the risk of 
eradication, for instance, more farmers may be expected 
to grow illicit crops. 
There are a number of examples that demonstrate the 
impact of drug control interventions during specific peri-
ods in various countries:
 t Opium production and consumption were widespread 
in China during the last decades of the nineteenth cen-
tury, the inter-war period and the Second World War. 
Stringent drug control measures implemented during 
the 1950s led to a drastic decline of the problem. Ever 
since, China has had a relatively small drug problem 
and prevalence of opiate use among the adult popula-
tion is currently about 0.25 per cent. 
129 United States, Department of Health and Human Services, Substance 
Abuse and Mental Health Services Administration, “Analyzing Data 
Online”. Available from www.icpsr.umich.edu/icpsrweb/SAMHDA/
sdatools/resources (accessed 30 March 2012).
130 Hoare and Moon, Drug Misuse Declared: Findings from the 2009/10 
British Crime Survey.
 t In the 1970s, Iran used to be among the large opium-
producing countries worldwide. Following the Iranian 
revolution in 1979, however, opium production basi-
cally ceased, and opium was largely replaced by opiates 
produced in neighbouring Afghanistan.
 t Thailand was a significant opium producer in the early 
1960s, with most of the cultivation concentrated in the 
country’s northern areas. Following concerted alterna-
tive development efforts in those areas, opium produc-
tion in Thailand declined, and is now marginal. 
 t Java, one of the main islands of present-day Indonesia, 
had one of the largest areas under coca bush cultivation 
in the inter-war period. Intervention by the United 
States after the Second World War stopped this pro-
duction and cocaine has since remained a negligible 
problem in Indonesia. 
 t After the Second World War, Japan had large stocks 
of methamphetamine, which gradually leaked into 
the market and caused a methamphetamine epidemic. 
Curtailing the leaks, stopping local production and 
introducing control measures for precursor chemicals 
in the early 1950s reduced Japan’s methamphetamine 
problem for several decades. 
 t In the early 2000s, Australian law enforcement authori-
ties, in close cooperation with their South-East Asian 
counterparts, managed to dismantle some key heroin 
trafficking networks. As a result, Australia experienced 
a heroin shortage, causing a steep increase in purity-
adjusted heroin prices. The increase prompted a large 
number of heroin users to leave the market, by giving 
up illicit drug use, entering treatment or shifting to 
other drugs. Heroin consumption declined by some 75 
per cent.131 Although the heroin supply was eventually 
re-established, consumption has remained at the lower 
level. 
 t Colombia saw a massive decline in coca leaf production 
(and thus also cocaine production) as the area under 
coca bush cultivation declined by 65 per cent between 
2000 and 2010, following the implementation of Plan 
Colombia and large-scale eradication efforts.132 In the 
wake of the declining coca leaf production, financial 
flows to the illegal armed groups and their activities 
also declined. 
Most of the above-mentioned results were achieved largely 
through supply-side measures. There are also a number of 
primarily demand-side successes, however, that are perhaps 
less well-known: 
 t Illicit drug use has been declining sharply in the United 
States since the early 1980s, among the general popula-
tion as well as among youth. Annual prevalence of the 
131 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report. 
132 World Drug Report 2011.
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use of all illicit drugs fell by some 25 per cent among 
12th grade students between 1980 and 2011 and co-
caine use fell by 76 per cent over the same period.133 
Most of these reductions appear to have been related 
to decreasing demand rather than falling supply. The 
recent massive declines in cocaine use (2006-2010), 
however, appear to have been supply-driven. 
 t Western European countries, alongside Australia, 
Canada and New Zealand, were among the first to 
introduce a broad range of measures aimed at reducing 
the adverse consequences of drug abuse. Significant 
declines in HIV infections among injecting drug users 
were subsequently recorded134 and the heroin market 
declined. Moreover, drug-related deaths stabilized and, 
in some places, declined. 
Formal theories 
In addition to the factors mentioned above, others have 
been proposed in theories aimed at explaining the evolu-
tion of the various aspects of the drug problem. These 
include the availability of illicit drugs and perceptions of 
133 L. D. Johnston and others, “Marijuana use continues to rise among 
U.S. teens, while alcohol use hits historic lows”, Ann Arbor, Michigan, 
University of Michigan News Service, 14 December 2011. Available 
from http://monitoringthefuture.org/data/11data.html#2011data-
drugs. 
134 European Centre for the Epidemiological Monitoring of HIV/AIDS, 
“HIV/AIDS surveillance in Europe”, Mid-Year Report 2007 No. 76 
(Saint-Maurice, France, French Institute for Public Health Surveil-
lance, 2007); European Centre for Disease Prevention and Control 
and WHO Regional Office for Europe, HIV/AIDS Surveillance in 
Europe 2010 (Stockholm, 2011); Joint United Nations Programme 
on HIV/AIDS, Global Report: UNAIDS Report on the Global AIDS 
Epidemic 2010 (2010); Joint United Nations Programme on HIV/
AIDS, AIDSinfo Country fact sheets. Available from www.unaids.org/
en/dataanalysis/tools/aidsinfo/countryfactsheets/.
risk from using such drugs, the analysis of drug use as epi-
demics and the importance of social control to prevent 
illicit drug production.
Drug availability and risk perceptions
Among the key parameters that define illicit drug use are 
the availability of drugs and the perception of risk created 
by the use of the drugs. The tendency is that the higher 
the availability of drugs, the higher the consumption. In 
parallel, the higher the risks associated with drug use, the 
lower the consumption. 
Data for the United States show these correlations clearly 
(see figure 22). Among 12th grade students, there is a very 
strong positive correlation between the perceived availabil-
ity of major drugs and the annual prevalence of drug use. 
Cannabis is the substance most readily available and it also 
has the highest prevalence rate. In contrast, other drugs, 
notably methamphetamine and heroin, are far less readily 
available and also register lower prevalence rates. 
The data also show a very strong negative correlation 
between perceived risks and annual prevalence for key illicit 
drugs; that is, the higher the risks associated with the use 
of a specific drug, the less likely it is that that drug is con-
sumed (see figure 23). The risks are perceived to be highest 
for the use of methamphetamine and heroin and lowest 
for cannabis use, and the prevalence rates are highest for 
cannabis use and lowest for the use of heroin and 
methamphetamine. 
The same United States data also show that the prevalence 
rates over time are a function of availability and perceived 
risk. An analysis over the period 1975-2011 for cannabis 
shows a relatively strong positive correlation between 
perceived availability and annual prevalence (R=0.65) (see 
Fig. 23. Annual prevalence and perceived risks 
of drugs as reported by 12th grade  
students in the United States, 2011a
Source: National Institute on Drug Abuse, Monitoring the Future 
survey, 2011. 
aPercentage of 12th grade students saying that using a specific drug  
“once or twice” would be a “great risk”. 
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Fig. 22. Annual prevalence and availability  
of drugs as perceived by 12th grade 
students in the United States, 2011a
Source: National Institute on Drug Abuse, Monitoring the Future 
survey, 2011.  
aPercentage of 12th grade students saying that it would be “fairly easy” or 
“very easy” to obtain the respective drug. 
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figure 24). That is, during most of those years, cannabis 
use increased or declined in line with perceived availability. 
The correlation over time is even stronger (R=0.94) when 
it comes to annual prevalence of cannabis use (“using can-
nabis occasionally”) and perceived risk. The higher the 
perceived risks, the lower the prevalence of cannabis use, 
and vice versa. 
Combining “availability” and “risk” for the period 1975-
2011135 gives an extremely good fit, which suggests that 
90 per cent of the actual changes in the annual prevalence 
rates during that period can be explained by changes in 
perceived risk and availability (see figure 25). 
Drug epidemics 
In some cases, drug consumption may develop into drug 
use epidemics, which acquire a momentum of their own 
and defy control measures. While drug use may, for long, 
increase only slightly, at a certain moment it will start to 
increase exponentially, before reaching a plateau and 
eventually declining. Several well-known instances of rapid 
drug use increases have been fruitfully analysed as 
epidemics comprised of separate stages with different 
characteristics.136
In the first stage of an epidemic, initiation of drug use takes 
on a contagious character, although, of course, there is no 
135 Combining availability and risks as inputs (X-values) for prevalence 
(Y-values) as output in a multiple linear regression model gives a mul-
tiple R of 0.95 and thus an R-square of 0.90.
136 See, for example, J. P. Caulkins, “Models pertaining to how drug policy 
should vary over the course of a drug epidemic”, in Substance Use: Indi-
vidual Behaviour, Social Interactions, Markets and Politics, B. Lindgren 
and M. Grossman, eds., Advances in Health Economics and Health 
Services Research, vol. 16 (Amsterdam, Elsevier, 2005), pp. 397-429.
pathogen that spreads it. Most people obtain their first 
dose of illicit drugs from a friend, family member or 
romantic partner. A small base of existing users may thus 
recruit a significant number of new ones from their imme-
diate environment. Friendship networks can become effec-
tive vehicles for spreading drug use, as can neighbourhoods, 
schools or prisons, where it is easy for drug users to estab-
lish social relationships (and pass on their drug habit). 
Eventually some drug users will become dependent and 
may face problems to finance their habit. They may thus 
get involved in drug trafficking and develop an interest in 
expanding the market. In this way, consumption may 
spread exponentially, much faster than any underlying 
socio-economic or demographic changes that may be 
occurring simultaneously.
This is not to say that everyone who comes into contact 
with illicit drug users is likely to try using drugs. Some 
people are more susceptible than others, for a variety of 
reasons. Moreover, the group of individuals susceptible to 
drug use may be subdivided into “stayers”, individuals who 
are considered not to be at risk of infection, and the 
“movers”, who are at risk.137 This means that out of a large 
group of people who may interact with current drug users, 
only a few proceed to problem drug use.
Following this phase of rapid expansion of the drug user 
base, initiation eventually peaks, and then starts to decline. 
There are two main explanations for this. The one that is 
most closely aligned to models of pathogenic epidemics 
relates the surge in consumption to the spread of the drug 
137 C. Rossi, “A mover-stayer type model for epidemics of problematic 
drug use”, Bulletin on Narcotics, vol. LIII, Nos. 1 and 2 (2001) (United 
Nations publication, Sales No. E.02.XI.6), pp. 39-64. 
Fig. 24. Cannabis use and perceived availabil-
ity among 12th grade students in the 
United States, 1975-2011a
Source: National Institute on Drug Abuse, Monitoring the Future 
survey, 2011. 
aPercentage of 12th grade students saying that it would be “fairly easy” or 
“very easy” to obtain cannabis.
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Fig. 25. Cannabis use and perceived risks 
among 12th grade students in the  
United States, 1975-2011a
Source: National Institute on Drug Abuse, Monitoring the Future 
survey, 2011.  
aPercentage of 12th grade students saying that “smoking marijuana  
occasionally” would be a “great risk”.
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in question through a finite pool of susceptible individuals 
with no previous exposure to that particular drug. Once 
that pool is drained, initiation will naturally come to a 
halt.138 The other explanation emphasizes the importance 
of a drug’s image. Over time, some illicit drug users pro-
gress to heavy drug use and possibly dependence. The hard-
ships faced by this group sour the drug’s reputation and 
hamper initiation among susceptible individuals.139 These 
explanations are not mutually exclusive.
While drug control interventions during the phase of expo-
nential growth may reduce growth rates (and accelerate 
the reaching of a plateau), they are generally not able to 
reduce illicit drug use. This may create the impression that 
the interventions have failed and that new approaches are 
called for. It is difficult to claim an increase of “just” 100 
per cent as a success (though, without interventions, drug 
use levels would have tripled or quadrupled). The challenge 
is to accurately model drug epidemics in order to enable 
policymakers to measure the reductions. Analyses of the 
cocaine epidemic that affected the United States in the 
1970s and early 1980s suggest that law enforcement and 
prevention would have been the most appropriate responses 
in the early phases, while in the later phase the emphasis 
should have been on treatment. The ability of law enforce-
ment to suppress drug use in entrenched illicit drug mar-
kets tends to be more limited. Nonetheless, law enforcement 
still has a role to play in mature drug markets, notably by 
promoting abstinence among offenders under supervision 
and in increasing participation and retention in 
treatment.140 
Applying epidemic models to the current global situation 
with respect to illicit drug use, it may be posited that 
South-East Asia is in the midst of an epidemic initiation 
phase with regard to the use of ATS, notably metham-
phetamine. There are also signs that illicit drug use is 
increasing in several African countries, although the cur-
rently available data — in particular from Africa — are 
often insufficient for reliable analysis. In contrast, with 
regard to cocaine, North America appears to have passed 
the plateau and levels of cocaine use are declining. 
Social capital
“Social capital” is a sociological concept that refers to the 
value of social cohesion, social relations and the role of 
cooperation to achieve collective or economic results. Just 
as physical or human capital can increase productivity, 
social contacts — which form the basis of social capital 
— also affect productivity. Indications of the existence of 
138 See, for example, C. Rossi and G. Schinaia, “The mover-stayer model 
for the HIV/AIDS epidemic in action”, Interfaces, vol. 28, No. 3 
(1998), pp. 127-143.
139 This “negative advertisement” theory has been most prominently 
advanced by David Musto (see D. F. Musto, The American Disease: 
Origins of Narcotic Control (New Haven, Connecticut, Yale University 
Press, 1973)).
140 Strang and others, “Drug policy and the public good: evidence for 
effective interventions”.
social capital in a society include civic participation, trust 
in government and acceptance of the rule of law (or alter-
native generally accepted value systems).141 Social capital 
builds on shared norms or values that promote social coop-
eration. Conversely, the lack of social capital may make a 
society vulnerable to exploitation by organized criminal 
groups. 
Once trust in government and a strong civil society are 
created or restored and the rule of law becomes generally 
accepted, it is likely that the prominence of the illicit drug 
sector will decline. For countries more severely affected by 
the drug industry, this means that economic development 
and related benefits alone are not sufficient to deter such 
involvement. 
Unforeseeable factors changing the 
patterns of the drug problem 
In addition to the largely foreseeable factors discussed 
above, a set of additional factors, mainly beyond the capa-
bilities of ordinary forecasts, help shape the drug problem. 
Such events have, at least in the past, proved to be highly 
significant. 
Events 
Many events seemingly unrelated to the drug problem have 
had an unintended but extensive impact on drug-related 
situations. One example is the eastward expansion of the 
British Empire in the eighteenth century, which led to 
large-scale opium production in British India and subse-
quent export of that opium to China. This only stopped 
more than a century later. 
Another prominent example of such an event is the war in 
Viet Nam in the 1960s. The war prompted a strong anti-
war movement that contributed to the spread of the use 
of illicit drugs (notably marijuana) as a means of rebelling 
against the establishment. While the protest movement 
eventually disappeared with the end of the war in 1975, 
illicit drug use had become entrenched. 
The profound political and economic transformations that 
followed the end of the cold war in many of the former 
East bloc countries also entailed rapid increases in illicit 
drug consumption where there used to be very little. Crim-
inals “integrated” those countries into the world’s illicit 
drug networks and developed new drug trafficking routes. 
For opiates, the routes led — and indeed still lead — from 
Afghanistan via the various Central Asian countries to the 
Russian Federation and beyond. At the same time, syn-
thetic drugs, produced in Western Europe, made their way 
eastwards. 
A major change for Africa, notably the countries in South-
ern Africa, was the abolition of apartheid in South Africa 
in 1994. The subsequent end to decades of international 
141 F. E. Thoumi, “What creates comparative advantage for drug produc-
tion? Lessons from Colombia”, Policy, vol. 23, No. 1 (Autumn 2007).
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isolation also increased South Africa’s exposure to transna-
tional drug trafficking, which led in turn to increased 
domestic illicit drug use. Traffickers also took advantage 
of the country’s good infrastructure and South Africa 
emerged as a transit hub for cocaine shipments from South 
America destined for Europe, as well as for heroin ship-
ments from Afghanistan and Pakistan destined for Europe. 
The Al-Qaida attacks of 11 September 2001 also changed 
the world drug situation. The subsequent armed interven-
tion against the Taliban regime in Afghanistan, which had 
supported Al-Qaida, de facto ended the opium ban that 
had been proclaimed in July 2000 (and drastically reduced 
opium production in 2001). Large-scale opium produc-
tion re-emerged in Afghanistan, promoted by the ousted 
Taliban, who started again to tax the opium trade. In par-
allel, international attention somewhat shifted away from 
drug control towards the fight against terrorism in the 
region. 
Fashion and trends
As with many other mainly recreational products, some of 
the changes in the choice of illicit drugs and modes of 
consumption have been influenced by largely unpredict-
able fashion-type evolutions. LSD and other hallucino-
genic substances, for instance, were broadly popular in the 
1960s and part of a much wider psychedelic culture. While 
the use of hallucinogenic substances has not disappeared, 
it is now much less widespread.
Recreational cocaine use was considered trendy in North 
America in the 1970s. With the emergence of “crack” 
cocaine in the 1980s, however, the image of cocaine 
changed there. Cocaine use was no longer considered rela-
tively benign, but as something that might have severe 
consequences for one’s family and community. That change 
in perception is likely to have contributed to the strong 
decline in cocaine use witnessed in North America since 
the mid-1980s. 
Methaqualone, a sedative-hypnotic drug and central nerv-
ous system depressant, used to be popular in the United 
States in the 1970s and over the next few decades in South 
Africa, where it is known as Mandrax. While the use of 
Mandrax is still relatively widespread in South Africa, the 
opening of the country’s borders after the 1994 democratic 
transition meant that new fashions and trends also reached 
that country. Subsequently, Mandrax became less 
popular. 
The use of “ecstasy” has been linked, starting in the late 
1980s, to dance events, notably rave parties. The increas-
ing popularity of such events also led to a rise in “ecstasy” 
use. The popularity of such parties appears to have peaked, 
and there have also been some indications of declining 
“ecstasy” use over the past few years.
The popularity of heroin has declined in several Western 
European countries over the past decade as the image of 
the drug has changed. It is no longer seen as fashionable, 
but as the drug of an ageing population of users who are 
ill and need medical attention. Despite the revival of 
Afghanistan’s heroin production and record harvests until 
2007, heroin consumption among the younger generation 
has not increased in Western Europe in recent years.
Unintended effects of drug control  
interventions
The implementation of a drug control system appears to 
have had the desirable long-term effect of containing the 
expansion of the drug problem and of limiting the spread 
of illicit drug use and addiction. At the same time, a 
number of unintended consequences have appeared. 
The development of black markets and the opportunities 
they create for organized crime have been among the 
unintended side effects. Black markets are not specific to 
controlled psychoactive substances, of course, as they affect 
a broad range of regulated or prohibited goods and services. 
Effective drug control measures seem to have given rise to 
another main category of unintended consequences in 
illicit drug markets. These are various replacement or dis-
placement effects, sometimes generically referred to as the 
“balloon effect”. There are several examples of such effects 
at work: 
 t When opium production was halted in the Islamic Re-
public of Iran in 1979, it first shifted to Pakistan and 
then to Afghanistan. Opium production in Thailand 
declined from the 1960s onwards, but it increased in 
Burma (later Myanmar) until the early 1990s (before 
falling after 1996). Declining ATS manufacture in 
Thailand in the 2000s prompted rises in neighbouring 
Myanmar. 
 t Declining coca leaf production in Bolivia and Peru in 
the 1990s occurred in parallel with rising coca leaf pro-
duction in Colombia; similarly, declining coca leaf pro-
duction in Colombia in the 2000s was accompanied by 
increases in Bolivia and Peru. 
 t Another case of displacement concerns so-called new 
psychoactive substances, some of which appeared in 
the wake of precursor control efforts in many coun-
tries. For example, effective control of 3,4-MDP-2-P 
in Europe led to decline in “ecstasy” production and 
the emergence of new psychoactive substances such as 
mephedrone.
The net results of such displacement effects vary, but from 
a global perspective they always reduce the intended impact 
of interventions. 
Balloon effects do not only occur on the supply side, how-
ever. In the United Kingdom, for instance, policy interven-
tions appear to have contributed to massive declines in the 
illicit use of amphetamines. The annual prevalence of 
amphetamine use fell by two thirds between 1996 and 
2010/11 in England and Wales. While the decline was 
offset in part by strong increases in the use of cocaine, there 
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was still a net decline of some 20 per cent in the use of 
stimulants there.142 In Australia, the heroin drought of 
2001 reduced prevalence of heroin use from 0.8 per cent 
to 0.2 per cent in 2001. Heroin use remained low until 
2010. The misuse of synthetic opioids, however, rose, from 
previously low levels.143 While there was a net reduction 
in the overall use of those substances, some heroin users 
may have shifted to using other opioids. 
Outlook: the likely, the possible and 
the unknown 
Based on the previous discussion, what can be said about 
identifiable threats and risks and the possible evolution of 
the drug problem in the coming years? While some devel-
opments are likely to materialize, others seem possible, 
based on current knowledge. Finally, the past has taught 
us that there are a large number of unforeseeable events 
and factors that can have a profound and unpredictable 
impact on the drug problem. 
The likely
The best forecasts — those most likely to materialize and 
have a direct bearing on illicit drug use — can be derived 
from demographic projections. At the end of October 
2011, the world population reached 7 billion, having 
increased by some 77 million persons annually since 2005. 
Given the ongoing declines in fertility rates, the global 
population growth is expected to slow considerably over 
the next decades. Nonetheless, the world population is 
expected to increase to 9.3 billion by 2050 and to 10.1 
billion by 2100.144 
The increasing number of people is also likely to bring 
with it an increase in the absolute number of illicit drug 
users. While prevalence of illicit drug use remained rela-
tively constant over the past decade, the overall number of 
drug users increased, in line with population increases. 
Assuming that the drug control system will not change 
fundamentally and that the overall annual prevalence of 
illicit drug use will remain stable at about 5 per cent of the 
population aged 15-64, there may be some 65 million 
additional drug users by 2050 as compared to 2009/10, 
or 74 million more by 2100. This would bring the total 
number of annual drug users close to 300 million persons 
by the end of the present century.145 
Basic demographic figures also provide some indications 
of the likely geographical distribution of the future drug 
142 Hoare and Moon, Drug Misuse Declared: Findings from the 2009/10 
British Crime Survey. 
143 Australian Institute of Health and Welfare, 2010 National Drug Strat-
egy Household Survey Report.
144 United Nations, World Population Prospects (medium variant) (World 
Population Prospects: The 2010 Revision, vol. I, Comprehensive Tables 
(ST/ESA/SER.A/313)).
145 Demographic projections from the Population Division of the Depart-
ment of Economic and Social Affairs of the Secretariat (World Popula-
tion Prospects: The 2010 Revision, vol. I, Comprehensive Tables (ST/ESA/
SER.A/313)). 
users. The population in the developing countries is pro-
jected to rise from 5.7 billion in 2011 to 8 billion by 2050 
and 8.8 billion in 2100. In contrast, the population in the 
more developed regions146 is expected to increase mini-
mally, from 1.24 billion in 2011 to 1.34 billion in 2100. 
This suggests that most of the increase in drug users over 
the next 90 years will occur in developing countries. 
Illicit drug use is likely to continue to be linked primarily 
to young people as it is probable that youth culture will 
continue to play a key role in shaping drug use behaviour. 
The importance of youth culture may increase further as 
the importance of traditional family ties and value systems 
declines. Developing countries may be particularly affected.
The world’s population is now getting older, a trend that 
can be seen in both developed and developing countries. 
The average age in the more developed regions reached 
39.9 years in 2011, and it will continue to be significantly 
higher than in the less developed regions (27.2 years in 
2011, forecast to rise to 36.8 by 2050). In the context of 
illicit drug use, the ageing population may explain at least 
in part the stabilization of drug use in several developed 
countries in recent years. 
Another demographic pattern, discussed in detail earlier, 
is the pronounced gender differences in drug use behav-
iour, with men consuming far more drugs than women. 
Given the larger gender gap in developing countries, there 
may be a greater risk of further increases in female drug 
use in such countries as sociocultural barriers gradually 
disappear with more societies experiencing modernization 
and increasing gender equality. 
This trend may also be exacerbated by increasing urbani-
zation, given this phenomenon’s link to illicit drug use. 
The population in urban areas in the more developed 
regions is projected to rise moderately, from 0.9 billion in 
2011 to 1.1 billion in 2050. In comparison, the urban 
population in the less developed regions is expected to 
more than double, from 2.6 billion in 2011 to 5.3 billion 
in 2050. 
The factors discussed so far suggest that developing coun-
tries are at a high risk of experiencing increased illicit drug 
use over the next few decades. Africa, in particular, may 
be faced with growing numbers of drug users in the near 
future. The population aged 15-59 is forecast to grow by 
2.1 per cent per year in Africa over the period 2011-2050, 
which is far more than in any other region. Given the pre-
viously discussed link between disposable income and drug 
use and assuming that disposable income will be rising in 
Africa, there is a risk of increasing drug use there. 
146 According to the Department of Economic and Social Affairs, the 
“more developed regions” comprise all regions of Europe plus Aus-
tralia/New Zealand, Japan and North America. “Less developed 
regions” comprise all regions of Africa, Asia (excluding Japan) and 
Latin America and the Caribbean, as well as Melanesia, Micronesia and 
Polynesia. Countries or areas in the more developed regions are desig-
nated “developed countries”, countries or areas in the less developed 
regions are designated “developing countries”.
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The likely net impact on global drug use prevalence is less 
clearly identifiable. While population growth, urbanization 
and reduced gender gaps in drug use may lead to a higher 
consumption level overall, the ageing of the global 
population should help reduce it. The net effect is likely 
to be a relatively stable overall prevalence rate but a larger 
number of drug users as a result of the growing population.
Assuming no fundamental changes to the drug control 
system or the manner in which it is implemented, its effects 
can be assumed to remain similar in the future. This would 
imply an overall containment of the problem, and in par-
ticular a containment to young people. This scenario also 
suggests that drug control efforts will continue to face the 
existence of black markets for drugs for the decades to 
come. The question of whether, globally, the value of black 
markets for drugs will grow or decline is open. More con-
sumers could mean more illicit drug revenues, although 
there are also factors pulling in the opposite direction. 
Illicit drug markets are expected to increase primarily in 
developing countries where drug prices are low, while the 
market may be stable, or even decline, in developed coun-
tries. The average price of drugs is thus likely to decline. 
The total size of the black market for illicit drugs should 
not increase significantly. As a proportion of global GDP 
it is likely to fall to 0.5 per cent or even less. 
The possible 
While it is quite likely that overall annual prevalence of 
illicit drug use will remain stable (at about 5 per cent of 
the population aged 15-64), it is very unlikely that the 
relative importance of the various drugs will remain 
unchanged. Current supply and demand factors suggest 
that the prominence of the two main problem drugs at the 
international level, heroin and cocaine, could decline.
The bulk of both opium poppy and coca bush is currently 
cultivated in limited areas in a few countries. Efforts 
engaged by the Governments concerned, with support 
from the international community, should eventually lead 
to a sustainable elimination of large-scale illicit cultivation 
in those areas, something that several countries such as 
Thailand, have achieved before. Links between drug pro-
duction and the activities of illegal armed groups, as well 
as the violence and insecurity associated with transnational 
trafficking in cocaine and heroin in some places, have cre-
ated additional incentives to solve the problem. History 
has also shown Governments that a closely coordinated 
approach at the international level is required to prevent 
the balloon effect. 
On the demand side, there has been a stabilization or even 
reduction of heroin use in the large Western European 
market. The heroin-using population is ageing and the 
drug’s image has turned negative there. Moreover, treat-
ment, including substitution treatment using other opi-
oids, has been reducing the size of the heroin market, and 
these trends are likely to continue. Heroin use has contin-
ued to rise in the main producer country, however, as well 
as in a number of transit or relatively new destination 
countries, and these tendencies are not likely to end 
quickly. Nevertheless, if more countries continue to create 
or expand treatment programmes, including substitution 
treatment programmes, there is a chance that the pull effect 
of global demand for heroin will decline, helping supply-
side efforts and reducing the risk of cultivation displace-
ment. The use of diverted prescription opioids has also 
increased in many countries in recent years, however.147 
In contrast to heroin, there is still no substitution treat-
ment for cocaine. Nonetheless, there have been massive 
declines in cocaine use in the United States, the world’s 
largest illicit cocaine market. While the decline witnessed 
since 2006 seems to have been largely supply-driven, data 
suggest that most of the long-term decline over the past 
three decades has been demand-driven.148 North America 
may be seeing the end of a cocaine epidemic. In Europe, 
cocaine use increased strongly until 2006/07. Since then, 
a peak appears to have been reached in Europe, as well as 
in several South American countries, where illicit demand 
for cocaine may have started to decline. The danger of an 
ongoing expansion of cocaine use in Africa, Asia and Oce-
ania remains, though those illicit markets are still relatively 
small. Even high growth rates do not translate into a large 
number of new cocaine users, at least for the time being. 
Ongoing research on the development of so-called “cocaine 
vaccines” are showing interesting preliminary results. Such 
vaccines could help fight cocaine dependency. However, 
it will still be years, if not decades, before they are ready 
for use. 
Prospects for the other major illicit drug markets are less 
promising. There are currently no indications that cannabis 
production and use are going to diminish. While remote 
sensing can assist in identifying and eventually eradicating 
large-scale cannabis cultivation sites, this may be offset by 
the ongoing trend towards indoor cultivation of high-
potency cannabis. Following years of increase, cannabis 
consumption appears to have levelled off in several coun-
tries. While the prevalence rate at the global level is not 
likely to change significantly from today’s level (close to 4 
per cent of the population aged 15-64), the total number 
of cannabis users is still likely to increase. 
The strongest consumption growth rates for the decades 
to come may be expected for synthetic drugs, notably ATS 
and diverted prescription drugs, as well as a large number 
of synthetic substances that are not yet under international 
control. Information about the production of synthetic 
drugs is now widely available and is likely to continue to 
spread even further. As a result, much of the illicit manu-
facture of synthetic drugs now takes place close to consum-
ers, which tends to make it more difficult for law 
enforcement to identify and disrupt the drug traffickers. 
147 Strang and others, “Drug policy and the public good: evidence for 
effective interventions”.
148 See World Drug Report 2011.
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Though precursor controls have helped limit access to key 
chemicals, clandestine drug manufacturers have developed 
alternative methods of production using slightly modified 
chemicals that are not yet controlled. 
The unknown
The forecasts made so far have relied on a ceteris paribus 
(all other things being equal) clause. History has shown, 
however, that unforeseen events can play a bigger role in 
shaping the drug problem than many of the other factors. 
It is safe to assume that unpredictable developments will 
occur in the decades to come.
Political evolutions are hard to predict. What is known, 
however, is that societies moving from authoritarian con-
trol to a more liberal system have generally faced a rise in 
illicit drug use. New democratic governments thus need 
to take into account an increased risk of illicit drug use, in 
particular in urban areas.
Overall, public opinion on drug policy has remained rela-
tively constant over time. For example, an opinion poll 
conducted throughout the European Union among young 
people between the ages of 15 and 24 in 2011 revealed 
that only 13 per cent were in favour of making drugs legal. 
More than 90 per cent wanted to ban heroin, cocaine and 
“ecstasy”. Even for cannabis, 59 per cent were in favour of 
a ban and only 5 per cent wanted it to be made available 
without restrictions.149 Opinion polls in the United States 
generally show similar results150 and a proposal to legalize 
cannabis in California was rejected by referendum at the 
end of 2010. 
In the unlikely event of a fundamentally changed drug 
control system, however, what could be the repercussions? 
According to one in-depth review of the literature, legal-
izing drugs would likely lead to increased consumption.151 
The effects are thought to be most pronounced for cocaine 
or heroin, though an increase could also be expected for 
cannabis152 and other drugs. 
From a market perspective, one key driver of the likely 
consumption increases is the lower price level of illicit 
drugs once control is removed. For licit psychoactive sub-
stances, price elasticities cluster around -0.4 for cigarettes 
and -0.7 for alcoholic beverages.153 Calculations of the 
149 Gallup Organization, Youth Attitudes on Drugs: Analytical Report, Flash 
Eurobarometer series No. 330 (Luxembourg, European Commission, 
July 2011). 
150 Regarding the preferred status of cannabis, 9 out of 10 opinion polls 
conducted nationwide in the United States in 2010 and 2011 on this 
topic found a majority against legalization. On average, some 43 per 
cent of those interviewed favoured legalization of cannabis versus some 
52 per cent who opposed it. (Based on opinion polls conducted in the 
United States by CBC, CBS, Gallup, AP/CNBC, Newsweek, ABC 
News/Washington Post, CNN and Pew Research.)
151 MacCoun and Reuter, Drug War Heresies, Learning from Other Vices, 
Times, and Places.
152 According to the authors, depenalization (decriminalization) of can-
nabis use would not necessarily lead to increased use. 
153 W. G. Manning and others, The Costs of Poor Health Habits (Cam-
bridge, Massachusetts, Harvard University Press, 1991). 
price elasticity for opium in the first part of the twentieth 
century (until the 1930s) have ranged from 0.6154 to 
-1.0.155 For cannabis, the elasticity has been estimated 
in the range of -0.4156 to -1.5,157 and those of more 
expensive illicit drugs are probably even larger. Calcula-
tions and analyses from the 1990s158 suggest that the 
price elasticity for cocaine may range from -0.7 to -2.0, 
which means that a 10 per cent decline in the price of 
cocaine would result, ceteris paribus, in consumption 
increases ranging from 7 to 20 per cent. As heroin and 
cocaine prices in the developed countries are far above the 
otherwise normal market prices, owing to prohibition, 
massive price cuts would, again ceteris paribus, result in 
massive consumption increases. Previous research has sug-
gested that cocaine was sold at eight times the potential 
licit price in the United States.159 In 2010, cocaine was 
sold in Colombia at about $2,400 per kilogram. When it 
reached the United States, the wholesale price rose to 
approximately $33,300,160 whereas the retail price is some 
$120,000 per kilogram.161 In comparison, a package deliv-
ery service could deliver a kilogram of a legal product for 
some $50.162 The cost of transport alone cannot explain 
this massive increase, which leaves plenty of scope for price 
reductions — and potential consumption increases — were 
cocaine to be legalized. The idea of offsetting falling prices 
with taxes would not necessarily solve the problem, as the 
incentives for smuggling activities would remain. The price 
effect would probably be weaker for cannabis. The avail-
ability of cannabis is already very high in most countries 
and price declines would probably be less significant than 
154 A. de Landgraaf, “Price elasticity of hard drugs: practical assignment 
for advanced methods for applied economic reasoning”. Available from 
www.alextreme.org/docs/paper-amaer.pdf.
155 J. C. van Ours, “The price elasticity of hard drugs: the case of opium 
in the Dutch East Indies, 1923-1938”, Journal of Political Economy, 
vol. 103, No. 2 (1995), pp. 261-279. 
156 R. J. Pacula, Examining the impact of Marijuana Legalization on 
Marjiuana Consumption: Insights from the Economic Literature, Santa 
Monica, CA; RAND, 2010.
157 M. H. Moore, “Supply reduction and drug law enforcement”, in Drugs 
and Crime, M. Tonry and J. Q. Wilson, eds., Crime and Justice: A 
Review of Research, vol. 13 (Chicago, Illinois, University of Chicago 
Press, 1990), pp. 109-158; G. S. Becker, M. Grossmann and K. M. 
Murphy, “Rational addiction and the effect of price on consumption”, 
in Choice over Time, G. Loewenstein and J. Elster, eds. (New York, 
Russell Sage Foundation, 1992), pp. 361-370. 
158 J. P. Caulkins, “Estimating the elasticities and cross elasticities of 
demand for cocaine and heroin”, Heinz School of Public Policy and 
Management Working Paper 95-13 (Pittsburgh, Pennsylvania, Carn-
egie Mellon University, 1995); M. Grossman, F. J. Chaloupka and C. 
C. Brown, The Demand for Cocaine by Young Adults: A Rational Addic-
tion Approach, NBER Working Paper No. 5713 (Cambridge, Massa-
chusetts, National Bureau of Economic Research, 1996); H. Saffer and 
F. Chaloupka, “The demand for illicit drugs”, NBER Working Paper 
No. 5238 (Cambridge, Massachusetts, National Bureau of Economic 
Research, 1995). 
159 Moore, “Supply reduction and drug law enforcement”. 
160 Range: $11,500-55,000. UNODC, data from the annual report ques-
tionnaire. 
161 Or $120 per gram (range: $8-300).
162 T. Babor and others, Drug Policy and the Public Good (Oxford, Oxford 
University Press, 2010). 
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in the case of cocaine or heroin. Price declines in developed 
countries would be, however, still substantial. Estimates 
for the United States suggest  that wholesale prices for sin-
semilla type cannabis could fall by 80-90 per cent, as com-
pared to the current price level.163 Most predictions suggest 
that cannabis use would increase in the wake of 
legalization. 
As discussed in this chapter, price is far from being the 
only factor influencing drug consumption. Laws, norms, 
values and perceptions also have strong effects that are easy 
to detect but hard to measure. 
D. CONCLUSION 
Drugs have been consumed throughout history, but the 
contemporary drug problem, which started to unfold in 
the 1960s, is characterized by both an expansion and a 
relative concentration of illicit drug use among young 
males living in urban settings. The drug control system 
has not averted the problem, but seems to have contained 
it to much lower levels of use than those society has expe-
rienced with more readily available legal psychoactive 
substances. 
Data also suggest that the relative concentration of illicit 
drug use among youth may not be the result of a higher 
propensity of people to use psychoactive substances in their 
younger years, but of their lower propensity to transgress 
laws and social norms as they get older. The use of legal 
substances tends, indeed, to be far more homogenously 
distributed across age groups than the use of illegal sub-
stances. In other words, young people start using legal and 
illegal psychoactive substances more or less at the same 
time, but tend to continue using legal products and to stop 
using illegal ones as they get older. In this view, illegality 
appears to have largely kept the adult population away 
from illicit drug use.
Another significant characteristic of illicit drug use is the 
disproportionate representation of males among the user 
population. Prevalence of illicit drug use among females 
is only about two thirds of the prevalence among males in 
the United States and about half in Europe. In some devel-
oping countries, including Argentina and Brazil, illicit drug 
use among females is about one third as high as among 
males, while in other countries, such as India, Indonesia, 
Pakistan and the Philippines, it is only a tenth. 
With notable exceptions, illicit drug use has tended, so far, 
to affect Western countries more than the rest of the world, 
but the pattern is shifting. While prevalence of drug use is 
stabilizing or even declining in some respects in Western 
countries, it is rising in others.
163 J. P. Caulkins, J. P. Kilmer, B. MacCoun, R. J. Pacula, R. L. and P. 
Reuter, (2012) Design considerations for legalizing cannabis: lessons 
inspired by analysis of California's Proposition 19. Addiction, 107: 
865-871. doi: 10.1111/j.1360-0443.20111.03561.x
The first and most worrisome impact of illicit drug use is 
on health. UNODC estimates that about 12 per cent of 
annual users develop dependency and become problem 
drug users, of whom there are currently fewer than 30 mil-
lion. Injecting drug use, in particular, is also a significant 
vector for spreading HIV and hepatitis B and C. Addition-
ally, according to WHO, close to 250,000 people die every 
year from overdoses and drug-related illnesses. In compari-
son, alcohol claims some 2.3 million lives per year and 
tobacco some 5.1 million.
Drug-dependent persons require treatment. In 2009, some 
4.5 million people worldwide were receiving treatment for 
problems related to illicit drug use, though the need is 
much higher. Providing treatment to all who need it would 
be costly; rough estimates show that treating all drug-
dependent persons worldwide would cost some $200 bil-
lion-250 billion. 
Research shows that illicit drug use also has an important 
impact on society’s productivity. Productivity losses gener-
ally occur through the incapacitation of individuals or by 
confinement in residential treatment programmes, hospi-
tals or prisons. The costs arising from productivity losses 
due to drug use may be 4-8 times higher than the health-
related costs.
Illicit drug use is also closely linked to crime, in various 
ways. For example, drug users often resort to acquisitive 
crime to finance their drug habits, thus incurring substan-
tial costs for society. Moreover, many criminals are under 
the influence of illicit drugs when they commit crime. 
Criminals, in general, tend to show far higher levels of drug 
use than the rest of the population. Crime and drugs are 
also linked through drug trafficking. Competition between 
different trafficking groups can generate violence. In some 
cases, the profits generated from involvement in the illicit 
drug trade have also been used to finance the activities of 
illegal armed groups. 
Within the overall characteristics summarized above, the 
patterns of drug trafficking and illicit drug use have shifted 
significantly over the past decades. Cannabis was and con-
tinues to be the world’s most widely produced, trafficked 
and consumed drug. Hydroponic cultivation of cannabis 
plants, which results in more potent cannabis, is now 
common in many developed countries. While cannabis 
use is stabilizing or declining in several large developed 
countries, it is growing in many developing ones.
Global production of cocaine increased strongly in the 
1980s and the 1990s but stabilized over the past decade, 
and the amounts available on the illicit market appear to 
have declined. Significant declines in cocaine consumption 
in North America have been offset in part by rising con-
sumption levels in Europe and South America, though 
recent data for South America also show a decline in several 
countries of the Southern Cone. 
Illicit opium and heroin production are now mainly con-
centrated in Afghanistan. Heroin consumption in Western 
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Europe, for long the key illicit market for heroin, has been 
stabilizing or declining over the past decade. The same is 
true for heroin consumption in parts of South-East Asia 
and for Oceania, where illicit drug use declined strongly 
after 2001 and remained at the lower levels thereafter. 
South-West Asia and Eastern Europe, in contrast, have 
experienced rising levels of drug use over the past few dec-
ades. In recent years, heroin consumption also appears to 
have been increasing in Africa. 
While the situation with regard to plant-based drugs in 
general appear to be showing signs of stabilization, follow-
ing many years of increases in the 1980s and the 1990s, 
the illicit production and use of ATS continue to rise. 
Global seizures of ATS increased some threefold over the 
period 1998-2010, while increases in the seizures of plant-
based drugs were less than twofold. 
The evolution of the contemporary drug problem has been 
influenced by a range of drivers. Some relate to demo-
graphic trends, such as gender, population age and levels 
of urbanization, whereas others are socioeconomic, such 
as levels of disposable income, inequality and unemploy-
ment. A third broad category includes sociocultural factors, 
such as value systems, religion and youth culture. Children 
and adolescents who suffer from neglect, abuse, household 
dysfunction, exposure to violence and instability are at 
particular risk of substance abuse.
The drug control system and the way it has been imple-
mented have also profoundly shaped the evolution of the 
drug problem. Moreover, a range of events, largely unfore-
seeable and without an explicit link to drug issues, have 
also fundamentally altered the shape of the drug problem 
that the world is faced with today. 
Assuming that annual prevalence of illicit drug use (about 
5 per cent of the population aged 15-64) will not change 
significantly over the next few decades, demographics sug-
gest that the total number of drug users could, in line with 
the growth of the world population, increase by a quarter 
before 2050. Most of these increases are likely to take place 
in currently developing countries. Though some ageing of 
the drug-using population may be expected, overall drug 
use is likely to continue to be linked primarily to youth. 
In parallel, the larger gender gap of drug use in developing 
countries may lead to future increases in female drug use 
as sociocultural barriers disappear and gender equality 
improves. As drug use is also linked to urbanization and 
the urban population in developing countries is expected 
to double between 2011 and 2050 while remaining largely 
stable in the developed countries, a much more marked 
growth in the number of illicit drug users can be expected 
in the developing countries. This suggests that a relative 
shift of the burden of the global drug problem from the 
developed countries to the currently developing countries 
will continue over the coming decades.
The prominence of heroin and cocaine in illicit drug mar-
kets may decline over the next few decades. In contrast, 
there are currently no signs that the popularity of cannabis 
is going to fall, overall, and it is most likely going to remain 
the most widely used illegal substance. The use of synthetic 
drugs, notably ATS, diverted prescription drugs and large 
numbers of synthetic substances not under international 
control is likely to continue to increase worldwide. All 
these forecasts rely on a ceteris paribus clause. History has 
shown, however, that the evolution of the drug problem 
has been significantly influenced by unforeseen circum-
stances and factors. The further into the future one looks, 
the more unpredictable that evolution becomes. States and 
societies will most likely continue to face difficult policy 
choices when tackling issues related to illicit drugs and 
crime while securing international peace and development 
and upholding human rights. 
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ANNEX
Regional groupings
This report uses a number of regional and subregional 
designations. These are not official designations. They are 
defined as follows:
 s East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, Uganda and United Republic of 
Tanzania. 
 s North Africa: Algeria, Egypt, Libya, Morocco, South 
Sudan, Sudan and Tunisia.
 s Southern Africa: Angola, Botswana, Lesotho, Malawi, 
Mozambique, Namibia, South Africa, Swaziland, Zam-
bia and Zimbabwe.
 s West and Central Africa: Angola, Benin, Burkina Faso, 
Cameroon, Cape Verde, Central African Republic, 
Chad, Congo, Côte d’Ivoire, Democratic Republic of 
the Congo, Equatorial Guinea, Gabon, Gambia, Gha-
na, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra 
Leone and Togo. 
 s Caribbean: Antigua and Barbuda, Bahamas, Barbados, 
Bermuda, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines and Trinidad 
and Tobago.
 s Central America: Belize, Costa Rica, El Salvador, Gua-
temala, Honduras, Nicaragua and Panama.
 s North America: Canada, Mexico and United States of 
America. 
 s South America: Argentina, Bolivia (Plurinational State 
of ), Brazil, Chile, Colombia, Ecuador, Guyana, Para-
guay, Peru, Suriname, Uruguay and Venezuela (Bolivar-
ian Republic of ).
 s Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmen-
istan and Uzbekistan.
 s East and South-East Asia: Brunei Darussalam, Cam-
bodia, China, Democratic People’s Republic of Korea, 
Indonesia, Japan, Lao People’s Democratic Republic, 
Malaysia, Mongolia, Myanmar, Philippines, Republic 
of Korea, Singapore, Thailand, Timor-Leste and Viet 
Nam. 
 s Near and Middle East/South-West Asia: Afghanistan, 
Bahrain, Iran (Islamic Republic of ), Iraq, Israel, Jor-
dan, Kuwait, Lebanon, Oman, Pakistan, Qatar, Saudi 
Arabia, Syrian Arab Republic, United Arab Emirates 
and Yemen. The Near and Middle East refers to a sub-
region that includes Bahrain, Israel, Jordan, Kuwait, 
Lebanon, Oman, Qatar, Saudi Arabia, the Syrian Arab 
Republic, the United Arab Emirates and Yemen.
 s South Asia: Bangladesh, Bhutan, India, Maldives, Ne-
pal and Sri Lanka. 
 s Eastern Europe: Belarus, Republic of Moldova, Russian 
Federation and Ukraine.
 s South-Eastern Europe: Albania, Bosnia and Herzego-
vina, Bulgaria, Croatia, Montenegro, Romania, Ser-
bia, the former Yugoslav Republic of Macedonia and 
Turkey.
 s Western and Central Europe: Andorra, Austria, Bel-
gium, Cyprus, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxem-
bourg, Malta, Monaco, Netherlands, Norway, Poland, 
Portugal, San Marino, Slovakia, Slovenia, Spain, Swe-
den, Switzerland and United Kingdom of Great Britain 
and Northern Ireland.
 s Oceania: Australia, Fiji, Kiribati, Marshall Islands, Mi-
cronesia (Federated States of ), Nauru, New Zealand, 
Palau, Papua New Guinea, Samoa, Solomon Islands, 
Tonga, Tuvalu, Vanuatu and small island territories.
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amphetamine-type stimulants — a group of substances com-
prised of synthetic stimulants from the group of substances 
called amphetamines, which includes amphetamine, meth-
amphetamine, methcathinone and the “ecstasy”-group sub-
stances (methylenedioxymethamphetamine (MDMA) and 
its analogues) 
annual prevalence — the total number of people of a given 
age range who have used a given drug at least once in the 
past year divided by the number of people of a given age 
coca paste (or coca base) — an extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride) 
cocaine (base and salts) — coca paste, cocaine base and 
cocaine hydrochloride referred to in the aggregate
“crack” cocaine — cocaine base obtained from cocaine 
hydrochloride through conversion processes to make it 
suitable for smoking
opiates — a subset of opioids comprised of the various 
products derived from the opium poppy plant, including 
opium, morphine and heroin
opioids — a generic term applied to alkaloids from opium 
poppy, their synthetic analogues, and compounds synthe-
sized in the body 
poppy straw — all parts (except the seeds) of the opium 
poppy, after mowing
problem drug users — people who engage in the high-risk 
consumption of drugs, for example people who inject 
drugs, people who use drugs on a daily basis and/or people 
diagnosed as drug-dependent based on clinical criteria con-
tained in the International Classification of Diseases (tenth 
revision) of the World Health Organization and the Diag-
nostic and Statistical Manual of Mental Disorders (fourth 
edition) of the American Psychiatric Association, or any 
similar criteria or definition that may be used
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Illicit drug markets have global dimensions and require coordinated responses on a 
comparable scale. In this context, the World Drug Report aims to improve understanding of 
the illicit drug problem and contribute to more international cooperation for countering it. 
This year’s edition begins with an overview of recent trends and the current situation in 
terms of production, trafficking and consumption and the consequences of illicit drug use 
in terms of treatment, drug-related diseases and drug-related deaths. The second chapter 
presents a long-term perspective: it looks at the main characteristics of the contemporary 
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